US 20250255853A1

(19) United States
(12) Patent Application Publication
ZAID et al.
(10) Pub. No.: US 2025/0255853 A1
(43) Pub. Date: Aug. 14, 2025

(54) **HUMAN THERAPEUTIC AGENTS**

(71) Applicant: **ANKH LIFE SCIENCES LIMITED**, Dublin (IE)

(72) Inventors: **Gene H. ZAID**, Sterling, KS (US); **Thomas W. BURGOYNE**, Lake Zurich, IL (US)

(73) Assignee: **ANKH LIFE SCIENCES LIMITED**, Dublin (IE)

(21) Appl. No.: **19/175,484**

(22) Filed: **Apr. 10, 2025**

Related U.S. Application Data

(63) Continuation of application No. 18/629,507, filed on Apr. 8, 2024, which is a continuation of application No. 17/589,060, filed on Jan. 31, 2022, now Pat. No. 11,951,099, which is a continuation of application No. 17/000,164, filed on Aug. 21, 2020, now Pat. No. 11,266,634, which is a continuation of application No. 16/724,979, filed on Dec. 23, 2019, now Pat. No. 10,751,330, which is a continuation of application No. 16/541,665, filed on Aug. 15, 2019, now Pat. No. 10,576,067, which is a continuation of application No. 16/213,774, filed on Dec. 7, 2018, now Pat. No. 10,471,049, which is a continuation of application No. 15/826,101, filed on Nov. 29, 2017, now abandoned, which is a continuation of application No. 15/337,987, filed on Oct. 28, 2016, now Pat. No. 9,907,786, which is a continuation-in-part of application No. PCT/US2015/055968, filed on Oct. 16, 2015, which is a continuation-in-part of application No. 14/721,011, filed on May 26, 2015, now Pat. No. 9,402,834, said application No. 15/337,987 is a continuation of application No. PCT/IB2016/000723, filed on Apr. 20, 2016, which is a continuation-in-part of application No. 14/721,011, filed on May 26, 2015, now Pat. No. 9,402,834.

(60) Provisional application No. 62/184,051, filed on Jun. 24, 2015, provisional application No. 62/161,090, filed on May 13, 2015, provisional application No. 62/184,051, filed on Jun. 24, 2015, provisional application No. 62/161,090, filed on May 13, 2015.

Publication Classification

(51) **Int. Cl.**

A61K 31/437	(2006.01)
A61K 31/11	(2006.01)
A61K 31/12	(2006.01)
A61K 31/4375	(2006.01)
A61K 45/06	(2006.01)
A61K 47/10	(2017.01)

(52) **U.S. Cl.**
CPC ***A61K 31/437*** (2013.01); ***A61K 31/11*** (2013.01); ***A61K 31/12*** (2013.01); ***A61K 31/4375*** (2013.01); ***A61K 45/06*** (2013.01); ***A61K 47/10*** (2013.01)

(57) **ABSTRACT**

Human therapeutic treatment compositions comprising a curcumin component, a harmine component, and an isovanillin component, preferably all three in combination. The agents are synergistically effective for treatment of human conditions, especially human cancers, such as pancreatic cancers.

Fig. 1


Head and Neck Cancer
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
-20
0
0.16
0.4
1
2.5
6.25
15.6
39
97.6
244
610
1525
3814
GZ17Syn 06.02 on HN5
GZ17Syn 06.02 on OSC19
GZ17-6.02 dose (µg/mL)

Fig. 2A


Pediatric Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
GZ17Syn 06.02
0
0.0
0.1
0.2
0.5
1.0
2.0
4.0
8.0
16.0
32.0
64.0
128.0
GZ17-6.02 dose (µg/mL)

Fig. 2B


Pediatric Osteosarcoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
GZ17Syn 08.02
0
0.16
0.4
1
2.5
6.25
15.62
39.06
97.65
244.14
610.35
1525.88
3814.69
9537.23
23843.08
59607.69
149019.23
372548.08
931370.19
2328425.48
GZ17-6.02 dose (µg/mL)

Fig. 3A


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.78
1.56
3.125
6.25
12.5
25
50
100
200
400
GZ17Syn 06.02 Dose (µg/mL)

Fig. 3B


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
GZ17-6.02 dose (µg/mL)

Fig. 4A


Ovarian Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.16
0.4
1.6
6.4
25.6
102.4
409.6
1638.4
6553.6
26214.4
104857.6
419430.4
GZ17-6.02 dose (µg/mL)

Fig. 4B


Prostate Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.75
1.5
3
6
12
24
48
95
191
381
GZ17-6.02 Dose (µg/mL)

Fig. 5A


Breast Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.75
1.5
3
6
12
24
48
95
191
381
GZ17-6.02 Dose (µg/mL)

Fig. 5B


Pancreatic Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.75
1.5
3
6
12
24
48
95
191
381
GZ17-6.02 Dose (µg/mL)

Fig. 6


Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.16
0.31
0.62
1.25
2.5
5
10
20
40
80
160
320
640
1280
2560
5120
10240
20480
Fibroblasts
Prostate Cancer
Ovarian Cancer
GZ17-6.02 dose (µg/mL)

Fig. 7A


Migration relative to Vehicle Control (%)
120
100
80
60
40
20
0
Vehicle Control
GZ17-6.02

Fig. 7B


Invasion relative to Vehicle Control (%)
120
100
80
60
40
20
0
Vehicle Control
GZ17-6.02

Fig. 8


Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
2e-3
5e-3
0.0158
0.05
0.158
0.5
1.58
5
15.8
50
Doxorubicin Dose (μM)
Doxorubicin Alone
Doxorubicin + 0.2 mg/mL GZ17Syn 06.02
Doxorubicin + 0.4 mg/mL GZ17Syn 06.02



Fig. 9A



Fig. 9B

Fig. 10A


% of Baseline
220
200
180
160
140
120
100
80
60
40
0
0.75
1.49
2.98
5.96
11.92
23.84
47.68
95.36
190.73
GZ17-6.02 Dose (µg/ml)
cell number (presto)
caspase 9
caspase 3/7

Fig. 10B


% Baseline
500
400
300
200
100
0
0
0.75
1.49
2.98
5.96
11.92
23.84
47.68
95.36
190.73
GZ17-6.02 Dose (µg/ml)
cell number (presto)
caspase 6

Fig. 10C


% of Baseline
140
120
100
80
60
40
0
0.75
1.49
2.98
5.96
11.92
23.84
47.68
95.36
GZ17-6.02 Dose (µg/ml)
Mitochondrial Toxicity (ATP Luminescence)
Cell Number (Presto)

Fig. 11A


% of Baseline
220
200
180
160
140
120
100
80
60
40
0
0.75
1.49
2.98
5.96
11.92
23.84
47.68
95.36
GZ17-6.02 Dose (µg/ml)
Caspase 3/7 Luminescence
Cell Number (presto)

Fig. 11B


% of Baseline
200
180
160
140
120
100
80
60
40
0
0.75
1.49
2.98
5.96
11.92
23.84
47.68
95.36
GZ17-6.02 Dose (µg/ml)
Caspase 6 Luminescence
Cell Number (Presto)

Fig. 11C


% Baseline
200
180
160
140
120
100
80
60
40
0
0.75
1.49
2.98
5.96
11.92
23.84
47.68
95.36
190.73
381.45
GZ17-6.02 Dose (µg/ml)
Caspase 8 Luminescence
Cell Number (presto)

Fig. 11D


% of Baseline
180
160
140
120
100
80
60
40
0
0.75
1.49
2.98
5.96
11.92
23.84
47.68
95.36
GZ17-6.02 Dose (µg/ml)
Caspase 9 Luminescence
Cell Number (Presto)

Fig. 11E


% of Baseline
700
600
500
400
300
200
100
0
0
0.75
1.49
2.98
5.96
11.92
23.84
47.68
95.36
190.73
GZ17-6.02 Dose (mg/ml)
mitotoxicity
cell number (presto)
caspase 8

Fig. 12A


% of Baseline
300
250
200
150
100
50
0
0
0.75
1.49
2.98
5.96
11.92
23.84
47.68
95.36
GZ17-6.02 Dose (µg/ml)
Caspase 3/7 Luminescence
Cell Number (presto)

Fig. 12B


% of Baseline
200
180
160
140
120
100
80
60
0
0.75
1.49
2.98
5.96
11.92
23.84
47.68
95.36
GZ17-6.02 Dose (µg/ml)
Caspase 6 Luminescence
Cell Number (presto)

Fig. 12C


% of Baseline
130
120
110
100
90
80
70
60
0
0.75
1.49
2.98
5.96
11.92
23.84
47.68
95.36
GZ17-6.02 Dose (µg/ml)
Caspase 2 Luminescence
Cell Number (presto)

Fig. 12D


% of Baseline
140
120
100
80
60
40
20
0
0.75
1.49
2.98
5.96
11.92
23.84
47.68
95.36
GZ17-6.02 Dose (µg/ml)
Caspase 9 Luminescence
Cell Number (presto)

Fig. 13


Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.75
1.5
3
6
12
24
48
95
191
381
GZ17-6.02 Dose (µg/mL)



Fig. 14B



Fig. 14A

Fig. 15A


Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.75
1.5
3
6
12
24
48
96
191
381
GZ17-6.02 Dose (µg/ml) (L)
Test One
Test Two

Fig. 15B


Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
-20
0
0.75
1.5
3
6
12
24
48
95
191
381
GZ17-6.02 Dose (µg/ml)
Test One
Test Two

Fig. 16A


Vehicle
GZ17 6.02
Tumor Volume (mm³)
60
50
40
30
20
10
0
5
10
15
20
25
30
Days Post Tumor Inoculation

Fig. 16B


Contralateral Tumors
Vehicle control
GZ17 6.02
Tumor volume (mm³)
100
80
60
40
20
0
1
7
14
18
21
25
28
Day post inoculation


Veh. Ctrl.
GZ17-06.02
Fractional Tumor Volume
2.0
1.5
1.0
0.5
0.0
P<0.05
P<0.01
P<0.001
0
3
5
7
10
12
14
17
19
30 mg/kg
50 mg/kg
Days of treatment

Fig. 16C

Fig. 17A


Ovarian Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.16
0.41
2.08
5.96
11.92
23.84
47.68
95.36
190.73
381.45
GZ17-6.02 Dose (µg/ml)
1/3 of each component
GZ17Syn 06.02

Fig. 17B


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.16
0.4
1.6
6.4
25.6
102.4
409.6
1638.4
6553.6
26214.4
104857.6
1/3 of each component
GZ17Syn 06.02
GZ17-6.02 Dose (µg/ml)

Fig. 17C


Prostate Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.16
0.4
1
2.5
6.3
16
40
100
250
630
1600
4000
1/3 of each component
GZ17Syn 06.02
GZ17-6.02 Dose (µg/ml)

Fig. 18A


Ovarian Cancer
Induced Cancer Cell Death (%)
100
80
60
40
20
0
Iso
Iso/Curcumin
Iso/Harmine
GZ17-6.02
Isovanillin at constant 0.78 mg/mL

Fig. 18B


Lung Cancer
Induced Cancer Cell Death (%)
100
80
60
40
20
0
Iso
Iso/Curcumin
Iso/Harmine
GZ17-6.02
Isovanillin at constant 0.78 mg/mL

Fig. 18C


Prostate Cancer
Induced Cancer Cell Death (%)
100
80
60
40
20
0
Iso
Iso/Curcumin
Iso/Harmine
GZ17-6.02
Isovanillin at constant 0.78 mg/mL

Fig. 18D


Lymphoma
Induced Cancer Cell Death (%)
100
80
60
40
20
0
Iso
Iso/Curcumin
Iso/Harmine
GZ17-6.02
Isovanillin at constant 0.78 mg/mL

Fig. 19A


Ovarian Cancer
Induced Cancer Cell Death (%)
100
80
60
40
20
0
Cur
Cur/Isovanillin
Cur/Harmine
GZ17-6.02
Curcumin at constant 0.78 mg/mL

Fig. 19B


Lung Cancer
Induced Cancer Cell Death (%)
100
80
60
40
20
0
Cur
Cur/Isovanillin
Cur/Harmine
GZ17-6.02
Curcumin at constant 0.78 mg/mL

Fig. 19C


Prostate Cancer
Induced Cancer Cell Death (%)
100
80
60
40
20
0
Cur
Cur/Isovanillin
Cur/Harmine
GZ17-6.02
Curcumin at constant 0.78 mg/mL

Fig. 19D


Lymphoma
Induced Cancer Cell Death (%)
100
80
60
40
20
0
Cur
Cur/Isovanillin
Cur/Harmine
GZ17-6.02
Curcumin at constant 0.78 mg/mL

Fig. 20A


Ovarian Cancer
Induced Cancer Cell Death (%)
100
80
60
40
20
0
Har
Har/Isovanillin
Har/Curcumin
GZ17-6.02
Harmine at constant 0.78 mg/mL

Fig. 20B


Lung Cancer
Induced Cancer Cell Death (%)
100
80
60
40
20
0
Har
Har/Isovanillin
Har/Curcumin
GZ17-6.02
Harmine at constant 0.78 mg/mL

Fig. 20C


Prostate Cancer
Induced Cancer Cell Death (%)
100
80
60
40
20
0
Har
Har/Isovanillin
Har/Curcumin
GZ17-6.02
Harmine at constant 0.78 mg/mL

Fig. 20D


Lymphoma
Induced Cancer Cell Death (%)
100
80
60
40
20
0
Har
Har/Isovanillin
Har/Curcumin
GZ17-6.02
Harmine at constant 0.78 mg/mL

Fig. 21A


Cancer Lethality (% decline in viable cells)
30
25
20
15
10
5
0
6.02 at 12 µg/ml
Isovanillin
Curcumin
Harmine
Theoretical Additive Effect
6.02

Fig. 21B


Cancer Lethality (% decline in viable cells)
40
30
20
10
0
6.02 at 24 µg/ml
Isovanillin
Curcumin
Harmine
Theoretical Additive Effect
6.02

Fig. 21C


Cancer Lethality (% decline in viable cells)
70
60
50
40
30
20
10
0
6.02 at 48 µg/ml
Isovanillin
Curcumin
Harmine
Theoretical Additive Effect
6.02

Fig. 21D


Cancer Lethality (% decline in viable cells)
100
80
60
40
20
0
6.02 at 96 µg/ml
Isovanillin
Curcumin
Harmine
Theoretical Additive Effect
6.02

Fig. 22A


Cancer Lethality (% decline in viable cells)
18
16
14
12
10
8
6
4
2
0
6.02 at 12 µg/ml
Isovanillin
Curcumin
Harmine
Theoretical Additive Effect
6.02

Fig. 22B


6.02 at 24 µg/m
Cancer Lethality (% decline in viable cells)
35
30
25
20
15
10
5
0
Isovanillin
Curcumin
Harmine
Theoretical Additive Effect
6.02

Fig. 22C


Breast Cancer
6.02 at 24 µg/mL
Cancer Lethality (% decline in viable cells)
100
80
60
40
20
0
Isovanillin
Curcumin
Harmine
Theoretical Additive Effect
6.02

Fig. 23A


Vanillin on Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0.064
0.13
0.25
0.5
1
2
4
8
16
33
Vanillin Dose (mM)
Vanillin

Fig. 23B


Isovanillic Acid on Lung Cancer
Cell Number (Percent of Baseline)
130
120
110
100
90
80
70
60
0
0.012
0.024
0.048
0.095
0.18
0.37
0.77
1.49
2.97
5.95
Isovanillic Acid Dose (mM)
Isovanillic Acid

Fig. 23C


O-Vanillin on Lung Cancer
Cell Number (Percent of Baseline)
110
100
90
80
70
60
50
40
O-Vanillin
0
0.19
0.39
0.77
1.54
3.08
6.16
12.32
24.65
49.29
98.59
O-Vanillin Dose (μM)

Fig. 23D


Isovanillyl Alcohol on Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.06
0.13
0.25
0.5
1
2
4.1
8.1
16.2
32.4
Isovanillyl Alcohol Dose (mM)
Isovanillyl Alcohol

Fig. 23E


Vanillin on Ovarian Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
Vanillin
0
0.064
0.13
0.25
0.5
1
2
4
8
16
33
Vanillin Dose (mM)

Fig. 23F


Isovanillic Acid on Ovarian Cancer
Cell Number (Percent of Baseline)
110
100
90
80
70
60
50
0
0.012
0.024
0.048
0.095
0.18
0.37
0.77
1.49
2.97
5.95
Isovanillic Acid Dose (mM)
Isovanillic Acid

Fig. 23G


O-vanillin on Ovarian Cancer
Cell Number (Percent of Baseline)
110
100
90
80
70
60
50
O-vanillin
0
0.19
0.39
0.77
1.54
3.08
6.16
12.32
24.65
49.29
98.59
O-vanillin Dose (μM)

Fig. 23H


Isovanillyl Alcohol on Ovarian Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.06
0.13
0.25
0.5
1
2
4.1
8.1
16.2
32.4
Isovanillyl Alcohol Dose (mM)
Isovanillyl Alcohol

Fig. 23I


Vanillin on Prostate Cancer
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
-20
-40
0
0.064
0.13
0.25
0.5
1
2
4
8
16
33
Vanillin Dose (mM)
Vanillin

Fig. 23J


Isovanillic Acid on Prostate Cancer
Cell Number (Percent of Baseline)
110
100
90
80
70
60
50
Isovanillic Acid
0
0.012
0.024
0.048
0.095
0.18
0.37
0.77
1.49
2.97
5.95
Isovanillic Acid Dose (mM)

Fig. 23K


O-vanillin on Prostate Cancer
Cell Number (Percent of Baseline)
110
100
90
80
70
60
50
O-vanillin
0
0.19
0.39
0.77
1.54
3.08
6.16
12.32
24.65
49.29
98.59
O-vanillin Dose (μM)

Fig. 23L


Isovanillyl Alcohol on Prostate Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.06
0.13
0.25
0.5
1
2
4.1
8.1
16.2
32.4
Isovanillyl Alcohol Dose (mM)
Isovanillyl Alcohol

Fig. 24A


Harmaline on Lung Cancer
Cell Number (Percent of Baseline)
115
110
105
100
95
90
85
0
0.03
0.05
0.09
0.18
0.36
0.73
1.46
2.92
5.83
11.67
Harmaline Dose (µM)
Harmaline


Fig. 24B
Tetrahydro-Harmine on Lung Cancer
Cell Number (Percent of Baseline)
120
110
100
90
80
70
0
0.1
0.2
0.4
0.7
1.4
2.9
5.8
11.6
23.1
46.2
Tetrahydro-Harmine Dose (μM)
Tetrahydro-Harmine

Fig. 24C


Harmol Hydrochloride on Lung Cancer
Cell Number (Percent of Baseline)
110
100
90
80
70
60
50
0
0.1
0.2
0.3
0.6
1.3
2.7
5.3
10.7
21.3
42.6
Harmol Hydrochloride Dose (μM)
Harmol Hydrochloride

Fig. 24D


Harmalol Hydrochloride Dihydrate on Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
-40
0
0.03
0.05
0.11
0.18
0.37
0.73
1.43
2.86
5.72
11.48
Harmalol Hydrochloride Dihydrate Dose (mM)
Harmalol Hydrochloride Dihydrate

Fig. 24E


Harmane on Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
2.81
5.63
11.25
22.5
45
90
170
340
680
1370
Harmane Dose (μM)
Harmane

Fig. 24F


Harmaline on Ovarian Cancer
Cell Number (Percent of Baseline)
106
104
102
100
98
96
94
Harmaline
0
0.03
0.05
0.09
0.18
0.36
0.73
1.46
2.92
5.83
11.67
Harmaline (μM)

Fig. 24G


Tetrahydro-Harmine on Ovarian Cancer
Cell Number (Percent of Baseline)
120
115
110
105
100
95
90
85
0
0.1
0.2
0.4
0.7
1.4
2.9
5.8
11.6
23.1
46.2
Tetrahydro-Harmine Dose (μM)
Tetrahydro-Harmine

Fig. 24H


Harmol Hydrochloride on Ovarian Cancer
Cell Number (Percent of Baseline)
110
100
90
80
70
60
50
Harmol Hydrochloride
0
0.1
0.2
0.3
0.6
1.3
2.7
5.3
10.7
21.3
42.6
Harmol Hydrochloride Dose (μM)

Fig. 24I


Harmalol Hydrochloride Dihydrate on Ovarian Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.03
0.05
0.11
0.18
0.37
0.73
1.43
2.86
5.72
11.48
Harmalol Hydrochloride Dose (mM)
Harmalol Hydrochloride Dihydrate

Fig. 24J


Harmane on Ovarian Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
2.81
5.63
11.25
22.5
45
90
170
340
680
1370
Harmane Dose (μM)
Harmane

Fig. 24K


Harmaline on Prostate Cancer
Cell Number (Percent of Baseline)
106
104
102
100
98
96
94
92
90
88
86
84
Harmaline
0
0.03
0.05
0.09
0.18
0.36
0.73
1.46
2.92
5.83
11.67
Harmaline Dose (μM)

Fig. 24L


Tetrahydro-Harmine on Prostate Cancer
Cell Number (Percent of Baseline)
120
110
100
90
80
70
60
50
0
0.1
0.2
0.4
0.7
1.4
2.9
5.8
11.6
23.1
46.2
Tetrahydro-Harmine Dose (μM)
Tetrahydro-Harmine

Fig. 24M


Harmol Hydrochloride on Prostate Cancer
120
110
100
90
80
70
60
50
40
0
0.1
0.2
0.3
0.6
1.3
2.7
5.3
10.7
21.3
42.6
Harmol Hydrochloride Dose (μM)
Harmol Hydrochloride

Fig. 24N


Harmalol Hydrochloride Dihydrate on Prostate Cancer
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
-20
-40
-60
0
0.03
0.05
0.11
0.18
0.37
0.73
1.43
2.86
5.72
11.48
Harmalol Hydrochloride Dihydrate Dose (mM)
Harmalol Hydrochloride Dihydrate

Fig. 24O


Harmane on Prostate Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
2.81
5.63
11.25
22.5
45
90
170
340
690
1370
Harmane Dose (μM)
Harmane

Fig. 25A


Bisdemethoxy Curcumin on Lung Cancer
Cell Number (Percent of Baseline)
110
100
90
80
70
60
50
0
0.65
1.28
2.53
5.06
10.15
20.27
40.54
81.08
162.16
324.33
Bisdemethoxy Curcumin (μM)
Bisdemethoxy Curcumin

Fig. 25B


Bisdemethoxy Curcumin on Ovarian Cancer
Cell Number (Percent of Baseline)
110
100
90
80
70
60
50
40
30
Bisdemethoxy Curcumin
0
0.65
1.26
2.53
5.06
10.15
20.27
40.54
81.08
162.16
324.33
Bisdemethoxy Curcumin (μM)

Fig. 25C


Bisdemethoxy Curcumin on Prostate Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.65
1.26
2.53
5.06
10.15
20.27
40.54
81.08
162.16
324.33
Bisdemethoxy Curcumin Dose (µM)
Bisdemethoxy Curcumin

Fig. 26


Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.75
1.49
2.98
5.96
11.92
23.84
47.68
95.36
190.73
381.45
GZ17-6.02 Dose (µg/mL)
-20°C
4°C

Fig. 27


Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.75
1.49
2.98
5.96
11.92
23.84
47.68
95.36
190.73
381.45
GZ17-6.02 Dose (μg/mL)
Test 0
Test 1
Test 2
Test 3
Test 4
Test 6
Test 8
Test 10

Figure 28A


GZ17-8.02
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
-20
0
0.015
0.03
0.05
0.1
0.2
0.39
0.78
1.56
3.13
6.25
GZ17-8.02 Dose (mg/mL)
Ovarian Cancer
Lung Cancer
Prostate Cancer
Pancreatic Cancer
Fibroblasts

Figure 28B


GZ17-8.03
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.015
0.03
0.05
0.1
0.2
0.39
0.78
1.56
3.13
6.25
GZ17-8.03 Dose (mg/mL)
Ovarian Cancer
Lung Cancer
Prostate Cancer
Pancreatic Cancer
Fibroblasts

Figure 28C


GZ17-8.04
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
-20
0
0.015
0.03
0.05
0.1
0.2
0.39
0.78
1.56
3.13
6.25
GZ17-8.04 dose mg/mL
Ovarian Cancer
Lung Cancer
Prostate Cancer
Pancreatic Cancer
Fibroblasts

Figure 28D


GZ17-8.05
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.015
0.03
0.05
0.1
0.2
0.39
0.78
1.56
3.13
6.25
GZ17-8.05 dose mg/mL
Ovarian Cancer
Lung Cancer
Prostate Cancer
Pancreatic Cancer
Fibroblasts

Figure 28E


GZ17-8.06
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.015
0.03
0.05
0.1
0.2
0.39
0.78
1.56
3.13
6.25
GZ17-8.06 dose mg/mL
Ovarian Cancer
Lung Cancer
Prostate Cancer
Pancreatic Cancer
Fibroblasts

Figure 28F


GZ17-8.07
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.015
0.03
0.05
0.1
0.2
0.39
0.78
1.56
3.13
6.25
GZ17-8.07 dose mg/mL
Ovarian Cancer
Lung Cancer
Prostate Cancer
Pancreatic Cancer
Fibroblasts

Figure 28G


GZ17-8.08
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.015
0.03
0.05
0.1
0.2
0.39
0.78
1.56
3.13
6.25
GZ17-8.08 dose mg/mL
Ovarian Cancer
Lung Cancer
Prostate Cancer
Pancreatic Cancer
Fibroblasts

Figure 28H


GZ17-8.09
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
-20
0
0.015
0.03
0.05
0.1
0.2
0.39
0.78
1.56
3.13
6.25
GZ17-8.09 dose mg/mL
Ovarian Cancer
Lung Cancer
Prostate Cancer
Pancreatic Cancer
Fibroblasts

Figure 28I


GZ17-8.10
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
0
0.015
0.03
0.05
0.1
0.2
0.39
0.78
1.56
3.13
6.25
GZ17-8.10 dose mg/mL
Ovarian Cancer
Lung Cancer
Prostate Cancer
Pancreatic Cancer
Fibroblasts


Ovarian Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.11
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 29A


Lung Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.11
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 29B


Prostate Cancer
GZ17-8.11
Cell Number (Percent of Baseline)
100
80
60
40
20
0
Dose (µg/mL)
0
0.142
0.284
0.569
1.138
2.275
4.55
9.1
18.2
36.4

Fig. 29C


Head and Neck Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.11
0
0.762
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 29D


Breast Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.11
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 29E


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.11
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 29F


Lymphoma
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.11
0
0.762
1.904
2.969
5.908
11.818
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 29G


Ovarian Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.12
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 30A


Lung Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.12
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 30B


Prostate Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.12
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 30C


Head and Neck Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.12
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 30D


Breast Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.12
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 30E


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.12
0
0.762
1.524
2.286
5.588
11.176
22.75
45.5
91
182
364
Dose (µg/mL)

Fig. 30F


Lymphoma
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.12
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 30G


Ovarian Cancer
GZ17-8.13
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 31A


Lung Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.13
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 31B


Prostate Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.13
0
0.142
0.427
1.28
3.84
11.5
34.6
103
310
930
2.79
8.36
25.1
75.3
226
679
2.03
6.09
18.3
54.9
165
495
1.48
4.45
13.4
40.2
121
363
Dose (µg/mL)

Fig. 31C


Head and Neck Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.13
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 31D


Breast Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.13
0
0.142
0.284
0.569
1.138
2.275
4.55
9.1
18.2
36.4
72.8
145.6
291.2
582.4
1164.8
2329.6
4659.2
9318.4
18636.8
37273.6
74547.2
149094.4
298188.8
596377.6
1192755.2
2385510.4
Dose (µg/mL)

Fig. 31E


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.13
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 31F


Lymphoma
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.13
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 31G


Ovarian Cancer
GZ17-8.14
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 32A


Lung Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.14
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 32B


Prostate Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.14
0
0.142
0.428
1.286
3.858
11.575
34.725
104.175
312.525
937.575
2812.725
8438.175
25314.525
75943.575
227830.725
683492.175
2050476.525
6151429.575
18454288.725
55362866.175
166088598.525
498265795.575
1494797386.725
4484392160.175
13453176480.525
Dose (µg/mL)

Fig. 32C


Head and Neck Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.14
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 32D


Breast Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.14
0
0.142
0.427
1.28
3.86
11.6
34.7
104
312
Dose (µg/mL)

Fig. 32E


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.14
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 32F


Lymphoma
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.14
0
0.742
1.484
2.968
5.936
11.87
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 32G


Ovarian Cancer
GZ17-8.15
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 33A


Lung Cancer
GZ17-8.15
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 33B


Prostate Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.15
0
0.762
1.904
2.969
5.969
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 33C


Head and Neck Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.15
0
0.142
0.428
2.569
5.708
11.416
22.75
45.5
91
182
364
Dose (µg/mL)

Fig. 33D


Breast Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.15
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
760
Dose (µg/mL)

Fig. 33E


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.15
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 33F


Lymphoma
GZ17-8.15
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.064
0.256
0.64
1.28
2.56
5.12
10.24
20.48
40.96
81.92
163.84
327.68
Dose (µg/mL)

Fig. 33G


Ovarian Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.16
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 34A


Lung Cancer
GZ17-8.16
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 34B



Dose (µg/mL)

Fig. 34C


Head and Neck Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.16
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 34D


Breast Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.16
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 34E


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.16
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 34F


Lymphoma
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.16
0
0.142
0.444
1.389
4.167
12.5
37.5
112.5
337.5
Dose (µg/mL)

Fig. 34G


Ovarian Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.17
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 35A


Lung Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.17
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 35B


Prostate Cancer
GZ17-8.17
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 35C


Head and Neck Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.17
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 35D


Breast Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.17
0
0.742
1.484
2.968
5.936
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 35E


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.17
0
0.0125
0.025
0.05
0.1
0.2
0.4
0.8
1.6
3.2
6.4
12.8
25.6
51.2
102.4
Dose (µg/mL)

Fig. 35F


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.17
0
0.142
0.284
0.569
1.138
2.275
4.55
9.1
18.2
36.4
Dose (μg/mL)

Fig. 35G


Ovarian Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)
GZ17-8.18

Fig. 36A


Lung Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.18
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 36B


Prostate Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.18
0
0.142
0.284
0.569
1.138
2.275
4.55
9
18
36
Dose (µg/mL)

Fig. 36C


Head and Neck Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.18
0
0.142
0.284
0.568
1.136
2.272
4.545
9.09
18.18
36.36
72.72
145.4
290.9
581.8
1163
2327
Dose (µg/mL)

Fig. 36D


Breast Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.18
0
0.142
0.428
1.28
3.85
11.5
34.6
104
312
940
2820
Dose (µg/mL)

Fig. 36E


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.18
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 36F


Lymphoma
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.18
0
0.142
0.284
0.569
1.138
2.275
4.55
9.1
18.2
36.4
72.8
Dose (µg/mL)

Fig. 36G


Ovarian Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.19
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 37A


Lung Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.19
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 37B


Prostate Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.19
0
0.142
0.284
0.568
1.136
2.273
4.545
9
18.2
36.4
Dose (µg/mL)

Fig. 37C


Head and Neck Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.19
0
0.12
0.24
0.49
0.98
1.95
3.9
7.8
15.6
31.25
62.5
125
250
500
Dose (µg/mL)

Fig. 37D


Breast Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.19
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 37E


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.19
0
0.142
0.284
0.568
1.136
2.273
4.545
9.09
18.18
36.36
Dose (μg/mL)

Fig. 37F


Lymphoma
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
GZ17-8.19
0
0.142
0.427
1.28
3.84
11.5
34.6
103
300
Dose (μg/mL)

Fig. 37G


Ovarian Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.20
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 38A


Lung Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.20
0
0.742
1.484
2.968
5.938
11.875
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 38B


Prostate Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.20
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 38C


Head and Neck Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.20
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 38D


Breast Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.20
0
0.0125
0.025
0.05
0.1
0.2
0.4
0.8
1.6
3.2
6.4
12.8
25.6
51.2
102.4
204.8
409.6
819.2
1638.4
3276.8
Dose (µg/mL)

Fig. 38E


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.20
0
0.142
0.469
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 38F


Lymphoma
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
GZ17-8.20
0
0.122
0.244
0.488
0.975
1.95
3.9
7.8
15.6
31.3
62.5
125
250
500
Dose (µg/mL)

Fig. 38G


Ovarian Cancer
GZ17-8.21
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.762
1.44
2.86
5.68
11.36
22.72
45.5
90
180
360
Dose (µg/mL)

Fig. 39A


Lung Cancer
GZ17-8.21
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 39B


Prostate Cancer
GZ17-8.21
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 39C


Head and Neck Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.21
0
0.142
0.284
0.568
1.136
2.272
4.545
9
18
36
72
Dose (µg/mL)

Fig. 39D


Breast Cancer
GZ17-8.21
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 39E


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.21
0
0.142
0.424
1.269
3.808
11.425
34.275
102.825
308.475
925.425
2776.275
8328.825
Dose (µg/mL)

Fig. 39F


Lymphoma
GZ17-8.21
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 39G


Ovarian Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.22
0
0.762
1.524
2.286
5.969
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 40A


Lung Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.22
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 40B


Prostate Cancer
GZ17-8.22
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.142
0.428
1.28
3.86
11.6
35
105
316
950
2860
Dose (µg/mL)

Fig. 40C


Head and Neck Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
GZ17-8.22
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 40D


Breast Cancer
GZ17-8.22
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.142
0.284
1.969
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 40E


Leukemia
GZ17-8.22
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 40F


Lymphoma
GZ17-8.22
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.1562
0.3125
0.625
1.25
2.5
5
10
20
40
Dose (μg/mL)

Fig. 40G


Ovarian Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.23
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 41A


Lung Cancer
GZ17-8.23
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 41B


Prostate Cancer
GZ17-8.23
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.142
0.284
0.569
1.138
2.276
4.55
9
18.2
36.4
Dose (µg/mL)

Fig. 41C


Head and Neck Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.23
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 41D


Breast Cancer
GZ17-8.23
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.142
0.284
0.568
1.136
2.273
4.545
9
18
36
Dose (µg/mL)

Fig. 41E


Leukemia
GZ17-8.23
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 41F


Lymphoma
GZ17-8.23
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.142
0.484
1.69
5.638
19.75
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 41G


Ovarian Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.24
0
0.762
1.524
2.286
5.08
11.43
25.4
57.15
127
381
Dose (µg/mL)

Fig. 42A


Lung Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)
GZ17-8.24

Fig. 42B


Prostate Cancer
GZ17-8.24
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 42C


Head and Neck Cancer
GZ17-8.24
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.762
1.524
2.968
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 42D


Breast Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.24
0
0.142
0.428
1.28
3.86
11.6
34.8
104
312
Dose (µg/mL)

Fig. 42E


Leukemia
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.24
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 42F


Lymphoma
GZ17-8.24
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.782
1.563
3.125
6.25
12.5
25
50
100
200
Dose (µg/mL)

Fig. 42G


Ovarian Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.25
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 43A


Lung Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)
GZ17-8.25

Fig. 43B


Prostate Cancer
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)
GZ17-8.25

Fig. 43C


Head and Neck Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.25
0
0.142
0.284
0.569
1.138
2.275
4.55
9.1
18.2
36.4
Dose (µg/mL)

Fig. 43D


Breast Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.25
0
0.142
0.284
0.569
1.138
2.275
4.55
9.1
18.2
36.4
Dose (µg/mL)

Fig. 43E


Leukemia
GZ17-8.25
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 43F


Lymphoma
GZ17-8.25
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.142
0.284
2.969
5.969
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 43G


Ovarian Cancer
GZ17-8.26
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.142
0.428
1.284
3.856
11.568
34.704
104.112
312.336
Dose (µg/mL)

Fig. 44A


Lung Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.26
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 44B


Prostate Cancer
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)
GZ17-8.26

Fig. 44C


Head and Neck Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
GZ17-8.26
0
0.782
1.563
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 44D


Breast Cancer
GZ17-8.26
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.142
0.284
0.568
1.136
2.275
4.5
9
18
36
Dose (µg/mL)

Fig. 44E


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.26
0
0.142
0.284
0.569
1.138
2.275
4.55
9.1
18.2
36.4
72.8
145.6
291.2
582.4
1164.8
2329.6
Dose (µg/mL)

Fig. 44F


Lymphoma
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.26
0
0.142
0.284
0.569
1.138
2.275
4.55
9.1
18.2
36.4
Dose (µg/mL)

Fig. 44G


Ovarian Cancer
GZ17-8.27
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.142
0.284
0.569
1.138
2.275
4.55
9.1
18.2
36.4
Dose (µg/mL)

Fig. 45A


Lung Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)
GZ17-8.27

Fig. 45B


Prostate Cancer
Cell Number (Percent of Baseline)
160
140
120
100
80
60
40
20
0
GZ17-8.27
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 45C


Head and Neck Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.27
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 45D


Breast Cancer
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
GZ17-8.27
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 45E


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.27
0
0.1562
0.3125
0.625
1.25
2.5
5
10
20
40
80
160
320
Dose (µg/mL)

Fig. 45F


Lymphoma
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.27
0
0.762
1.464
2.969
5.908
11.816
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 45G


Ovarian Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.28
0
0.142
0.284
0.569
1.138
2.275
4.55
9.1
18.2
36.4
72.8
145.6
Dose (µg/mL)

Fig. 46A


Lung Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.28
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 46B


Prostate Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.28
0
0.142
0.428
1.28
3.86
11.57
34.7
104
312
Dose (µg/mL)

Fig. 46C


Head and Neck Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
GZ17-8.28
0
0.142
0.284
0.569
1.138
2.275
4.55
9.1
18.2
36.4
Dose (µg/mL)

Fig. 46D


Breast Cancer
GZ17-8.28
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.142
0.284
0.568
1.136
2.273
4.545
9.09
18.18
36.36
Dose (µg/mL)

Fig. 46E


Leukemia
GZ17-8.28
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 46F


Lymphoma
GZ17-8.28
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 46G


Ovarian Cancer
GZ17-8.29
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.1
0.2
0.4
1
2
4
8
16
32
64
128
256
Dose (μg/mL)

Fig. 47A


Lung Cancer
GZ17-8.29
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 47B


Prostate Cancer
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
GZ17-8.29
0
0.142
0.4
1.6
2.56
6.56
11.36
23.2
47.5
95
190
380
Dose (µg/mL)

Fig. 47C


Head and Neck Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.29
0
0.142
0.284
0.569
1.138
2.275
4.55
9.1
18.2
36.4
Dose (µg/mL)

Fig. 47D


Breast Cancer
GZ17-8.29
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 47E


Leukemia
GZ17-8.29
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.762
1.907
2.986
5.966
11.976
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 47F


Lymphoma
GZ17-8.29
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 47G


Ovarian Cancer
GZ17-8.30
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.7812
1.562
3.125
6.25
12.5
25
50
100
200
Dose (µg/mL)

Fig. 48A


Lung Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.30
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 48B


Prostate Cancer
Cell Number (Percent of Baseline)
160
140
120
100
80
60
40
20
0
GZ17-8.30
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 48C


Head and Neck Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
GZ17-8.30
0
0.142
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 48D


Breast Cancer
GZ17-8.30
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 48E



Dose (µg/mL)

Fig. 48F


Lymphoma
GZ17-8.30
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 48G


Ovarian
GZ17-8.31
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.1875
0.375
0.75
1.5
3
6
12
24
48
96
Dose (µg/mL)

Fig. 49A


Lung Cancer
GZ17-8.31
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 49B


Lymphoma
GZ17-8.31
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 49C


Leukemia
GZ17-8.31
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 49D


Ovarian
GZ17-8.32
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 50A


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.32
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 50B


Lymphoma
GZ17-8.32
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 50C


Leukemia
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.32
0
0.142
0.427
1.28
3.84
11.5
34.6
104
312
938
Dose (μg/mL)

Fig. 50D


Ovarian
GZ17-8.33
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 51A


Lung Cancer
GZ17-8.33
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.142
0.284
1.42
2.96
5.68
11.875
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 51B


Lymphoma
GZ17-8.33
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 51C


Leukemia
GZ17-8.33
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 51D


Ovarian
GZ17-8.34
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 52A


Lung Cancer
GZ17-8.34
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.142
0.284
0.568
1.136
2.272
4.545
9
18
36
Dose (μg/mL)

Fig. 52B


Lymphoma
GZ17-8.34
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 52C


Leukemia
GZ17-8.34
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 52D


Ovarian
GZ17-8.35
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
Dose (µg/mL)
0
0.1
0.2
0.4
0.8
1.6
3.2
6.4
12.8
25.6
51.2
102.4
204.8

Fig. 53A


Lung Cancer
GZ17-9.35
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.12
0.24
0.49
0.98
1.95
3.9
7.8
15.6
31.2
62.5
125
250
500
Dose (µg/mL)

Fig. 53B


Lymphoma
GZ17-8.35
Cell Number (Percent of Baseline)
100
80
60
40
20
0
-20
0
0.142
0.284
0.569
1.138
2.275
4.55
9
18
36
Dose (µg/mL)

Fig. 53C


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.35
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 53D


Ovarian
GZ17-9.38
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.142
0.284
0.569
1.138
2.275
4.55
9.1
18.2
36.4
Dose (µg/mL)

Fig. 54A


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.36
0
0.142
0.284
0.568
1.136
2.272
4.544
9.088
18.176
36.352
72.704
145.408
290.816
Dose (μg/mL)

Fig. 54B


Lymphoma
GZ17-8.36
Cell Number (Percent of Baseline)
100
80
60
40
20
0
-20
0
0.742
1.484
2.968
5.936
11.872
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 54C


Leukemia
GZ17-8.36
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 54D


Ovarian
GZ17-8.37
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
0
0.142
0.284
0.569
1.138
2.275
4.55
9.1
18.2
36.4
72.8
145.6
291.2
582.4
1164.8
2329.6
4659.2
9318.4
18636.8
37273.6
74547.2
149094.4
298188.8
596377.6
1192755.2
2385510.4
4771020.8
9542041.6
19084083.2
38168166.4
76336332.8
152672665.6
305345331.2
610690662.4
1221381324.8
2442762649.6
4885525299.2
9771050598.4
19542101196.8
39084202393.6
78168404787.2
156336809574.4
312673619148.8
625347238297.6
1250694476595.2
2501388953190.4
5002777906380.8
10005555812761.6
20011111625523.2
40022223251046.4
80044446502092.8
160088893004185.6
320177786008371.2
640355572016742.4
1280711144033484.8
2561422288066969.6
5122844576133939.2
10245689152267878.4
20491378304535756.8
40982756609071513.6
81965513218143027.2
163931026436286054.4
327862052872572108.8
655724105745144217.6
1311448211490288435.2
2622896422980576870.4
5245792845961153740.8
10491585691922307481.6
20983171383844614963.2
41966342767689229926.4
83932685535378459852.8
167865371070756919705.6
335730742141513839411.2
671461484283027678822.4
1342922968566055357644.8
2685845937132110715289.6
5371691874264221430579.2
10743383748528442861158.4
21486767497056885722316.8
42973534994113771444633.6
85947069988227542889267.2
171894139976455085778534.4
343788279952910171557068.8
687576559905820343114137.6
1375153119811640686228275.2
2750306239623281372456550.4
5500612479246562744913100.8
10001224958493125489826201.6
20002449916986250979652403.2
40004899833972501959304806.4
80009799667945003918609612.8
160019599335890007837219225.6
320039198671780015674438451.2
640078397343560031348876902.4
1280156794687120062697753804.8
2560313589374240125395507609.6
5120627178748480250791015219.2
10241254357496960501582030438.4
20482508714993921003164060876.8
40965017429987842006328121753.6
81930034859975684012656243507.2
163860069719951368025312487014.4
327720139439902736050624974028.8
655440278879805472101249948057.6
1310880557759610944202499896115.2
2621761115519221888404999792230.4
5243522231038443776809999584460.8
10487044462076887553619999168921.6
20974088924153775107239998337843.2
41948177848307550214479996675686.4
83896355696615100428959993351372.8
167792711393230200857919986702745.6
335585422786460401715839973405491.2
671170845572920803431679946810982.4
1342341691145841606863359893621964.8
2684683382291683213726719787243929.6
5369366764583366427453439574487859.2
10738733529166732854906879148975718.4
21477467058333465709813758297951436.8
42954934116666931419627516595902873.6
85909868233333862839255033191805747.2
171819736466667725678510066383611494.4
343639472933335451357020132767222988.8
687278945866670902714040265534445977.6
1374557891733341805428080531068891955.2
2749115783466683610856161062137783910.4
5498231566933367221712322124275567820.8
10996463133866734443424644248551135641.6
21992926267733468886849288497102271283.2
43985852535466937773698576994204542566.4
87971705070933875547397153988409085132.8
175943410141867751094794307976818170265.6
351886820283735502189588615953636340531.2
703773640567471004379177231907272681062.4
1407547281134942008758354463814545362124.8
2815094562269884017516708927629090724249.6
5630189124539768035033417855258181448499.2
11260378249079536070066835710516362896998.4
22520756498159072140133671421032725793996.8
45041512996318144280267342842065451587993.6
90083025992636288560534685684130903175987.2
180166051985272577121069371368261806351974.4
360332103970545154242138742736523612703948.8
720664207941090308484277485473047225407897.6
1441328415882180616968554970946094450815795.2
2882656831764361233937109941892188901631590.4
5765313663528722467874219883784377803263180.8
11530627327057444935748439767568755606526361.6
23061254654114889871496879535137511213052723.2
46122509308229779742993759070275022426105446.4
92245018616459559485987518140550044852210892.8
184490037232919118971975036281100089704421785.6
368980074465838237943950072562200179408843571.2
737960148931676475887900145124400358817687142.4
1475920297863352951775800290248800717635374284.8
2951840595726705903551600580497601435270748569.6
5903681191453411807103201160995202870541497139.2
11807362382906823614206402321990405741082994278.4
23614724765813647228412804643980811482165988556.8
47229449531627294456825609287961622964331977113.6
94458899063254588913651218575923245928663954227.2
188917798126509177827302437151846491857327908454.4
377835596253018355654604874303692983714655816908.8
755671192506036711309209748607385967429311633817.6
1511342385012073422618419497214771934858623267635.2
3022684770024146845236838994429543869717246535270.4
6045369540048293690473677988859087739434493070540.8
12090739080096587380947355977718175478868986141081.6
24181478160193174761894711955436350957737972282163.2
48362956320386349523789423910872701915475944564326.4
96725912640772699047578847821745403830951889128652.8
193451825281545398095157695643490807661903778257305.6
386903650563090796190315391286981615323807556514611.2
773807301126181592380630782573963230647615113029222.4
1547614602252363184761261565147926461295230226058444.8
3095229204504726369522523130295852922590460452116889.6
6190458409009452739045046260591705845180920904233779.2
12380916818018905478090092521183411690361841808467558.4
24761833636037810956180185042366823380723683616935116.8
49523667272075621912360370084733646761447367233870233.6
99047334544151243824720740169467293522894734467740467.2
198094669088302487649441480338934587045789468935480934.4
396189338176604975298882960677869174091578937870961868.8
792378676353209950597765921355738348183157875741923737.6
1584757352706419901195531842711476696366315751483847475.2
3169514705412839802391063685422953392732631502967694950.4
6339029410825679604782127370845906785465263005935389900.8
12678058821651359209564254741691813570930526011870779801.6
25356117643302718419128509483383627141861052023741559603.2
50712235286605436838257018966767254283722104047483119206.4
101424470573210873676514037933534508567444208094966238412.8
202848941146421747353028075867068017134888416189932476825.6
405697882292843494706056151734136034269776832379864953651.2
811395764585686989412112303468272068539553664759729907302.4
1622791529171373978824224606936544137079107329519459814604.8
3245583058342747957648449213873088274158214659038919629209.6
6491166116685495915296898427746176548316429318077839258419.2
12982332233370991830593796855492353096632858636155678516838.4
25964664466741983661187593710984706193265717272311357033676.8
51929328933483967322375187421969412386531434544622714067353.6
103858657866967934644750374843938824773062869089245428134707.2
207717315733935869289500749687877649546125738178490856269414.4
415434631467871738579001499375755299092251476356981712538828.8
830869262935743477158002998751510598184502952713963425077657.6
1661738525871486954316005997503021196369005905427926850155315.2
3323477051742973908632011995006042392738011810855853700310630.4
6646954103485947817264023990012084785476023621711707400621260.8
13293908206971895634528047980024169570952047243423414801242521.6
26587816413943791269056095960048339141904094486846829602485043.2
53175632827887582538112191920096678283808188973693659204970086.4
106351265655775165076224383840193356567616377947387318409940172.8
212702531311550330152448767680386713135232755894774636819880345.6
425405062623100660304897535360773426270465511789549273639760691.2
850810125246201320609795070721546852540931023579098547279521382.4
1701620250492402641219590141443093705081862047158197094559042764.8
3403240500984805282439180282886187410163724094316394189118085529.6
6806481001969610564878360565772374820327448188632788378236171058.2
13612962003939221129756721131544749640654896377265576756472342116.4
27225924007878442259513442263089499281309792754531153512944684232.8
54451848015756884519026884526178998562619585509062307025889368465.6
108903696031513769038053769052357997125239171018124614051778736931.2
217807392063027538076107538104715994250478342036249228103557473862.4
435614784126055076152215076209431988500956684072498456207114947724.8
871229568252110152304430152418863977001913368144996912414229895449.6
1742459136504220304608860304837727954003826736289993824828459790899.2
3484918273008440609217720609675455908007653472579987649656919581798.4
6969836546016881218435441219350911816015306945159975299313839163596.8
13939673092033762436870882438701823632030613890319950598627678327193.6
27879346184067524873741764877403647264061227780639901197255356654387.2
55758692368135049747483529754807294528122455561279802394510713308774.4
111517384736270099494967059509614589056244911122559604789021426617548.8
223034769472540198989934119019229178112489822245119209578042853235097.6
446069538945080397979868238038458356224979644490238419156085706470195.2
892139077890160795959736476076916712449959288980476838312171412940390.4
1784278155780321591919472952153833424899918577960953676624342825880781.6
3568556311560643183838945904307666849799837155921907353248685651761562.4
7137112623121286367677891808615333699599674311843814706497371303523124.8
14274225246242572735355783617230667399199348623687629412994742607046249.6
28548450492485145470711567234461334798398697247375258825989485214092499.2
57096900984970290941423134468922669596797394494750517651978970428184998.4
114193801969940581882846268937845339193594788989501035303957940856369996.8
228387603939881163765692537875690678387189577979002070607915881712739993.6
456775207879762327531385075751381356774379155958004141215831763425479987.2
913550415759524655062770151502762713548758311916008282431663526850959974.4
1827100831519049310125540303005525427097516623832016564863327053701919948.8
3654201663038098620251080606011050854195033247664033129726654107403839897.6
7308403326076197240502161212022101708390066495328066259453308214807679795.2
14616806652152394481004322424044203416780132990656132518906616429615359590.4
29233613304304788962008644848088406833560265981312265037813232859230719180.8
58467226608609577924017289696176813667120531962624530075626465718461438361.6
116934453217219155848034579392353627334241063925249060151252931436922876723.2
233868906434438311696069158784707254668482127850498120302505862873845753446.4
467737812868876623392138317569414509336964255700996240605011725747691506892.8
935475625737753246784276635138829018673928511401992481210023451495383013785.6
1870951251475506493568553270277658037347857022803984962420046902990766027571.2
3741902502951012987137106540555316074695714045607969924840093805981532055142.4
7483805005902025974274213081110632149391428091215939849680187611963064110284.8
14967610011804051948548426162221264298782856182431879699360375223926128220569.6
29935220023608103897096852324442528597565712364863759398720750447852256441138.2
59870440047216207794193704648885057195131424729727518797441500895704512882276.4
119740880094432415588387409297770114390262849459455037594883001791409025764552.8
239481760188864831176774818595540228780525698918910075189766003582818051529105.6
478963520377729662353549637191080457561051397837820150379532007165636103058211.2
957927040755459324707099274382160915122102795675640300759064014331272206116422.4
1915854081510918649414198548764321830244205591351280601518128028662544412232844.8
3831708163021837298828397097528643660488411182702561203036256057325088824465689.6
7663416326043674597656794195057287320976822365405122406072512114650177648931378.2
15326832652087349195313588390114574641953644730810244812145024229300355297862756.4
30653665304174698390627176780229149283907289461620489624290048458600710595725512.8
61307330608349396781254353560458298567814578923240979248580096917201421191451025.6
122614661216698793562508707120916597135629157846481958497160193834402842382902051.2
245229322433397587125017414241833194271258315692963916994320387668805684765804102.4
490458644866795174250034828483666388542516631385927833988640775337611369531608204.8
980917289733590348500069656967332777085033262771855667977281550675222739063216409.6
1961834579467180697000139313934665554170066525543711335954563101350445478126432819.2
3923669158934361394000278627869331108340133051087422671909126202700890956252865638.4
7847338317868722788000557255738662216680266102174845343818252405401781912505731276.8
15694676635737445576001114511477324433360532204349690687636504810803563825011462553.6
31389353271474891152002229022954648866721064408699381375273009621607127650022925107.2
62778706542949782304004458045909297733442128817398762750546019243214255300045850214.4
125557413085899564608008916091818595466884257634797525501092038486428510600091700428.8
251114826171799129216017832183637190933768515269595050992184076972857021200183400857.6
502229652343598258432035664367274381867537030539190101984368153945714042400366801715.2
1004459304687196516864071328734548763735074061078380203968736307891428084800733603430.4
2008918609374393033728142657469097527470148122156760407937472615782856169601467206860.8
4017837218748786067456285314938195054940296244313520815874945231565712339202934413721.6
8035674437497572134912570629876390109880592488627041631749890463131424678405868827443.2
16071348874995144269825141259752780219761184977254083263499780926262849356811737654886.4
32142697749990288539650282519505560439522369954508166526999561852525698713623475309772.8
64285395499980577079300565038911120879044739909016333053999123705051397427246950619544.8
128570790999961154158601130077822241758089479818032666107998247410102794854493901239089.6
257141581999922308317202260155644483516178959636065332215996494820205589708987802478179.2
514283163999844616634404520311288967032357919272130664431992989640411179417975604956358.4
1028566327999689233268809040622577934064715838544261328863985979280822358835951209912716.8
2057132655999378466537618081245155868129431677088522657727971958561644717671902419825433.6
4114265311998756933075236162490311736258863354177045315455943917123289435343804839650867.2
8228530623997513866150472324980623472517726708354090630911887834246578870687609679301734.4
16457061247995027732300944649961246945035453416708181261823775668493157741375219358603468.8
32914122495990055464601889299922493890070906833416362523647551336986315482750438717206937.6
65828244991980110929203778599844987780141813666832725047295102673972630965500877434413875.2
131656489983960221858407557199689975560283627333665450094590205347945261931001754868827750.4
263312979967920443716815114399379951120567254667330900189180410695890523862003509737655501.8
526625959935840887433630228798759902241134509334661800378360821391781047724007019475311003.6
1053251919871681774867260457597519804482269018669323600756721642783562095448014038950622007.2
2106503839743363549734520915195039608964538037338647201513443285567124190896028077901244014.4
4213007679486727099469041830390079217929076074677294403026886571134248381792056155802488028.8
8426015358973454198938083660780158435858152149354588806053773142268496763584112311604976057.6
16852030717946908397876167321560316871716304298709177612107546284536993527168224623209952115.2
33704061435893816795752334643120633743432608597418355224215092569073987054336449246419904230.4
67408122871787633591504669286241267486865217194836710448430185138147974108672898492839808460.8
134816245743575267183009338572482534973730434389673420896860370276295948217345796985679616921.6
269632491487150534366018677144965069947460868779346841793720740552591896434691593971359233843.2
539264982974301068732037354289930139894921737558693683587441481105183792869383187942718467686.4
1078529965948602137464074708579860279789843475117387367174882962210367585738766375885436935372.8
2157059931897204274928149417159720559579686950234774734349765924420735171477532751770873870745.6
4314119863794408549856298834319441119159373900469549468699531848841470342955065503541747741491.2
8628239727588817099712597668638882238318747800939098937398063697682940685910131007083495482982.4
17256479455177634199425195337277764476637495601878197874796127395365881371820262014166990965964.8
34512958910355268398850390674555528953274991203756395749592254790731762743640524028333981931929.6
69025917820710536797700781349111057906549982407512791499184509581463525487281048056667963863858.2
138051835641421073595401562698222115813099964815025582998369019162927050974562096113335927727716.4
276103671282842147190803125396444231626199929630051165996738038325854101949124192226671855455432.8
552207342565684294381606250792888463252399859260102331993476076651708203898248384453343710910865.6
1104414685131368588763212501585776926504799718520204663986952153303416407796496768906687421821731.2
2208829370262737177526425003171553853009599437040409327973904306606832815592993537813374843643462.4
4417658740525474355052850006343107706019198874080818655947808613213665631185987075626749687286924.8
8835317481050948710105700012686215412038397748161637311895617226427331262371974151253499374573849.6
17670634962101897420211400025372430824076795496323274623791234452854662524743948302506998749147698.2
35341269924203794840422800050744861648153590992646549247582468905709324849487896605013997498295396.4
70682539848407589680845600101489723296307181985293098495164937811418649698975793210027994996590792.8
141365079696815179361691200202979446592614363970586196990329875622837299397951586420055989993181585.6
282730159393630358723382400405958893185228727941172393980659751245674598795903172840111979986363170.2
565460318787260717446764800811917786370457455882344787961319502491349197591806345680223959972726340.4
1130920637574521434893529601623835572740914911764689575922639004982698395183612691360447919945452680.8
2261841275149042869787059203247671145481829823529379151845278009965396790367225382720895839890905361.6
4523682550298085739574118406495342290963659647058758303690556019930793580734450765441791679781810723.2
9047365100596171479148236812990684581927319294117516607381112039861587161468901530883583359563621446.4
18094730201192342958296473625981369163854638588235033214762224079723174322937803061767166719127242892.8
36189460402384685916592947251962738327709277176470066429524448159446348645875606123534333438254485785.6
72378920804769371833185894503925476655418554352940132859048896318892697291751212247068666876508971570.2
144757841609538743666371789007850953310837108705880265718097792637785394583502424494137333753017943140.4
289515683219077487332743578015701906621674217411760531436195585275570789167004848988274667506035886280.8
579031366438154974665487156031403813243348434823521062872391170551141578334009697976549335012071772561.6
1158062732876309949330974312062807626486696869647042125744782341102283156668019395953098670024143545123.2
2316125465752619898661948624125615252973393739294084251489564682204566313336038791906197340048287090246.4
4632250931505239797323897248251230505946787478588168502979129364409132626672077583812394680096574180492.8
9264501863010479594647794496502461011893574957176337005958258728818265253344155167624789360193148360985.6
18529003726020959189295588993004922023787149914352674011916517457636530506688310335249578720386296721970.2
37058007452041918378591177986009844047574299828705348023833034915273061013376620670499157440772593443940.4
74116014904083836757182355972019688095148599657410696047666069830546122026753241340998314881545186887880.8
148232029808167673514364711944039376190297199314821392095332139661092244053506482681996629763090373775761.6
296464059616335347028729423888078752380594398629642784190664279322184488107012965363993259526180747551522.2
592928119232670694057458847776157504761188797259285568381328558644368976214025930727986519052361495103044.4
1185856238465341388114917695552315009522377594518571136762657117288737952428051861455973038104722990206088.8
2371712476930682776229835391104630019044755189037142273525314234577475904856103722911946076209445980412177.6
4743424953861365552459670782209260038089510378074284547050628469154951809712207445823892152418891960824354.2
9486849907722731104919341564418520076179020756148569094101256938309903619424414891647784304837783921648708.4
18973699815445462209838683128837040152358041512297138188202513876619807238848829783295568609675567843297416.8
37947399630890924419677366257674080304716083024594276376405027753239614477697659566591137219351135686594833.6
75894799261781848839354732515348160609432166049188552752810055506479228955395319133182274438702271373189666.2
151789598523563697678709465030696321218864332098377105505620111012958457910790638266364548877404542746379332.4
303579197047127395357418930061392642437728664196754211011240222025916915821581276532729097754809085492758664.8
607158394094254790714837860122785284875457328393508422022480444051833831643162553065458195509618170985517329.6
1214316788188509581429675720245570569750914656787016844044960888103667663286325106130916391019236341971034658.2
2428633576377019162859351440491141139501829313574033688089921776207335326572650212261832782038472683942069316.4
4857267152754038325718702880982282279003658627148067376179843552414670653145300424523665564076945367884138632.8
9714534305508076651437405761964564558007317254296134752359687104829341306290600849047331128153890735768277265.6
19429068611016153302874811523929129116014634508592269504719374209658682612581201698094662256307781471536554531.2
38858137222032306605749623047858258232029269017184539009438748419317365225162403396189324512615562943073109062.4
77716274444064613211499246095716516464058538034369078018877496838634730450324806792378649025231125886146218124.8
155432548888129226422998492191433032928117076068738156037754993677269460900649613584757298050462251772292436249.6
310865097776258452845996984382866065856234152137476312075509987354538921801299227169514596100924503544584872498.2
621730195552516905691993968765732131712468304274952624151019974709077843602598454339029192201849007089169744996.4
1243460391105033811383987937531464263424936608549905248302039949418155687205196908678058384403698014178339489992.8
2486920782210067622767975875062928526849873217099810496604079898836311374410393817356116768807396028356678979985.6
4973841564420135245535951750125857053699746434199620993208159797672622748820787634712233537614792056713357959970.2
9947683128840270491071903500251714107399492868399241986416319595345244497641575269424467075229584113426715919940.4
19895366257680540982143807000503428214798985736798483972832639190690488995283150538848934150459168226853431839880.8
39790732515361081964287614001006856429597971473596967945665278381380977990566301077697868300918336453706863679761.6
79581465030722163928575228002013712859195942947193935891330556762761955981132602155395736601836672907413727359523.2
159162930061444327857150456004027425718391885894387871782661113525523911962265204310791473203673345814827454719046.4
318325860122888655714300912008054851436783771788775743565322227051047823924530408621582946407346691629654909438092.8
636651720245777311428601824016109702873567543577551487130644454102095647849060817243165892814693383259309818876185.6
1273303440491554622857203648032219405747135087155102974261288908204191295698121634486331785629386766518619637752371.2
2546606880983109245714407296064438811494270174310205948522577816408382591396243268972663571258773533037239275504742.4
5093213761966218491428814592128877622988540348620411897045155632816765182792486537945327142517547066074478551009484.8
10186427523932436982857629184257755245977080697240823794090311265633530365584973075890654285035094132148957102018969.6
20372855047864873965715258368515510491954161394481647588180622531267060731169946151781308570070188264297914204037938.2
40745710095729747931430516737031020983908322788963295176361245062534121462339892303562617140140376528595828408075876.4
81491420191459495862861033474062041967816645577926590352722490125068242924679784607125234280280753057191656816151752.8
162982840382918991725722066948124083935633291155853180705444980250136485849359569214250468560561506114383313632303505.6
325965680765837983451444133896248167871266582311706361410889960500272971698719138428500937121123012228766627264607010.2
651931361531675966902888267792496335742533164623412722821779921000545943397438276857001874242246024457533254529214020.4
1303862723063351933805776535584992671485066329246825445643559842001091886794876553714003748484492048915066509058428040.8
2607725446126703867611553071169985342970132658493650891287119684002183773589753107428007496968984097830133018116856081.6
5215450892253407735223106142339970685940265316987301782574239368004367547179506214856014993937968195660266036233712163.2
10430901784506815470446212284679941371880530633974603565148478736008735094359012429712029987875936391320532072467424326.4
20861803569013630940892424569359882743761061267949207130296957472017470188718024859424059975751872782641064144934848652.8
41723607138027261881784849138719765487522122535898414260593914944034940377436049718848119951503745565282128289869697305.6
83447214276054523763569698277439530975044245071796828521187829888069880754872099437696239903007491130564256579739394610.2
166894428552109047527139396554879061950088490143593657042375659776139761509744198875392479806014982261128513159478789220.4
333788857104218095054278793109758123900176980287187314084751319552279523019488397750784959612029964522257026318957578440.8
667577714208436190108557586219516247800353960574374628169502639104559046038976795501569919224059929044514052637915156881.6
1335155428416872380217115172439032495600707921148749256339005278209118092077953591003139838448119858089028105275830313763.2
2670310856833744760434230344878064991201415842297498512678010556418236184155907182006279676896239716178056210551660627526.4
5340621713667489520868460689756129982402831684594997025356021112836472368311814364012559353792479432356112421103321255052.8
10681243427334979041736921379512259964805663369189994050712042225672944736623628728025118707584958864712224842206642510105.6
21362486854669958083473842759024519929611326738379988101424084451345889473247257456050237415169917729424449684413285020211.2
42724973709339916166947685518049039859222653476759976202848168902691778946494514912100474830339835458848899368826570040422.4
85449947418679832333895371036098079718445306953519952405696337805383557892989029824200949660679670917697798737653140080844.8
170899894837359664667790742072196159436890613907039904811392675610767115785978059648401899321359341835395597475306280161689.6
341799789674719329335581484144392318873781227814079809622785351221534231571956119296803798642718683670791194950612560323378.2
683599579349438658671162968288784637747562455628159619245570702443068463143912238593607597285437367341582389901225120646756.4
1367199158698877317342325936577569275495124911256319238491141404886136926287824477187215194570874734683164779802450241293512.8
2734398317397754634684651873155138550990249822512638476982282809772273852575648954374430389141749469366329559604900482587025.6
5468796634795509269369303746310277101980499645025276953964565619544547705151297908748860778283498938732659119209800965174051.2
10937593269591018538738607492620554203960999290050553907929131239089095410302595817497721556566997877465318238419601930348102.4
21875186539182037077477214985241108407921998580101107815858262478178190820605191634995443113133995754930636476839203860696204.8
43750373078364074154954429970482216815843997160202215631716524956356381641210383269990886226267991509861272953678407721392409.6
87500746156728148309908859940964433631687994320404431263433049912712763282420766539981772452535983019722545907356815442784819.2
175001492313456296619817719881928867263375988640808862526866099825425526564841533079963544905071966039445091814713630885569638.4
350002984626912593239635439763857734526751977281617725053732199650851053129683066159927089810143932078890183629427261771139276.8
700005969253825186479270879527715469053503954563235450107464399301702106259366132319854179620287864157780367258854523542278553.6
1400011938507650372958541759055430938107007909126470900214928798603404212518732264639708359240575728315560734517709047084557107.2
2800023877015300745917083518110861876214015818252941800429857597206808425037464529279416718481151456631121469035418094169114214.4
5600047754030601491834167036221723752428031636505883600859715194413616850074929058558833436962302913262242938070836188338228428.8
11200095508061202983668334072443447504856063273011767201719430388827233700149858117117666873924605826524485876141672376676456857.6
22400191016122405967336668144886895009712126546023534403438860777654467400299716234235333747849211653048971752283344753352913715.2
44800382032244811934673336289773790019424253092047068806877721555308934800599432468470667495698423306097943504566689506705827430.4
89600764064489623869346672579547580038848506184094137613755443110617869601198864936941334991396846612195887009133379013411654860.8
179201528128979247738693345159095160077697012368188275227510886221235739202397729873882669982793693224391774018266758026823309721.6
358403056257958495477386690318190320155394024736376550455021772442471478404795459747765339965587386448783548036533516053646619443.2
716806112515916990954773380636380640310788049472753100910043544884942956809590919495530679931174772897567096073067032107293238886.4
1433612225031833981909546761272761280621576098945506201820087089769885913619181838991061359862349545795134192146134064214586477772.8
2867224450063667963819093522545522561243152197891012403640174179539771827238363677982122719724699091590268384292268128429172955545.6
5734448900127335927638187045091045122486304395782024807280348359079543654476727355964245439449398183180536768584536256858345911091.2
11468897800254671855276374090182090244972608791564049614560696718159087308953454711928490878898796366361073537169072513716691822182.4
22937795600509343710552748180364180489945217583128099229121393436318174617906909423856981757797592732722147074338145027433383644364.8
45875591200818687421105496360728360979890435166256198458242786872636349235813818847713963515595185465444294148676290054866767288729.6
91751182401637374842210992721456721959780870332512396916485573745272698471627637695427927031190370930888588297352580109733534577458.2
183502364803274749684421985442913443919561740665024793832971147490545396943255275390855854062380741861777176594705160219467069154916.4
367004729606549499368843970885826887839123481330049587665942294981090793886510550781711708124761483723554353189410320438934138309832.8
734009459213098998737687941771653775678246962660099175331884589962181587773021101563423416249522967447108706378820640877868276619665.6
1468018918426197997475375883543307551356493925320198350663769179924363175546042203126846832499045934894217412757641281755736553239331.2
2936037836852395994950751767086615102712987850640396701327538359848726351092084406253693664998091869788434825515282563511473106478662.4
5872075673704791989901503534173230205425975701280793402655076719697452702184168812507387329996183739576869651030565127022946212957324.8
11744151347409583979803007068346460410851951402561586805310153439394905404368337625014774659992367479153739302061130254045892425914649.6
23488302694819167959606014136692920821703902805123173610620306878789810808736675250029549319984734958307478604122260508091784851829298.2
46976605389638335919212028273385841643407805610246347221240613757579621617473350500059098639969469916614957208244521016183569703658596.4
93953210779276671838424056546771683286815611220492694442481227515159243234946701000118197279938939833229914416489042032367139407317192.8
187906421558553343676848113093543366573631222440985388884962455030318486469893402000236394559877879666459828832978084064734278814634385.6
375812843117106687353696226187086733147262444881970777769924910060636972939786804000472789119755759332919657665956168129468557629268770.2
751625686234213374707392452374173466294524889763941555539849820121273945879573608000945578239511518665839315331912336258937115258537540.4
1503251372468426749414784904748346932589049779527883111079699640242547891759147216001891156479023037331678630663824672517874230517075080.8
3006502744936853498829569809496693865178099559055766222159399280485095783518294432003782312958046074663357261327649345035748461034150161.6
6013005489873706997659139618993387730356199118111532444318798560970191567036588864007564625916092149326714522655298690071496922068300323.2
12026010979747413995318279237986775460712398236223064888637597121940383134073177728015129251832184298653429045310597380142993844136600646.4
24052021959494827990636558475973550921424796472446129777275194243880766268146355456030258503664368597306858090621194760285987688273201292.8
48104043918989655981273116951947101842849592944892259554550388487761532536292710912060516987328737194613716181242389520571975376546402585.6
96208087837979311962546233903894203685699185889784519109100776975523065072585421824121033974657474389227432362484779041143950753092805171.2
192416175675958623925092467807788407371398371779569038218201553951046130145170843648242067949314948778454864724969558082287901506185610342.4
384832351351917247850184935615576814742796743559138076436403107902092260290341687296484135898629897556909729449939116164575803012371220685.8
769664702703834495700369871231153629485593487118276152872806215804184520580683374592968271797259795113819458899878232329151606024742441370.4
1539329405407668991400739742462307258971186974236552305745612431608369041161366749185936543594519590227638917799756464658303212049484882740.8
3078658810815337982801479484924614517942373948473104611491224863216738082322733498371873087189039180455277835599512929316606424098969765481.6
6157317621630675965602958969849229035884747896946209222982449726433476164645466996743746174378078360910555671199025858633212848197939530962.2
12314635243261351931205917939698458071769495793892418445964899452866952329290933993487492348756156721821111342398051717266425696395879061924.4
24629270486522703862411835879396916143538991587784836891929798905733904658581867986974984697512313443642222684796103434532851392791758123848.8
49258540973045407724823671758793832287077983175569673783859597811467809317163735973949969395024626887284445369592206869065702785583516247697.6
98517081946090815449647343517587664574155966351139347567719195622935618634327471947899938790049253774568890739184413738131405571167032495394.2
197034163892181630899294687035175329148311932702278695135438391245871237268654943895799877580098507549137781478368827476262811142334064990788.4
394068327784363261798589374070350658296623865404557390270876782491742474537309887791599755160197015098275562956737654952525622284668129981576.8
788136655568726523597178748140701316593247730809114780541753564983484949074619775583199510320394030196551125913475309905051244569336259963153.6
1576273311137453047194357496281402633186495461618229561083507129966969898149239551166399020640788060393102251826950619810102489138672519926307.2
3152546622274906094388714992562805266372990923236459122167014259933939796298479102332798041281576120786204503653901239620204978277344039852614.4
6305093244549812188777429985125610532745981846472918244334028519867879592596958204665596082563152241572409007307802479240409956554688079705228.8
12610186489099624377554859970251221065491963692945836488668057039735759185193916409331192165126304483144818014615604958480819913109376159410457.6
25220372978199248755109719940502442130983927385891672977336114079471518370387832818662384330252608966289636029231209916961639826218752318820915.2
50440745956398497510219439881004884261967854771783345954672228158943036740775665637324768660505217932579272058462419833923279652437504637641830.4
100881491912796995020438879762009768523935709543566691909344456317886073481551331274649537321010435865158544116924839667846559304875009275283660.8
201762983825593990040877759524019537047871419087133383818688912635772146963102662549299074642020871730317088233849679335693118609750018550567321.6
403525967651187980081755519048039074095742838174266767637377825271544293926205325098598149284041743460634176467699358671386237219500037101134643.2
807051935302375960163511038096078148191485676348533535274755650543088587852410650197196298568083486921268352935398717342772474439000074202269286.4
1614103870604751920327022076192156296382971352697067070549511301086177175704821300394392597136166973842536705870797434685544948878000148404538572.8
3228207741209503840654044152384312592765942705394134141099022602172354351409642600788785194272333947685073411741594869371089897756000296809077145.6
6456415482419007681308088304768625185531885410788268282198045204344708702819285201577570388544667895370146823483189738742179795512000593618154291.2
12912830964838015362616176609537250371063770821576536564396090408689417405638570403155140777089335790740293646966379477484359591024000187236308582.4
25825661929676030725232353219074500742127541643153073128792180817378834811277140806310281554178671581480587293932758954968719182048000374472617164.8
51651323859352061450464706438149001484255083286306146257584361634757669622554281612620563108357343162961174587865517909937438364096000748945234329.6
103302647718704122900929412876298002968510166572612292515168723269515339245108563225241126216714686325922349175731035819874876728192001497890468658.2
206605295437408245801858825752596005937020333145224585030337446539030678490217126450482252433429372651844698351462071639749753456384002995780937316.4
413210590874816491603717651505192011874040666290449170060674893078061356980434252900964504866858745303689396702924143279499506912768005991561874632.8
826421181749632983207435303010384023748081332580898340121349786156122713960868505801929009733717490607378793405848286558999013825536011983123749265.6
1652842363499265966414870606020768047496162665161796680242699572312245427921737011603858019467434981214757586811696573117998027651072023966247498531.2
3305684726998531932829741212041536094992325330323593360485399144624490855843474023207716038934869962429515173623392146235996055302144047932494997062.4
6611369453997063865659482424083072189984650660647186720970798289248981711686948046415432077869739924859030347246784292471992110604288095864989994125.8
13222738907994127731318964848166144379969301321294373441941596578497963423373896092830864155739479849718060694493568584943984221208576191729979988251.6
26445477815988255462637929696332288759938602642588746883883193156995926846747792185661728311478959699436121388987137169887968442417152383459959976503.2
52890955631976510925275859392664577519877205285177493767766386313991853693495584371323456622957919398872242777974274339775936884834304766919919953006.4
105781911263953021850551718785329154039754410570354987535532772627983707386991168742646913245915838797744485555948548679551873769668609533839839906012.8
211563822527906043701103437570658308079508821140709975071065545255967414773982337485293826491831677595488971111897097359103747539337219067679679812025.6
423127645055812087402206875141316616159017642281419950142131090511934829547964674970587652983663355190977942223794194718207495078674438135359359624051.2
846255290111624174804413750282633232318035284562839900284262181023869659095929349941175305967326710381955884447588389436414990157348876270718719248103.4
1692510580223248349608827500565266464636070569125679800568524362047739318191858699882350611934653420763911768895176778872829980314697752541437438496207.8
3385021160446496699217655001130532929272141138251359601137048724095478636383717399764701223869306841527823537790353557745659960629395505082875876992415.6
6770042320892993398435310002261065858544282276502719202274097448190957272767434799529402447738613683055647075580707115491319921258791010165751753984831.2
13540084641785986796870620004522131717088564553005438404548194896381914545534869599058804895477227366111294151161414230983639842517582020331503507969662.4
27080169283571973593741240009044263434177129106010876809096389792763829091069739198117609790954454732222588302322828461967279685035164040663007015939324.8
54160338567143947187482480018088526868354258212021753618192779585527658182139478396235219581908909464445176604645656923934559370070328081326014031878649.6
108320677134287894374964960036177053736708516424043507236385559171055316364278956792470439163817818928890353209291313847869118740140656162652028063757298.2
216641354268575788749929920072354107473417032848087014472771118342110632728557913584940878327635637857780706418582627695738237480281312325304056127514596.4
433282708537151577499859840144708214946834065696174028945542236684221265457115827169881756655271275715561412837165255391476474960562624650608112255029192.8
866565417074303154999719680289416429893668131392348057891084473368442530914231654339763513310542551431122825674330510782952949921125249301216224510058385.6
1733130834148606309999439360578832859787336262784696115782168946736885061828463308679526026621085102862245651348661021565905899842250498602432449020116771.2
3466261668297212619998878721157665719574672525569392231564337893473770123656926617358052053242170205724491302697322043131811799684500997204864898040233542.4
6932523336594425239997757442315331439149345051138784463128675786947540247313853234716104106484340411448982605394644086263623599368001994409729796080467084.8
13865046673188850479995514884630662878298690102277568926257351573895080494627706469432208212968680822897965210789288172527247198736003988819459592160934169.6
27730093346377700959991029769261325756597380204555137852514703147790160989255412938864416425937361645795930421578576345054494397472007977638919184321868339.2
55460186692755401919982059538522651513194760409110275705029406295580321978510825877728832851874723291591860843157152690108988794944015955277838368643736678.4
110920373385510803839964119077045303026389520818220551410058812591160643957021651755457665703749446583183721686314305380217977589888031910555676737287473356.8
221840746771021607679928238154090606052779041636441102820117625182321287914043303510915331407498893166367443372628610760435955179776063821111353474574946713.6
443681493542043215359856476308181212105558083272882205640235250364642575828086607021830662814997786332734886745257221520871910359552127642222706949149893426.2
887362987084086430719712952616362424211116166545764411280470500729285151656173214043661325629995572665469773490514443041743820719104255284445413898299786852.4
1774725974168172861439425905232724848422232333091528822560941001458570303312346428087322651259991145330939546981028886083487641438208510568890827796599573704.8
3549451948336345722878851810465449696844464666183057645121882002917140606624692856174645302519982290661879093962057772166975282876417021137781655593199147409.6
7098903896672691445757703620930899393688929332366115290243764005834281213249385712349290605039964581323758187924115544333950565752834042275563311186398294819.2
14197807793345382891515407241861798787377858664732230580487528011668562426498771424698581210079929162647516375848231088667901131505668084551126622372796589638.4
28395615586690765783030814483723597574755717329464461160975056023337124852997542849397162420159858325295032751696462177335802263011336169102245244745593179276.8
56791231173381531566061628967447195149511434658928922321950112046674249705995085698794324840319716650590065503392924354671604526022672338204490489491186358553.6
113582462346763063132123257934894390299022869317857844643900224093348499411990171397588649680639433301180131006785848709343209052045344676408980978982372717106.2
227164924693526126264246515869788780598045738635715689287800448186696998823980342795177298361278866602360262013571697418686418104090689352817961957964745434212.4
454329849387052252528493031739577561196091477271431378575600896373393997647960685590354596722557733204720524027143394837372836208



Dose (µg/mL)

Fig. 55B


Lymphoma
GZ17-8.37
Cell Number (Percent of Baseline)
100
80
60
40
20
0
-20
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 55C


Leukemia
GZ17-8.37
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.142
1.484
2.968
5.936
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 55D


Ovarian
GZ17-8.38
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
-20
0
0.742
1.484
2.968
5.936
11.873
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 56A


Lung Cancer
GZ17-8.38
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 56B


Lymphoma
GZ17-8.38
Cell Number (Percent of Baseline)
100
80
60
40
20
0
-20
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 56C


Leukemia
GZ17-8.38
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 56D


Ovarian
GZ17-8.39
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 57A


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.39
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 57B


Lymphoma
GZ17-9.39
Cell Number (Percent of Baseline)
100
80
60
40
20
0
-20
0
0.042
0.14
0.46
1.5
4.9
16
53
180
590
Dose (µg/mL)

Fig. 57C


Leukemia
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.39
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 57D


Ovarian
GZ17-8.40
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.1742
0.4974
1.968
2.968
5.968
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 58A


Lung Cancer
GZ17-8-40
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.1
0.2
0.4
1
2.5
5
10
20
40
80
160
320
640
1280
2560
5120
10240
20480
Dose (μg/mL)

Fig. 58B


Lymphoma
GZ17-8.40
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 58C


Leukemia
GZ17-8.40
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 58D


Ovarian Cancer
GZ17-8.41
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.142
0.284
0.569
1.138
2.275
4.55
9
18
36
Dose (µg/mL)

Fig. 59A


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.41
0
0.142
0.284
0.568
1.136
2.275
4.55
9.1
18.2
36.4
72.8
145.6
291.2
Dose (µg/mL)

Fig. 59B


Lymphoma
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.41
0
0.762
1.524
2.968
5.968
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 59C


Leukemia
GZ17-8.41
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.762
1.904
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 59D


Ovarian Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.42
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 60A


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.42
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 60B


Lymphoma
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.42
0
0.742
1.484
2.968
5.936
11.87
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 60C


Leukemia
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.42
0
0.762
1.904
2.857
5.238
11.429
23.810
47.5
95
190
380
Dose (µg/mL)

Fig. 60D


Ovarian Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.43
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 61A


Lung Cancer
GZ17-8.43
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.142
0.424
1.269
3.808
11.426
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 61B


Lymphoma
GZ17-8.43
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 61C


Leukemia
GZ17-8.43
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.762
1.907
2.966
5.966
11.876
23.752
47.5
95
190
380
Dose (µg/mL)

Fig. 61D


Ovarian Cancer
GZ17-8.44
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 62A


Lung Cancer
GZ17-8.44
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 62B


Lymphoma
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.44
0
0.142
0.426
1.28
3.83
11.5
34.5
103
310
930
Dose (μg/mL)

Fig. 62C


Leukemia
GZ17-8.44
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.968
5.935
11.87
23.73
47.5
95
190
380
Dose (µg/mL)

Fig. 62D


Ovarian Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.45
0
0.142
0.284
0.569
1.138
2.276
4.553
9.106
18.21
36.42
72.85
145.7
291.4
582.8
1165
2331
4662
9324
18648
37296
74592
Dose (µg/mL)

Fig. 63A


Lung Cancer
GZ17-8.45
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 63B


Lymphoma
GZ17-8.45
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.142
0.284
1.42
2.99
5.99
11.98
23.95
47.9
95
190
380
Dose (µg/mL)

Fig. 63C


Leukemia
GZ17-8.45
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 63D


Ovarian Cancer
GZ17-8.46
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.142
0.284
0.569
1.138
2.275
4.55
9.1
18.2
36.4
72.8
Dose (µg/mL)

Fig. 64A


Lung Cancer
GZ17-9.46
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 64B


Lymphoma
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.46
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 64C


Leukemia
GZ17-8.46
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.142
0.569
2.268
9.072
36.29
145.2
580.8
2322
9288
37152
Dose (µg/mL)

Fig. 64D


Ovarian Cancer
GZ17-8.47
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 65A


Lung Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.47
0
0.762
1.464
2.909
5.676
11.878
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 65B


Lymphoma
GZ17-8.47
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0.1562
0.3125
0.625
1.25
2.5
5
10
20
40
80
160
320
640
1280
2560
5120
10240
20480
40960
Dose (µg/mL)

Fig. 65C


Leukemia
GZ17-8.47
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.0172
0.0344
0.0688
0.137
0.275
0.55
1.1
2.2
4.4
8.8
17.6
35.2
70.4
140.8
281.6
Dose (µg/mL)

Fig. 65D


Ovarian Cancer
GZ17-8.48
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.142
0.424
1.269
3.808
11.426
34.278
102.835
308.505
Dose (µg/mL)

Fig. 66A


Lung Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.48
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 66B


Lymphoma
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.48
0
0.142
0.284
0.569
1.138
2.275
4.55
9.1
18.2
36.4
Dose (μg/mL)

Fig. 66C


Leukemia
GZ17-8.48
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.968
5.936
11.875
23.75
47.5
95
190
380
760
Dose (µg/mL)

Fig. 66D


Ovarian Cancer
GZ17-8.49
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 67A


Lung Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.49
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 67B


Lymphoma
GZ17-8.49
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.1172
0.4688
1.875
7.5
30
120
480
1920
7680
30720
122880
491520
1966080
Dose (µg/mL)

Fig. 67C


Leukemia
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.49
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 67D


Ovarian Cancer
GZ17-8.50
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 68A


Lung Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.50
0
0.142
0.284
0.569
1.138
2.276
4.5
9
18
36
Dose (μg/mL)

Fig. 68B


Lymphoma
GZ17-8.50
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 68C


Leukemia
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.50
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 68D


Ovarian Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.51
0
0.142
0.284
0.569
1.138
2.275
4.55
9
18
36
72
144
288
Dose (µg/mL)

Fig. 69A


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.51
0
0.142
0.428
2.569
5.708
11.416
22.832
45.665
91.329
182.658
365.316
Dose (µg/mL)

Fig. 69B


Lymphoma
GZ17-8.51
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.0762
0.152
0.305
0.610
1.22
2.44
4.88
9.76
19.5
39
78
156
312
Dose (µg/mL)

Fig. 69C

Fig. 69D


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)
GZ17-8.51

Fig. 70A


Ovarian Cancer
GZ17-8.52
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.142
0.494
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)


Lung Cancer
GZ17-9.52
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 70B


Lymphoma
GZ17-8.52
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 70C


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.52
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 70D


Ovarian Cancer
GZ17-8.53
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.142
0.284
1.42
2.968
5.936
11.872
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 71A


Lung Cancer
GZ17-8.53
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 71B


Lymphoma
GZ17-8.53
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.142
0.428
1.28
3.85
11.6
34.6
104
312
Dose (µg/mL)

Fig. 71C


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.53
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 71D


Ovarian Cancer
GZ17-8.54
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 72A


Lung Cancer
GZ17-8.54
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 72B


Lymphoma
GZ17-8.54
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 72C


Leukemia
GZ17-8.54
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 72D


Ovarian Cancer
GZ17-8.55
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 73A


Lung Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.55
0
0.1372
0.4116
1.234
3.703
11.109
33.327
100
300
900
2700
8100
24300
72900
Dose (μg/mL)

Fig. 73B


Lymphoma
GZ17-8.55
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.142
0.284
0.568
1.136
2.273
4.545
9
18
36
72
Dose (μg/mL)

Fig. 73C


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.55
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 73D


Ovarian Cancer
GZ17-8.56
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.142
0.284
0.569
2.269
5.678
11.36
22.73
45.45
90.9
181.8
363.6
Dose (µg/mL)

Fig. 74A


Lung Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.56
0
0.782
1.464
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 74B


Lymphoma
GZ17-8.56
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.1562
0.3125
0.625
1.25
2.5
5
10
20
40
Dose (µg/mL)

Fig. 74C


Leukemia
GZ17-8.56
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 74D


Ovarian Cancer
GZ17-8.57
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 75A


Lung Cancer
GZ17-8.57
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.142
0.284
0.568
1.136
2.273
4.545
9.09
18.18
36.36
72.73
145.5
291
582
1164
2327
Dose (μg/mL)

Fig. 75B


Lymphoma
GZ17-8.57
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 75C


Leukemia
GZ17-8.57
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 75D


Ovarian Cancer
GZ17-8.58
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 76A


Lung Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.58
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 76B


Lymphoma
GZ17-8.58
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 76C


Leukemia
GZ17-8.58
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (μg/mL)

Fig. 76D


Ovarian Cancer
GZ17-8.59
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 77A


Lung Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.59
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 77B


Lymphoma
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.59
0
0.142
0.428
1.28
3.85
11.6
34.6
103
310
930
Dose (μg/mL)

Fig. 77C


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.59
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 77D


Ovarian Cancer
GZ17-8.60
Cell Number (Percent of Baseline)
100
80
60
40
20
0
-20
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 78A


Lung Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.60
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 78B


Lymphoma
GZ17-8.60
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.142
0.427
1.28
3.84
11.52
34.56
103.7
311.1
933.3
2800
8400
25200
75600
227000
681000
2040000
6120000
18360000
Dose (µg/mL)

Fig. 78C


Leukemia
GZ17-8.60
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 78D


Ovarian Cancer
GZ17-8.61
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.142
0.428
1.28
3.85
11.6
34.6
104
312
Dose (µg/mL)

Fig. 79A


Lung Cancer
GZ17-8.61
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 79B


Lymphoma
GZ17-8.61
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
0.1562
0.3125
0.625
1.25
2.5
5
10
20
40
Dose (μg/mL)

Fig. 79C


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.61
0
0.742
1.484
2.969
5.938
11.875
23.75
47.5
95
190
380
Dose (µg/mL)

Fig. 79D


Ovarian Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-10.04
0
0.1461
1.4072
2.9644
5.9688
11.9375
23.875
47.75
95.5
191
382
Dose (µg/mL)

Fig. 80A


Ovarian Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-10.05
0
0.7461
1.4922
2.9844
5.9688
11.9375
23.875
47.75
95.5
191
382
Dose (µg/mL)

Fig. 80B


Ovarian Cancer
Cell Number (Percent of Baseline)
110
100
90
80
70
60
50
40
GZ17-10.06
0
0.7491
1.4982
2.9964
5.9928
11.9856
23.9712
47.95
95.9
191.8
383.6
Dose (µg/mL)

Fig. 80C


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-10.04
0
0.7461
1.4922
2.9844
5.9688
11.9375
23.875
47.75
95.5
191
382
Dose (µg/mL)

Fig. 80D


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-10.05
0
0.1461
1.4622
2.9244
5.8488
11.6975
23.395
46.79
93.5
187
374
Dose (µg/mL)

Fig. 80E


Lymphoma
Cell Number (Percent of Baseline)
110
100
90
80
70
60
GZ17-10.06
0
0.7461
1.4922
2.9844
5.9688
11.9375
23.875
47.75
95.5
191
382
Dose (µg/mL)

Fig. 80F


Lymphoma
Cancer Cell Lethality (% decline in viable cells)
100
80
60
40
20
0
10.04
10.05
10.06
Theoretical Additive Effect
Combination of 3

Fig. 80G


Lymphoma
Cancer Cell Lethality (% decline in viable cells)
80
60
40
20
0
10.04
10.06
Theoretical Additive Effect
Combination

Fig. 80H


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
0.7401
1.4802
2.9604
5.9208
11.8416
23.6832
47.365
95.3
191
382
Dose (µg/mL)
GZ17-10.04

Fig. 80I


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-10.05
0
0.7401
1.4802
2.9604
5.9208
11.8416
23.6832
47.175
94.5
189
378
Dose (µg/mL)

Fig. 80J


Leukemia
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
0.1461
1.4902
2.9844
5.9688
11.9375
23.875
47.75
95.5
191
382
Dose (µg/mL)
GZ17-10.06

Fig. 80K


Leukemia
Cancer Cell Lethality (% decline in viable cells)
100
80
60
40
20
0
10.04
10.05
10.06
Theoretical Additive Effect
Combination

Fig. 80L


Leukemia
Cancer Cell Lethality (% decline in viable cells)
70
60
50
40
30
20
10
0
10.04
10.06
Theoretical Additive Effect
Combination

Fig. 80M


Breast Cancer
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
-20
0
0.7461
1.4922
2.9844
5.9688
11.9375
23.875
47.75
95.5
191
382
Dose (µg/mL)
GZ17-10.04

Fig. 80N


Breast Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
GZ17-10.05
0
0.1491
1.4972
2.9944
5.9888
11.9775
23.9775
47.75
95.5
191
382
Dose (µg/mL)

Fig. 800


Breast Cancer
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
-20
0
0.1953
0.7813
1.4063
2.9688
5.9375
11.9375
23.875
47.75
95.5
191
382
Dose (µg/mL)
GZ17-10.06

Fig. 80P


Breast Cancer
Cancer Cell Lethality (% decline in viable cells)
80
60
40
20
0
10.04
10.05
10.06
Theoretical Additive Effect
Combination

Fig. 80Q


Breast Cancer
Cancer Cell Lethality (% decline in viable cells)
100
80
60
40
20
0
10.04
10.06
Theoretical Additive Effect
Combination

Fig. 80R


Ovarian Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.512
0
4.234e-3
8.468e-3
0.0169
0.0338
0.0676
0.1355
0.271
0.542
1.084
2.168
Dose (μM)

Fig. 81A


Lymphoma
GZ17-8.512
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
4.2e-4
8.4e-4
0.0169
0.0339
0.0678
0.135
0.271
0.542
1.08
2.16
Dose (μM)

Fig. 81B


Head and Neck Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.512
0
4.2e-4
8.4e-4
0.0168
0.0336
0.0672
0.135
0.27
0.542
1.08
2.16
Dose (μM)

Fig. 81C


Ovarian Cancer
GZ17-8.513
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
4.2305e-3
8.4609e-3
0.0169
0.0338
0.0677
0.135
0.270
0.540
1.083
2.166
Dose (μM)

Fig. 81D


Lymphoma
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.513
0
4.2e-05
8.4e-05
0.0169
0.0338
0.0677
0.135
0.270
0.540
1.080
2.160
Dose (μM)

Fig. 81E


Head and Neck Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.513
0
4.2e-05
8.4e-05
0.0169
0.0338
0.0677
0.135
0.270
0.540
1.08
2.16
Dose (μM)

Fig. 81F


Ovarian Cancer
GZ17-8.514
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
4.3105e-3
8.6219e-3
0.0172
0.0345
0.069
0.1379
0.2759
0.5518
1.1035
2.207
Dose (μM)

Fig. 81G


Lymphoma
GZ17-8.514
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
4.3105e-3
8.6211e-3
0.0172
0.0345
0.069
0.1379
0.2759
0.5518
1.1035
2.207
Dose (μM)

Fig. 81H


Head and Neck Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.514
0
4.3105e-3
8.6211e-3
0.0172
0.0345
0.069
0.1379
0.2759
0.5518
1.1035
2.207
Dose (μM)

Fig. 81I


Ovarian Cancer
GZ17-8.515
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
4.26178e-5
2.234e-8
0.017
0.03410
0.06820
0.13640
0.27280
0.5455
1.091
2.182
Dose (μM)

Fig. 81J


Lymphoma
GZ17-8.515
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
4.261e-3
8.522e-3
0.017
0.034
0.068
0.136
0.272
0.545
1.091
2.182
Dose (μM)

Fig. 81K


Head and Neck Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ17-8.515
0
4.267e-3
8.523e-3
0.017
0.034
0.068
0.136
0.272
0.545
1.091
2.182
Dose (μM)

Fig. 81L


Ovarian Cancer
GZ17-8.516
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
4.76e-06
9.53e-06
3
0.0171
0.0341
0.0683
0.136
0.273
0.545
1.09
2.18
4.36
Dose (μM)

Fig. 81M


Lymphoma
GZ17-8.516
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
4.76e-06
8.53e-05
0.0017
0.0034
0.0068
0.0137
0.0273
0.0546
0.1092
0.2184
Dose (μM)

Fig. 81N


Head and Neck Cancer
GZ17-8.516
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
4.26666e-3
9.53526e-3
0.0171
0.0341
0.0683
0.136
0.273
0.545
1.091
2.184
Dose (μM)

Fig. 81O


Ovarian Cancer
GZ17-8.517
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
4.2944e-3
8.4969e-3
0.0169
0.0339
0.0678
0.135
0.271
0.542
1.084
2.168
Dose (μM)

Fig. 81P


Lymphoma
GZ17-8.517
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
4.2344e-3
8.4688e-3
0.0169
0.0339
0.0678
0.1355
0.271
0.542
1.084
2.168
Dose (μM)

Fig. 81Q


Head and Neck Cancer
GZ17-8.517
Cell Number (Percent of Baseline)
100
80
60
40
20
0
Dose (μM)
0
4.23444e-3
8.46888e-3
0.0169
0.0339
0.0678
0.135
0.271
0.542
1.084
2.168

Fig. 81R


Ovarian Cancer
GZ17-8.518
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
2.305e-3
4.609e-3
0.0169
0.0338
0.0677
0.1354
0.2708
0.5415
1.083
2.166
Dose (μM)

Fig. 81S


Lymphoma
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.518
0
4.230e-3
8.460e-3
0.0169
0.0338
0.0677
0.135
0.270
0.540
1.080
2.160
Dose (μM)

Fig. 81T


Head and Neck Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.518
0
4.2305e-3
8.4609e-3
0.0169
0.0338
0.0677
0.1354
0.2708
0.5415
1.083
2.166
Dose (μM)

Fig. 81U


Ovarian Cancer
GZ17-8.519
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
4.3105e-3
8.6271e-3
0.0172
0.0345
0.069
0.1379
0.2759
0.5519
1.1039
2.207
Dose (μM)

Fig. 81V


Lymphoma
GZ17-8.519
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
4.3105e-3
8.6211e-3
0.0172
0.0345
0.069
0.1379
0.2759
0.5518
1.1035
2.207
Dose (μM)

Fig. 81W


Head and Neck Cancer
GZ17-8.519
Cell Number (Percent of Baseline)
100
80
60
40
20
0
4.3105e-3
8.621e-3
0.0172
0.0345
0.069
0.1379
0.2759
0.5518
1.1035
2.207
Dose (μM)

Fig. 81X


Ovarian Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.520
0
4.2617e-3
8.5234e-3
0.017
0.034
0.0682
0.136
0.273
0.545
1.09
2.182
Dose (μM)

Fig. 81Y


Lymphoma
GZ17-8.520
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
4.76e-17
8.52e-3
0.011
0.024
0.0682
0.136
0.272
0.545
1.09
2.182
Dose (μM)

Fig. 81Z


Head and Neck Cancer
GZ17-8.520
Cell Number (Percent of Baseline)
110
100
90
80
70
60
50
40
0
4.267e-3
8.523e-3
0.017
0.034
0.068
0.136
0.272
0.545
1.09
2.182
Dose (μM)

Fig. 81AA


Ovarian Cancer
GZ17-8.521
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
4.26969e-3
8.53939e-3
0.0171
0.0341
0.0683
0.136
0.273
0.546
1.092
2.184
Dose (μM)

Fig. 81BB


Lymphoma
GZ17-8.521
Cell Number (Percent of Baseline)
100
80
60
40
20
0
0
4.2666e-3
6.5536e-3
0.0171
0.0341
0.0683
0.1365
0.2731
0.5461
1.0923
2.1845
Dose (μM)

Fig. 81CC

Fig. 81DD


Head and Neck Cancer
Cell Number (Percent of Baseline)
100
80
60
40
20
0
GZ17-8.521
0
4.26666e-3
8.53333e-3
0.0171
0.0341
0.0683
0.1365
0.2731
0.5461
1.0923
2.1845
Dose (μM)



Dose (µg/mL)

Fig. 82-1


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.066
0
1.451
4.907
2.966
5.966
11.921
23.842
47.683
95.375
190.75
381.5
Dose (µg/mL)

Fig. 82-2


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.067
0
7.8125
15.625
31.25
62.5
125
250
500
1000
2000
4000
8000
16000
32000
64000
128000
256000
512000
Dose (µg/mL)

Fig. 82-3


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.068
0
1.465
4.690
2.660
5.960
11.920
23.840
47.680
95.370
190.75
381.5
Dose (µg/mL)

Fig. 82-4


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.069
0
1.561
3.123
6.246
12.492
25.984
50.968
101.936
203.872
407.744
815.488
1630.976
3261.952
6523.904
13047.808
26095.616
52191.232
104382.464
208764.928
417529.856
835059.712
1670119.424
3340238.848
6680477.696
13360955.392
26721910.784
53443821.568
106887643.136
213775286.272
427550572.544
855101145.088
1710202290.176
3420404580.352
6840809160.704
13681618321.408
27363236642.816
54726473285.632
109452946571.264
218905893142.528
437811786285.056
875623572570.112
1751247145140.224
3502494290280.448
7004988580560.896
14009977161121.792
28019954322243.584
56039908644487.168
112079817288974.336
224159634577948.672
448319269155897.344
896638538311794.688
1793277076623589.376
3586554153247178.752
7173108306494357.504
14346216612988715.008
28692433225977430.016
57384866451954860.032
114769732903909720.064
229539465807819440.128
459078931615638880.256
918157863231277760.512
1836315726462555521.024
3672631452925111042.048
7345262905850222084.096
14690525811700444168.192
29381051623400888336.384
58762103246801776672.768
117524206493603553345.536
235048412987207106691.072
470096825974414213382.144
940193651948828426764.288
1880387303897656853528.576
3760774607795313707057.152
7521549215590627414114.304
15043098431181254828228.608
30086196862362509656457.216
60172393724725019312914.432
120344787449450038625828.864
240689574898900077251657.728
481379149797800154503315.456
962758299595600309006630.912
1925516599191200618013261.824
3851033198382401236026523.648
7702066396764802472053047.296
15404132793529604944106094.592
30808265587059209888212189.184
61616531174118419776424378.368
123233062348236839552848756.736
246466124696473679105697513.472
492932249392947358211395026.944
985864498785894716422790053.888
1971728997571789432845580107.776
3943457995143578865691160215.552
7886915990287157731382320431.104
15773831980574315462764640862.208
31547663961148630925529281724.416
63095327922297261851058563448.832
126190655844594523702117126897.664
252381311689189047404234253795.328
504762623378378094808468507590.656
1009525246756756189616937015181.312
2019050493513512379233874030362.624
4038100987027024758467748060725.248
8076201974054049516935496121450.496
16152403948108099033870992242900.992
32304807896216198067741984485801.984
64609615792432396135483968971603.968
129219231584864792270967937943207.936
258438463169729584541935875886415.872
516876926339459169083871751772831.744
1033753852678918338167743503545663.488
2067507705357836676335486007091326.976
4135015410715673352670972014182653.952
8270030821431346705341944028365307.904
16540061642862693410683888056730615.808
33080123285725386821367776113461231.616
66160246571450773642735552226922463.232
132320493142901547285471104453844926.464
264640986285803094570942208907689852.928
529281972571606189141884417815379705.856
1058563945143212378283768835630759411.712
2117127890286424756567537671261518823.424
4234255780572849513135075342523037646.848
8468511561145699026270150685046075293.696
16937023122291398052540301370092150587.392
33874046244582796105080602740184301174.784
67748092489165592210161205480368602349.568
135496184978331184420322410960737204699.136
270992369956662368840644821921474409398.272
541984739913324737681289643842948818796.544
1083969479826649475362579287685897637593.088
2167938959653298950725158575371795275186.176
4335877919306597901450317150743590550372.352
8671755838613195802900634301487181100744.704
17343511677226391605801268602974362201489.408
34687023354452783211602537205948724402978.816
69374046708905566423205074411897448805957.632
138748093417811132846410148823794897611915.264
277496186835622265692820297647589795223830.528
554992373671244531385640595295179590447661.056
1109984747342489062771281190590359180895322.112
2219969494684978125542562381180718361790644.224
4439938989369956251085124762361436723581288.448
8879877978739912502170249524722873447162576.896
17759755957479825004340499049445746894325153.792
35519511914959650008680998098891493788650307.584
71039023829919300017361996197782987577300615.168
142078047659838600034723992395565975154601230.336
284156095319677200069447984791131950309202460.672
568312190639354400138895969582263900618404921.344
1136624381278708800277791939164527801236809842.688
2273248762557417600555583878329055602473619685.376
4546497525114835201111167756658111204947239370.752
9092995050229670402222335513316222409894478741.504
18185990100459340804444671026632444819788957483.008
36371980200918681608889342053264889639577914966.016
72743960401837363217778684106529779279155829932.032
145487920803674726435557368213059558558311659864.064
290975841607349452871114736426119117116623319728.128
581951683214698905742229472852238234233246639456.256
1163903366429397811484458945704476468466493278912.512
2327806732858795622968917891408952936932986557825.024
4655613465717591245937835782817905873865973115650.048
9311226931435182491875671565635811747731946231300.096
18622453862870364983751343131271623495463892462600.192
37244907725740729967502686262543246990927784925200.384
74489815451481459935005372525086493981855569850400.768
148979630902962919870010745050172987963711139700801.536
297959261805925839740021490100345975927422279401603.072
595918523611851679480042980200691951854844558803206.144
1191837047223703358960085960401383903709689117606412.288
2383674094447406717920171920802767807419378235212824.576
4767348188894813435840343841605535614838756470425649.152
9534696377789626871680687683211071229677512940851298.304
19069392755579253743361375366422142459355025881702596.608
38138785511158507486722750732844284918710051763405193.216
76277571022317014973445501465688569837420103526810386.432
152555142044634029946891002931377139674840207053620772.864
305110284089268059893782005862754279349680414107241545.728
610220568178536119787564011725508558699360828214483091.456
1220441136357072239575128023451017117398721656428966182.912
2440882272714144479150256046902034234797443312857932365.824
4881764545428288958300512093804068469594886625715864731.648
9763529090856577916601024187608136939189773251431729463.296
19527058181713155833202048375216273878379546502863458926.592
39054116363426311666404096750432547756759093005726917853.184
78108232726852623332808193500865095513518186011453835706.368
156216465453705246665616387001730191027036372022907671412.736
312432930907410493331232774003460382054072744045815342825.472
624865861814820986662465548006920764108145488091630685650.944
1249731723629641973324931096013841528216290976183261371301.888
2499463447259283946649862192027683056432581952366522742603.776
4998926894518567893299724384055366112865163904733045485207.552
9997853789037135786599448768110732225730327809466090970415.104
19995707578074271573198897536221464451460655618932181940830.208
39991415156148543146397795072442928902921311237864363881660.416
79982830312297086292795590144885857805842622475728727763320.832
159965660624594172585591180289771715611685244951457455526641.664
319931321249188345171182360579543431223370489902914911053283.328
639862642498376690342364721159086862446740979805829822106566.656
1279725284996753380684729442318173724893481959611659644213133.312
2559450569993506761369458884636347449786963919223319288426266.624
5118901139987013522738917769272694899573927838446638577852533.248
10237802279974027045477835538545389799147855676893277155705066.496
20475604559948054090955671077090779598295711353786554311410132.992
40951209119896108181911342154181559196591422707573108622820265.984
81902418239792216363822684308363118393182845415146217245640531.968
163804836479584432727645368616726236786365690830292434491281063.936
327609672959168865455290737233452473572731381660584868982562127.872
655219345918337730910581474466904947145462763321169737965124255.744
1310438691836675461821162948933809894290925526642339475930248511.488
2620877383673350923642325897867619788581851053284678951860497022.976
5241754767346701847284651795735239577163702106569357903720994045.952
10483509534693403694569303591470479154327404213138715807441988091.904
20967019069386807389138607182940958308654808426277431614883976183.808
41934038138773614778277214365881916617309616852554863229767952367.616
83868076277547229556554428731763833234619233705109726459535904735.232
167736152555094459113108857463527666469238467410219452919071809470.464
335472305110188918226217714927055332938476934820438905838143618940.928
670944610220377836452435429854110665876953869640877811676287237881.856
1341889220440755672904870859708221331753907739281755623352574475763.712
2683778440881511345809741719416442663507815478563511246705148951527.424
5367556881763022691619483438832885327015630957127022493410297903054.848
10735113763526045383238966877665770654031261914254044986820595806109.696
21470227527052090766477933755331541308062523828508089973641191612219.392
42940455054104181532955867510663082616125047657016179947282383224438.784
85880910108208363065911735021326165232250095314032359894564766448877.568
171761820216416726131823470042652330464500190628064719789129532897755.136
343523640432833452263646940085304660929000381256129439578259065795510.272
687047280865666904527293880170609321858000762512258879156518131591020.544
1374094561731333809054587760341218643716001525024517758313036263182041.088
2748189123462667618109175520682437287432003050049035516626072526364082.176
5496378246925335236218351041364874574864006100098071033252145052728164.352
10992756493850670472436702082729749149728012200196142066504290105456328.704
21985512987701340944873404165459498299456024400392284133008580210912657.408
43971025975402681889746808330918996598912048800784568266017160421825314.816
87942051950805363779493616661837993197824097601569136532034320843650629.632
175884103901610727558987233323675986395648195203138273064068641687301259.264
351768207803221455117974466647351972791296390406276546128137283374602518.528
703536415606442910235948933294703945582592780812553092256274566749205037.056
1407072831212885820471897866589407891165185561625106184512549133498410074.112
2814145662425771640943795733178815782330371123250212369025098266996820148.224
5628291324851543281887591466357631564660742246500424738050196533993640296.448
11256582649703086563775182932715263129321484493000849476100393067987280592.896
22513165299406173127550365865430526258642968986001698952200786135974561185.792
45026330598812346255100731730861052517285937972003397904401572271949122371.584
90052661197624692510201463461722105034571875944006795808803144543898244743.168
180105322395249385020402926923444210069143751888013591617606289087796489486.336
360210644790498770040805853846888420138287503776027183235212578175592978972.672
720421289580997540081611707693776840276575007552054366470425156351185957945.344
1440842579161995080163223415387553680553150015104108732940850312702371915890.688
2881685158323990160326446830775107361106300030208217465881700625404743831781.376
5763370316647980320652893661550214722212600060416434931763401250809487663562.752
11526740633295960641305787323100429444425200120832869863526802501618975327125.504
23053481266591921282611574646200858888850400241665739727053605003237950654250.008
46106962533183842565223149292401717777700800483331479454107210006475901308500.016
92213925066367685130446298584803435555401600966662958908214420012951802617000.032
184427850132735370260892597169606871110803201933325917816428840025903605234000.064
368855700265470740521785194339213742221606403866651835632857680051807210468000.128
737711400530941481043570388678427484443212807733303671265715360103614420936000.256
1475422801061882962087140777356854968886425615466607342531430720207228841872000.512
2950845602123765924174281554713709937772851230933214685062861440414457683744000.024
5901691204247531848348563109427419875545702461866429370125722880828915367488000.048
11803382408495063696697126218854839751091404923732858740251445761657830734976000.096
23606764816990127393394252437709679502182809847465717480502891523315661469952000.192
47213529633980254786788504875419358004365619694931434961005783046631322939904000.384
94427059267960509573577009750838716008731239389862869922011566093262645879808000.768
188854118535921019147154019501677432017462478779725739844023132186525291759616001.536
377708237071842038294308039003354864034924957559451479688046264373050583519232003.072
755416474143684076588616078006709728069849915118902959376092528746101167038464006.144
1510832948287368153177232156013419456139699830237805918752185057492202334076928012.288
3021665896574736306354464312026838912279399660475611837504370114984404668153856024.576
6043331793149472612708928624053677824558799320951223675008740229968809336307712049.152
12086663586298945225417857248107355649117598641902447350017480459937618672615424098.304
24173327172597890450835714496214711298235197283804894700034960919875237345230848196.608
48346654345195780901671428992429422596470394567609789400069921839750474690461696393.216
96693308690391561803342857984858845192940789135219578800139843679500949380923392786.432
193386617380783123606685715969717690385881578270439157600279687359001898761846785572.864
386773234761566247213371431939435380771763156540878315200559374718003797523693571145.728
773546469523132494426742863878870761543526313081756630401118749436007595047387142291.456
1547092939046264988853485727757741523087052626163513260802237498872015190094774284582.912
3094185878092529977706971455515483046174105252327026521604474997744030380189548569165.824
6188371756185059955413942911030966092348210504654053043208949995488060760379097138331.648
12376743512370119910827885822061932184696421009308106086417899990976121520758194276663.296
24753487024740239821655771644123864369392842018616212172835799981952243041516388553326.592
49506974049480479643311543288247728738785684037232424345671599963904486083032777106653.184
99013948098960959286623086576495457477571368074464848691343199927808972166065554213306.368
198027896197921918573246173152990914955142736148929697382686399855617944332131108426612.736
396055792395843837146492346305981829910285472297859394765372799711235888664262216853225.472
792111584791687674292984692611963659820570944595718789530745599422471777328524433706450.944
1584223169583375348585969385223927319641141889191437578061491198844943554657048867412901.888
3168446339166750697171938770447854639282283778382875156122982397689887109314097734825803.776
6336892678333501394343877540895709278564567556765750312245964795379774218628195469651607.552
12673785356667002788687755081791418557129135113531500624491929590759548437256390939303215.104
25347570713334005577375510163582837114258270227063001248983859181519096874512781878606430.208
50695141426668011154751020327165674228516540454126002497967718363038193749025563757212860.416
101390282853336022309502040654331348457033080908252004995935436726076387498051127514425720.832
202780565706672044619004081308662696914066161816504009991870873452152774996102255028851441.664
405561131413344089238008162617325393828132323633008019983741746904305549992204510057702883.328
811122262826688178476016325234650787656264647266016039967483493808611099984409020115405766.656
1622244525653376356952032650469301575312529294532032079934967987617222199968818040230811533.312
3244489051306752713904065300938603150625058589064064159869935975234444399937636080461623066.624
6488978102613505427808130601877206301250117178128128319739871950468888799875272160923246133.248
12977956205226810855616261203754412602500234356256256639479743900937777599750544321846492266.496
25955912410453621711232522407508825205000468712512513278959487801875555199501088643692984532.992
51911824820907243422465044815017650410000937425025026557918975603751110399002177287385969065.984
103823649641814486844930089630035300820001874850050053115837951207502220798004354574771938131.968
207647299283628973689860179260070601640003749700100106231675902415004441596008709149543876263.936
415294598567257947379720358520141203280007499400200212463351804830008883192017418299087752527.872
830589197134515894759440717040282406560014998800400424926703609660017766384034836598175505055.744
1661178394269031789518881434080564813120029997600800849853407219320035532768069673196351010111.488
3322356788538063579037762868161129626240059995201601699706814438640071065536139346392702020222.976
6644713577076127158075525736322259252480119990403203399413628877280142131072278692785404040445.952
13289427154152254316151051472644518504960239980806406798827257754560284262144557385570808080891.904
26578854308304508632302102945289037009920479961612813597654515509120568524289114771141616161783.808
53157708616609017264604205890578074019840959923225627195309031018241137048578229542283232323567.616
106315417233218034529208411781156148039681919846451254390618062036482274097156459084566464647135.232
212630834466436069058416823562312296079363839692902508781236124072964548194312918169132929294270.464
425261668932872138116833647124624592158727679385805017562472248145929096388625836338265858588540.928
850523337865744276233667294249248184317455358771610035124944496291858192777251672676531717177081.856
1701046675731488552467334588498496368634910717543220070249888992583716385554503345353063434354163.712
3402093351462977104934669176996992737269821435086440140499777985167432771108006690706126868708327.424
6804186702925954209869338353993985474539642870172880280999555970334865542216013381412253737416654.848
13608373405851908419738676707987970949079285740345760561999111940669731084432026762824507474833309.696
27216746811703816839477353415975941898158571480691521123998223881339462168864053525649014949666619.392
54433493623407633678954706831951883796317142961383042247996447762678924337728107051298029899333238.784
108866987246815267357909413663903767592634285922766084495992895525357848675456214102596059798666477.568
217733974493630534715818827327807535185268571845532168991985791050715697350912428205192119597332955.136
435467948987261069431637654655615070370537143691064337983971582101431394701824856410384239194665910.272
870935897974522138863275309311230140741074287382128675967943164202862789403649712820768478389331820.544
1741871795949044277726550618622460281482148574764257351935886328405725578807299425641536956778663641.088
3483743591898088555453101237244920562964297149528514703871772656811451157614598851283073913557327282.176
6967487183796177110906202474489841125928594299057029407743545313622902315229197702566147827114654564.352
13934974367592354221812404948979682251857188598114058815487090627245804630458395405132295654229309128.704
27869948735184708443624809897959364503714377196228117630974181254491609260916790810264591308458618257.408
55739897470369416887249619795918729007428754392456235261948362508983218521833581620529182616917236514.816
111479794940738833774499239591837458014857508784912470523896725017966437043667163241058365233834473029.632
222959589881477667548998479183674916029715017569824941047793450035932874087334326482116730467668946059.264
445919179762955335097996958367349832059430035139649882095586900071865748174668652964233460935337892118.528
891838359525910670195993916734699664118860070279299764191173800143731496349337305928466921870675784237.056
1783676719051821340391987833469399328237720140558599528382347600287462992698674611856933843741351568474.112
3567353438103642680783975666938798656475440281117199056764695200574925985397349223713867687482703136948.224
7134706876207285361567951333877597312950880562234398113529390401149851970794698447427735374965406273896.448
14269413752414570723135902667755194625901761124468796227058780802299703941589396894855470749930812547792.896
28538827504829141446271805335510389251803522248937592454117561604599407883178793789710941499861625095585.792
57077655009658282892543610671020778503607044497875184908235123209198815766357587579421882999723250191171.584
114155310019316565785087221342041557007214088995750369816470246418397631532715175158843765999446500382343.168
228310620038633131570174442684083114014428177991500739632940492836795263065430350317687531998893000764686.336
456621240077266263140348885368166228028856355983001479265880985673590526130860700635375063997786001529372.672
913242480154532526280697770736332456057712711966002958531761971347181052261721401270750127995572003058745.344
1826484960309065052561395541472664912115425423932005917063523942694362104523442802541500255991144006117490.688
3652969920618130105122791082945329824230850847864011834127047885388724209046885605083000511982288012234981.376
7305939841236260210245582165890659648461701695728023668254095770777448418093771210166001023964576024469962.752
14611879682472520420491164331781319296923403391456047336508191541554896836187542420332002047929152048939925.504
29223759364945040840982328663562638593846806782912094673016383083109793672375084840664004095858304097879850.008
58447518729890081681964657327125277187693613565824189346032766166219587344750169681328008191716608195759700.016
116895037459780163363929314654250554375387227131648378692065532332439174689500339362656016383433216391519400.032
233790074919560326727858629308501108750774454263296757384131064664878349379000678725312032766866432783038800.064
467580149839120653455717258617002217501548908526593514768262129329756698758001357450624065533732865566077600.128
935160299678241306911434517234004435003097817053187029536524258659513397516002714901248131067465731132155200.256
1870320599356482613822869034468008870006195634106374059073048517319026795032005429802496262134931462264310400.512
3740641198712965227645738068936017740012391268212748118146097034638053590064010859604992524269862924528620800.024
7481282397425930455291476137872035480024782536425496236292194069276107180128021719209985048539725849057241600.048
14962564794851860910582952275744070960049565072850992472584388138552214360256043438419970097079451698114483200.096
29925129589703721821165904551488141920099130145701984945168776277104428720512086876839940194158903396228966400.192
59850259179407443642331809102976283840198260291403969890337552554208857441024173753679880388317806792457932800.384
119700518358814887284663618205952567680396520582807939780675105108417714882048347507359760776635613584915865600.768
239401036717629774569327236411905135360793041165615879561350210216835429764096695014719521553271227169831731200.1536
478802073435259549138654472823810270721586082331231759122700420433670859528193390029438943106542454339663462400.3072
957604146870519098277308945647620541443172164662463518245400840867341719056386780058877886213084908679326924800.6144
1915208293741038196554617891295241082886344329324927036490801681734683438112773560117755772426169817358653849600.1228
3830416587482076393109235782590482165772688658649854072981603363469366876225547120235511544852339634717307699200.2456
7660833174964152786218471565180964331545377317299708145963206726938733752451094240471023089704679269434615398400.4912
15321666349928305572436943130361928663090754634599416291926413453877467504902188480942046179409358538869230796800.9824
30643332699856611144873886260723857326181509269198832583852826907754935009804376961884092358818717077738461593601.9648
61286665399713222289747772521447714652363018538397665167705653815509870019608753923768184717637434155476923187202.9296
122573330799426444579495545042895429304726037076795330335411307631019740039217507847536369435274868310953846374404.8592
245146661598852889158991090085790858609452074153590660670822615262039480078435015695072738870549736621907692748809.7184
490293323197705778317982180171581717218904148307181321341645230524078960156870031390145477741099473243815385497619.4368
980586646395411556635964360343163434437808296614362642683290461048157920313740062780290955482198946487630770995238.8736
1961173292790823113271928720686326868875616593228725285366580922096315840627480125560581910964397892975261541990477.7472
3922346585581646226543857441372653737751233186457450570733161844192631681254960251121163821928795785950523083980955.4944
7844693171163292453087714882745307475502466372914901141466323688385263362509920502242327643857591571901046167961910.9888
15689386342326584906175429765490614951004932745829802282932647376770526725019841004484655287715183143802092335923821.9776
31378772684653169812350859530981229902009865491659604565865294753541053450039682008969310575430366287604184671847643.9552
62757545369306339624701719061962459804019730983319209131730589507082106900079364017938621150860732575208369343695287.9104
125515090738612679249403438123924919608039461966638418263461179014164213800158728035877242301721465150416738687390575.8208
251030181477225358498806876247849839216078923933276836526922358028328427600317456071754484603442930300833477374781151.6416
502060362954450716997613752495699678432157847866553673053844716056656855200634912143508969206885860601666954749562303.2832
1004120725908901433995227504991399356864315695733107346107689432113313710401269824287017938413771721203333909499124606.5664
2008241451817802867990455009982798713728631391466214692215378864226627420802539648574035876827543442406667818998249213.1328
4016482903635605735980910019965597427457262782932429384430757728453254841605079297148071753655086884813335637996498426.2656
8032965807271211471961820039931194854914525565864858768861515456906509683210158594296143507310173769626671275992996852.5312
16065931614542422943923640079862389709829051131729717537723030913813019366420317188592287014620347539253342551985993705.0624
32131863229084845887847280159724779419658102263459435075446061827626038732840634377184574029240695078506685103971987410.1248
64263726458169691775694560319449558839316204526918870150892123655252077465681268754369148058481390157013370207943974820.2496
128527452916339383551389120638899117678632409053837740301784247310504154931362537508738296116962780314026740415887949640.4992
257054905832678767102778241277798235357264818107675480603568494621008309862725075017476592233925560628053480831775899280.9984
514109811665357534205556482555596470714529636215350961207136989242016619725450150034953184467851121256106961663551798561.9968
1028219623330715068411112965111192941429059272430701922414273978484033239450900300069906368935702242512213923103597123.9936
2056439246661430136822225930222385882858118544861403844828547956968066478901800600139812737871404485024427846207194247.9872
4112878493322860273644451860444771765716237089722807689657095913936132957803601200279625475742808970048855692414388495.9744
8225756986645720547288903720889543531432474179445615379314191827872265915607202400559250951485617940097711384828776991.9488
16451513973291441094577807441779087062864948358891230758628383655744531831214404801118501902971235880195422769657553983.8976
32903027946582882189155614883558174125729896717782461517256767311488063662428809602237003805942471760390845539315107967.7952
65806055893165764378311229767116348251459793435564923034513534622976127324857619204474007611884943520781691078630215935.5904
131612111786331528756622459534232696502919586871129846069027069245952254649715238408948015223769887041563382157260431871.1808
263224223572663057513244919068465393005839173742259692138054138491904509299430476817896030447539774083126764314520863742.3616
526448447145326115026489838136930786011678347484519384276108276983809018598860953635792060895079548166253528629041727484.7232
1052896894290652230052979676273861572023356694969038768552216553967618037197721907271584121790159096332507057258083454969.4464
2105793788581304460105959352547723144046713389938077537104433107935236074395443814543168243580318192665014114516166909938.8928
4211587577162608920211918705095446288093426779876155074208866215870472148790887629086336487160636385330028229032333819877.7856
8423175154325217840423837410190892576186853559752310148417732431740944297581775258172672974321272770660056458064667639755.5712
16846350308650435680847674820381785152373707119504620296835464863481888595163550516345345948642545541320112916129335279511.1424
33692700617300871361695349640763570304747414239009240593670929726963777190327101032690691897285091082640225832258670559022.2848
67385401234601742723390699281527140609494828478018481187341859453927554380654202065381383794570182165280451664516341118044.5696
134770802469203485446781398563054281218989656956036962374683718907855108761308404130762767589140364330560903328032682236089.1392
269541604938406970893562797126108562437979313912073924749367437815710217522616808261525535178280728661121806656065364472178.2784
539083209876813941787125594252217124875958627824147849498734875631420435045233616523050070356561457322243613312130728944356.5568
1078166419753627883574251188504434249751917255648295698997469751262840870090467232046100140713122914644487226624261457888713.1136
2156332839507255767148502377008868499503834511296591397994939502525681740180934464092200281426245829288974453248522915777426.2272
4312665679014511534297004754017736999007669022593182795989879005051363480361868928184400562852491658577948906497045831554852.4544
8625331358029023068594009508035473998015338045186365591979758010102726960723737856368801125704983317155897812994091663109704.9088
17250662716058046137188019016070947996030676090372731183959516020205453921447475712737602251409966634311795625988183326219409.8176
34501325432116092274376038032141895992061352180745462367919032040410907842894951425475204502819933268623591251976366652438819.6352
69002650864232184548752076064283791984122704361490924735838064080821815685789902850950409005639866537247182503952733304877639.2704
138005301728464369097504152128567583968245408722981849471676128161643631371579805701900818011279733074494365007905466609755278.5408
276010603456928738195008304257135167936490817445963698943352256323287262743159611403801636022559466148988730015810933219510557.0816
552021206913857476390016608514270335872981634891927397886704512646574525486319222807603272045118932297977460031621866438021114.1632
1104042413827714952780033217028540671745963269783854795773409025293148950972638445615206544090237864595954920063243732876042228.3264
2208084827655429905560066434057081343491926539567709591546818050586297901945276891230413088180475729191909840126487465752084456.6528
4416169655310859811120132868114162686983853079135419183093636101172595803890553782460826176360951458383819680252974931504168913.3056
8832339310621719622240265736228325373967706158270838366187272202345191607781107564921652352721902916767639360505949863008337826.6112
17664678621243439244480531472456650747935412316541676732374544404690383215562215129843304705443805833535278721011899726016675653.2224
35329357242486878488961062944913301495870824633083353464749088809380766431124430259686609410887611667070557442023799452033351306.4448
70658714484973756977922125889826602991741649266166706929498177618761532862248860519373218821775223334141114884047598904066702612.8896
141317428969947513955844251779653205983483298532333413858996355237523065724497721038746437643550446668282229768095197808133405225.7792
282634857939895027911688503559306411966966597064666827717992710475046131448995442077492875287100893336564459536190395616266810451.5584
565269715879790055823377007118612823933933194129333655435985420950092262897990884154985750574201786673128919072380791232533620903.1168
1130539431759580111646754014237225647867866388258667310871970841900184525795981768309971501148403573346257838144761582465067241806.2336
2261078863519160223293508028474451295735732776517334621743941683800369051591963536619943002296807146692515676289523164930134483612.4672
4522157727038320446587016056948902591471465553034669243487883367600738103183927073239886004593614293385031352579046329860268967224.9344
9044315454076640893174032113897805182942931106069338486975766735201476206367854146479772009187228586770062705158092659720537934449.8688
18088630908153281786348064227795610365885862212138676973951533470402952412735708292959544018374457173540125410316185319441075868899.7376
36177261816306563572696128455591220731771724424277353947903066940805904825471416585919088036748914347080250820632370638882151737799.4752
72354523632613127145392256911182441463543448848554707895806133881611809650942833171838176073497828694160501641264741277764303475598.9504
144709047265226254290784513822364882927086897697109415791612267763223619301885666343676352146995657388320983282529482555528606951197.9008
289418094530452508581569027644729765854173795394218831583224535526447238603771332687352704293991314776641966565058965111057213902395.8016
578836189060905017163138055289459531708347590788437663166449071052894477207542665374705408587982629553283933130117930222114427804791.6032
1157672378121810034326276110578919063416695181576875326332898142105788954415085330749410817175965259106567866260235860444228855609583.2064
2315344756243620068652552221157838126833390363153750652665796284211577908830170661498821634351930518213135732520471720888457711219166.4128
4630689512487240137305104442315676253666780726307501305331592568423155817660341322997643268703861036426271465040943441776915422438332.8256
9261379024974480274610208884631352507333561452615002610663185136846311635320682645995286537407722072852542930081886883553830844876664.5512
18522758049948960549220417769262705014667122905230005221326370273692623270641365291990573074815444145705085860163773767107661689753329.1024
37045516099897921098440835538525410029334245810460010442652740547385246541282730583981146149630888291410171720327547534215323379506658.2048
74091032199795842196881671077050820058668491620920020885305481094770493082565461167962292299261776582820343440655095068430646759013316.4096
148182064399591684393763342154101640117336983241840041770610962189540986165130922335924584598523553165640686881310190136861293518026632.8192
296364128799183368787526684308203280234673966483680083541221924379081972330261844671849169197047106331281373762620380273722587036053265.6384
592728257598366737575053368616406560469347932967360167082443848758163944660523689343698338394094212662562747525240760547445174072106531.2768
1185456515196733475150106737232813120938695865934720334164887697516327889321047378687396676788188425325125495050481521094890348144213062.5536
2370913030393466950300213474465626241877391731869440668329775395032655778642094757374793353576376850650250990100963042189780696288426125.1072
4741826060786933900600426948931252483754783463738881336659550790065311557284189514749586707152753701300501980201926084379561392576852250.2144
9483652121573867801200853897862504967509566927477762673319101580130623114568379029498173414305507402601003960403852168759122785153704500.4288
18967304243147735602401707795725009935019133854955525346638203160261246229136758058996346828611014805202007920807704337518245570307409000.8576
37934608486295471204803415591450019870038267709911050693276406320522492458273516117992693657222029610404015841615408675036491140614818001.7152
75869216972590942409606831182900039740076535419822101386552812641044984916547032235985387314444059220808031683230817350072982281229636003.4304
151738433945181884819213662365800079480153070839644202773105625282089969833094064471970774628888118441616063366461634700145964562459272006.8608
303476867890363769638427324731600158960306141679288405546211250564179939666188128943941549257776236883232126732923269400291929124918544013.7216
606953735780727539276854649463200317920612283358576811092422501128359879332376257887883098515552473766464253465846538800583858249837088027.4432
1213907471561455078553709298926400635841224566717153622184845002256719758664752515775766197031104947532928506931692077601167716499674176055.8864
2427814943122910157107418597852801271682449133434307244369690004513439517329505031551532394062209895065857013863384155202335432999348352111.7728
4855629886245820314214837195705602543364898266868614488739380009026879034659010063103064788124419790131714027726768310404670865998696704223.5456
9711259772491640628429674391411205086729796533737228977478760018053758069318020126206129576248839580263428055453536620809341731997393408447.0912
19422519544983281256859348782822410173459593067474457954957520036107516138636040252412259152497679160526856110907073241618683463994786816894.1824
38845039089966562513718697565644820346919186134948915909915040072215032277272080504824518304995358321053712221814146483237366927989573633788.3648
77690078179933125027437395131288640693838372269897831819830080144430064554544161009649036609990716642107424443628292966474733855979147267576.7296
155380156359866250054874790262577281387676744539795663639660160288860129109088322019298073219981433284214848887256585932949467711958294535153.4592
310760312719732500109749580525154562775353489079591327279320320577720258218176644038596146439962866568429697774513171865898935423916589070306.9184
621520625439465000219499161050309125550706978159182654558640641155440516436353288077192292879925733136859395549026343731797870847833178140613.8368
1243041250878930000438998322100618251101413956318365309117281282310881032872706576154384585759851466273718791098052687463595741695666356281227.6736
2486082501757860000877996644201236502202827912636730618234562564621762065745413152308769171519702932547437582196105374927191483391332712562455.3472
4972165003515720001755993288402472004405655825273461236469125129243524131490826304617538343039405865094875164392210749854382966782665425124911.6944
9944330007031440003511986576804944008811311650546922472938250258487048262981652609235076686078811730189750328784421499708765933565330850249823.3888
19888660014062880007023973153609888017622623301093844945876500516974096525963305218470153372157623460379500657568842999417531867130661700499646.7776
39777320028125760014047946307219776035245246602187689891753001033948193051926610436940306744315246920759001315137685998835063734261323400999293.5552
79554640056251520028095892614439552070490493204375379783506002067896386103853220873880613488630493841518002630275371997670127468522646801998587.1104
159109280112503040056191785228879104140980986408750759567012004135792772207706441747761226977260987683036005260550743995340254937045293603997174.2208
318218560225006080112383570457758208281961972817501519134024008271585544415412883495522453954521975366072010521101487990680509874090587207994348.4416
636437120450012160224767140915516416563923945635003038268048016543171088830825766991044907909043950732144021042202975981361019748181174415988696.8832
1272874240900024320449534281831032833127847891270006076536096033086342177661651533982089815818087901464288042084405951962722039496362348831977392.1664
2545748481800048640899068563662065666255695782540012153072192066172684355323303067964179631636175802928576084168811903925444078992724697663954784.3328
5091496963600097281798137127324131332511391565080024306144384132345368710646606135928359263272351605857152168337623807850888157985449395327909568.6656
10182993927200194563596274254648262665022783130160048612288768264690737421293212271856718526544703211714304336675247615701776315970898790655819137.3312
20365987854400389127192548509296525330045566260320097224577536529381474842586424543713436853089406423428608673350495231403552631941797581311638274.6624
40731975708800778254385097018593050660091132520640194449155073058762949685172849087426873706178812846857217346700990462807105263883595162623276549.3248
81463951417601556508770194037186101320182265041280388898310146117525899370345698174853747412357625693714434693401980925614210527767190325246553098.6496
162927902835203113017540388074372202640364530082560777796620292235051798740691396349707494824715251387428869386803961851228421055534380650493106197.2992
325855805670406226035080776148744405280729060165121555593240584470103597481382792699414989649430502774857738773607923702456842111068761300986212394.5984
651711611340812452070161552297488810561458120330243111186481168940207194962765585398829979298861005549715477547215847404913684222137522601972424789.1968
1303423222681624904140323104594977621122916240660486222372962337880414389925531170797659958597722011099430955094431694809827368444275045203944849578.3936
2606846445363249808280646209189955242245832481320972444745924675760828779851062341595319917195444022198861910188863389619654736888550090407889699156.7872
5213692890726499616561292418379910484491664962641944889491849351521657559702124683190639834390888044397723820377726779239309473777100180815779398313.5744
10427385781452999233122584836759820968983329925283889778983698703043315119404249366381279668781776088795447640755453558478618947554200361631558796627.1488
20854771562905998466245169673519641937966659850567779557967397406086630238808498732762559337563552177590895281510907116957237895108400723263117593254.2976
41709543125811996932490339347039283875933319701135559115934794812173260477616997465525118675127104355181790563021814233914475790216801446526235186508.5952
83419086251623993864980678694078567751866639402271118231869589624346520955233994931050237350254208710363581126043628467828951580433602892052470373017.1904
166838172503247987729961357388157135503733278804542236463739179248693041910467989862100474700508417420727162252087256935657903160867205784104940746034.3808
333676345006495975459922714776314271007466557609084472927478358497386083820935979724200949401016834841454324504174513871315806321734411568209881492069.7616
667352690012991950919845429552628542014933115218168945854956716994772167641871959448401898802033669682908649008349027742631612643468823136419762984139.5232
1334705380025983901839690859105257084029866230436337891709913433989544335283743918896803797604067339365817298016698055485263225286937646272839525968279.0464
2669410760051967803679381718210514168059732460872675783419826867979088670567487837793607595208134678731634596033396110970526450573875292545679051936558.0928
5338821520103935607358763436421028336119464921745351566839653735958177341134975675587215190416269357463269192066792221941052901147750585091358103873116.1856
10677643040207871214717526872842056672238929843490703133679307471916354682269951351174430380832538714926538384133584443882105802295501170182716207746232.3712
21355286080415742429435053745684113344477859686981406267358614943832709364539902702348860761665077429853076768267168887764211604591002340365432415492464.7424
42710572160831484858870107491368226688955719373962812534717229887665418729079805404697721523330154859706153536534337775528423209182004680730864830984929.4848
85421144321662969717740214982736453377911438747925625069434459775330837458159610809395443046660309719412307073068675551056846418364009361461729661969858.9696
170842288643325939435480429965472906755822877495851250138868919550661674916319221618790886093320619438824614146137351102113692836728018722923459323939717.9392
341684577286651878870960859930945813511645754991702500277737839101323349832638443237581772186641238877649228292274702204227385673456037445846918647879435.8784
683369154573303757741921719861891627023291509983405000555475678202646699665276886475163544373282477755298456584549404408454771346912074891693837295758871.7568
1366738309146607515483843439723783254046583019966810001110951356405293399330553772950327088746564955510596913169098808816909542693824149783387674590517743.5136
2733476618293215030967686879447566508093166039933620002221902712810586798661107545900654177493129911021193826338197617633818085387648299566775349181035486.0272
5466953236586430061935373758895133016186332079867240004443805425621173597322215091801308354986259822042387652676395235267636170775296599133550698362070972.0544
10933906473172860123870747517790266032372664159734480008887610851242347194644430183602616709972519644084775305352790470535272341550593198267101396724141944.1088
21867812946345720247741495035580532064745328319468960017775221702484694389288860367205233419945039288169550610705580941070544683101186396534202793448283888.2176
43735625892691440495482990071161064129490656638937920035550443404969388778577720734410466839890078576339101221411161882141089366202372793068405586896567776.4352
87471251785382880990965980142322128258981313277875840071100886809938777557155441468820933679780157152678202442822323764282178732404745586136811173793135552.8704
174942503570765761981931960284644256517962626555751680142201773619877555114310882937641867359560314305356404885644647528564357464809491172273622347586271105.7408
349885007141531523963863920569288513035925253111503360284403547239755110228621765875283734719120628610712809771289295057128714929618982344547244


Lung Cancer
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
GZ 08.070
0
1.953
3.906
7.813
15.625
31.25
62.5
125
250
500
1000
2000
4000
8000
16000
32000
64000
128000
256000
512000
Dose (µg/mL)

Fig. 82-6


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.071
0
1.953
3.906
7.812
15.625
31.25
62.5
125
250
500
1000
2000
4000
Dose (µg/mL)

Fig. 82-7


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.072
0
1.953
3.906
7.813
15.625
31.25
62.5
125
250
500
1000
2000
4000
Dose (µg/mL)

Fig. 82-8


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.073
0
1.4571
2.9142
5.8285
11.6569
23.3138
46.6275
93.3750
186.75
373.5

Fig. 82-9


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.074
0
7.813
1.4902
2.9805
5.9609
11.9219
23.8438
47.6875
95.375
190.75
381.5
Dose (µg/mL)

Fig. 82-10


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.075
0
7.813
15.625
31.25
62.5
125
250
500
1,000
2,000
4,000
8,000
16,000
32,000
64,000
128,000
256,000
512,000
Dose (µg/mL)

Fig. 82-11


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.076
0
1.451
1.4602
2.9605
5.9609
11.9219
23.8439
47.6879
95.375
190.75
381.5
Dose (µg/mL)

Fig. 82-12


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
1.561
3.125
6.25
12.5
25
50
100
200
400
800
1600
3200
6400
12800
25600
51200
102400
204800
409600
819200
GZ 08.077
Dose (µg/mL)

Fig. 82-13


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.078
0
7.4E-1
1.4E-02
2.9E-02
5.9E-02
1.2E-01
2.3E-01
4.7E-01
9.5E-01
1.9E+00
3.8E+00
Dose (µg/mL)

Fig. 82-14


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.079
0
1.953
3.906
7.812
15.625
31.25
62.5
125
250
500
1000
2000
4000
8000
16000
32000
Dose (µg/mL)

Fig. 82-15


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.080
0
1.5371
2.0697
2.9809
5.9609
11.9219
23.8438
47.6875
95.375
190.75
381.5
Dose (µg/mL)

Fig. 82-16


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.081
0
1.471
2.069
2.9809
5.9609
11.9219
23.8438
47.6875
95.375
190.75
381.5
Dose (µg/mL)

Fig. 82-17


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.082
0
7.451
1.4602
2.9605
5.9609
11.9219
23.8438
47.6875
95.375
190.75
381.5
Dose (µg/mL)

Fig. 82-18


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.063
0
1.953
3.906
7.813
15.625
31.25
62.5
125
250
500
1000
2000
4000
Dose (µg/mL)

Fig. 82-19


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.084
0
1.7451
2.0497
2.9805
5.9609
11.9219
23.8438
47.6875
95.375
190.75
381.5
Dose (µg/mL)

Fig. 82-20


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.085
0
1.5625
3.125
6.25
12.5
25
50
100
200
400
800
1600
3200
6400
12800
25600
51200
Dose (µg/mL)

Fig. 82-21


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.086
0
1.951
3.906
7.813
15.625
31.25
62.5
125
250
500
1000
2000
4000
8000
16000
32000
Dose (µg/mL)

Fig. 82-22


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.087
0
1.5625
3.125
6.25
12.5
25
50
100
200
400
Dose (µg/mL)

Fig. 82-23


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.088
0
1.471
2.942
5.884
11.769
23.538
47.077
94.153
188.305
376.611
Dose (µg/mL)

Fig. 82-24


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.089
0
1.951
3.906
7.813
15.625
31.250
62.500
125
250
500
1000
2000
4000
8000
16000
32000
64000
128000
Dose (µg/mL)

Fig. 82-25


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
7.451
1.4902
2.9805
5.9609
11.9219
23.8438
47.6875
95.375
190.75
381.5
Dose (µg/mL)
GZ 08.090

Fig. 82-26


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.091
0
1.451
4.602
9.605
19.209
38.419
76.838
153.675
307.35
Dose (µg/mL)

Fig. 82-27


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.092
0
1.751
1.4902
2.9605
5.9609
11.9219
23.8439
47.6879
95.3758
190.752
381.5
Dose (ug/mL)

Fig. 82-28


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.093
0
1.451
1.4902
2.0803
5.6609
11.9219
23.8438
47.6875
95.375
190.75
381.5
Dose (µg/mL)

Fig. 82-29


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.094
0
1.951
3.906
7.812
15.625
31.250
62.500
125.000
250.000
500.000
1000.000
2000.000
4000.000
Dose (µg/mL)

Fig. 82-30


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.095
0
1.953
3.906
7.812
15.625
31.25
62.5
125
250
500
1000
2000
4000
Dose (µg/mL)

Fig. 82-31


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.098
0
1.951
3.906
7.813
15.625
31.250
62.500
125.000
250.000
500.000
1000.000
2000.000
4000.000
Dose (µg/mL)

Fig. 82-32


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.097
0
1.953
3.906
7.813
15.625
31.25
62.5
125
250
500
1000
2000
4000
8000
16000
32000
Dose (µg/mL)

Fig. 82-33


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0
1.951
3.906
7.812
15.625
31.25
62.5
125
250
500
1000
2000
4000
GZ 08.098
Dose (µg/mL)

Fig. 82-34


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.099
0
1.951
3.906
7.812
15.625
31.250
62.500
125.000
250.000
500.000
1000.000
2000.000
4000.000
8000.000
16000.000
32000.000
64000.000
Dose (µg/mL)

Fig. 82-35


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.100
0
1.953
3.906
7.812
15.625
31.25
62.5
125
250
500
1000
2000
4000
8000
16000
32000
Dose (µg/mL)

Fig. 82-36


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08-101
0
1.561
1.4902
2.9605
5.9609
11.9219
23.8438
47.6875
95.375
190.75
381.5
Dose (µg/mL)

Fig. 82-37


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.102
0
1.4571
4.0072
2.0805
5.0809
11.9219
23.8438
47.6875
95.375
190.75
381.5
Dose (µg/mL)

Fig. 82-38


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08. 103
0
.7451
1.4902
2.9805
5.9609
11.9219
23.8438
47.6875
95.375
190.75
381.5
Dose (µg/mL)

Fig. 82-39


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08 104
0
1.953
3.906
7.812
15.625
31.25
62.5
125
250
500
1000
2000
4000
Dose (µg/mL)

Fig. 82-40


Lung Cancer
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.105
0
1.951
3.906
7.813
15.625
31.25
62.5
125
250
500
1000
2000
4000
8000
16000
32000
Dose (µg/mL)

Fig. 82-41


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
GZ 08.065
0
7.813
15.625
31.25
62.5
125
250
500
1000
2000
4000
8000
16000
32000
64000
128000
256000
Dose (µg/mL)

Fig. 82-42


Lymphoma
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
GZ 08.066
0
1.561
3.125
6.25
12.5
25
50
100
200
400
800
1600
3200
6400
12800
25600
51200
102400
204800
409600
819.2
1638.4
3276.8
6553.6
13107.2
26214.4
52428.8
104857.6
209715.2
419430.4
838860.8
1677721.6
3355443.2
6710886.4
13421772.8
26843545.6
53687091.2
107374182.4
214748364.8
429496729.6
859.5
1719.1
3438.2
6876.4
13752.8
27505.6
55011.2
110022.4
220044.8
440089.6
880179.2
1760358.4
3520716.8
7041433.6
14082867.2
28165734.4
56331468.8
112662937.6
225325875.2
450651750.4
901303500.8
1802607001.6
3605214003.2
7210428006.4
14420856012.8
28841712025.6
57683424051.2
115366848102.4
230733696204.8
461467392409.6
922934784819.2
1845869569638.4
3691739139276.8
7383478278553.6
14766956557107.2
Dose (µg/mL)

Fig. 82-43


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.067
0
1.953
7.813
31.250
125.000
500.000
2.000
8.000
32.000
128.000
512.000

Fig. 82-44


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
GZ 08.068
0
7.45E-1
1.49E-2
2.98E-2
5.96E-2
11.92E-2
23.84E-2
47.68E-2
95.37E-2
190.7E-2
381.5E-2
Dose (µg/mL)

Fig. 82-45


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.069
0
1.451
4.902
2.9805
6.9609
11.921
23.8438
47.6875
95.375
190.75
381.5
Dose (µg/mL)

Fig. 82-46


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.070
0
7.451
1.4902
2.9805
5.9609
11.9219
23.8438
47.6875
95.375
190.75
381.5
Dose (µg/mL)

Fig. 82-47


Lymphoma
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
GZ 08.071
0
1.5E-1
1.46E-1
2.09E-2
6.09E-2
5.96E-2
1.19E-1
2.38E-1
4.76E-1
9.52E-1
1.90E+0
3.79E+0
7.58E+0
1.51E+1
Dose (µg/mL)

Fig. 82-48


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.072
0
1.471
1.4902
2.9805
5.9609
11.9219
23.8438
47.6875
95.375
190.75
381.5
Dose (µg/mL)

Fig. 82-49


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.073
0
1.953
3.906
7.813
15.625
31.25
62.5
125
250
500
1000
2000
Dose (µg/mL)

Fig. 82-50


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
1.747
7.491
31.49
132.4
556.2
2336
9814
41.23
173.2
727.9
3058
12.85
54.00
226.9
953.3
4006
16.83
70.73
297.1
1248
5244
22.03
92.58
389.1
1635
6870
28.86
121.3
509.6
2142
9000
37.81
158.9
668
2807
11.79
49.54
208.2
875
3676
15.44
64.88
272.6
1146
4815
20.23
85.01
357.1
1500
6302
26.47
111.2
467.3
1963
8246
34.63
145.5
611.1
2567
10785
45.29
190.3
799.6
3359
Dose (µg/mL)
GZ 08.074

Fig. 82-51


Lymphoma
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
GZ 08.075
0
1.451
2.907
5.815
11.631
23.263
46.525
93.050
186.100
372.200
744.400
1,488.800
2,977.600
5,955.200
11,910.400
23,820.800
47,641.600
95,283.200
190,566.400
381,132.800
Dose (µg/mL)

Fig. 82-52


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08 076
0
1.541
2.0964
2.9605
5.9609
11.9219
23.8438
47.6875
95.375
190.75
381.5
Dose (µg/mL)

Fig. 82-53


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
7.813
15.625
31.25
62.5
125
250
500
1000
2000
4000
8000
16000
32000
GZ 08.077
Dose (µg/mL)

Fig. 82-54


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.078
0
1.953
3.906
7.812
15.625
31.25
62.5
125
250
500
1000
2000
4000
Dose (µg/mL)

Fig. 82-55


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.079
0
1.5625
3.125
6.25
12.5
25
50
100
200
400

Fig. 82-56


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.080
0
1.9531
3.9063
7.8125
15.625
31.25
62.5
125
250
500
1000
2000
4000
Dose (µg/mL)

Fig. 82-57


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.081
0
1.461
1.4902
2.9805
5.9609
11.9219
23.8438
47.6875
95.375
190.75
381.5
Dose (µg/mL)

Fig. 82-58


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
1.56E-1
3.12E-1
6.25E-1
1.25E+0
2.50E+0
5.00E+0
1.00E+1
2.00E+1
4.00E+1
8.00E+1
1.60E+2
3.20E+2
6.40E+2
1.28E+3
GZ 08.082
Dose (µg/mL)

Fig. 82-59


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
1.953
3.906
7.812
15.625
31.25
62.5
125
250
500
1000
2000
GZ 08.083
Dose (µg/mL)

Fig. 82-60


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
GZ 08.084
0
7.813
15.625
31.25
62.5
125
250
500
1000
2000
4000
8000
16000
32000
Dose (µg/mL)

Fig. 82-61


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.085
0
7.813
15.625
31.25
62.5
125
250
500
1000
2000
4000
8000
16000
32000
Dose (µg/mL)

Fig. 82-62


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
Dose (µg/mL)
0
1.953
3.906
7.812
15.625
31.25
62.5
125
250
500
1000
2000
4000
8000
16000
32000
GZ 08.086

Fig. 82-63


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.087
0
1.953
3.906
7.813
15.625
31.25
62.5
125
250
500
1000
2000
4000
Dose (µg/mL)

Fig. 82-64


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.088
0
1.561
3.125
6.250
12.500
25.000
50.000
100.000
200.000
400.000
800.000
1,600.000
3,200.000
6,400.000
12,800.000
25,600.000
51,200.000
Dose (ug/mL)

Fig. 82-65


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
GZ 08.069
0
1.471
1.4902
2.0605
5.9609
11.921
23.843
47.687
95.375
190.75
381.5
Dose (µg/mL)

Fig. 82-66


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
Dose (µg/mL)
0
1.562
3.125
6.25
12.5
25
50
100
200
400
800
1600
3200
6400
12800
25600
51200
GZ 08.090

Fig. 82-67


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
1.561
3.123
6.246
12.492
25.984
50.968
101.936
203.872
407.744
815.488
1630.976
3261.5
Dose (µg/mL)
GZ 08.091

Fig. 82-68


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.092
0
7.8125
15.625
31.25
62.5
125
250
500
1000
2000
4000
8000
16000
32000
Dose (µg/mL)

Fig. 82-69


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
GZ 08.093
0
7.8125
15.625
31.25
62.5
125
250
500
1000
2000
4000
8000
16000
32000
64000
128000
Dose (µg/mL)

Fig. 82-70


Lymphoma
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
GZ 08.094
0
7.8125
15.625
31.25
62.5
125
250
500
1000
2000
4000
8000
16000
32000
Dose (µg/mL)

Fig. 82-71


Lymphoma
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
-20
0
1.953
3.906
7.813
15.625
31.25
62.5
125
250
500
1000
2000
4000
GZ 08.095
Dose (µg/mL)

Fig. 82-72


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
1.571
2.094
2.6605
5.9605
11.9219
23.8438
47.6875
95.375
190.75
381.5
Dose (µg/mL)
GZ 08.096

Fig. 82-73


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
0
1.561
3.125
6.25
12.5
25
50
100
200
400
GZ 08.097
Dose (µg/mL)

Fig. 82-74


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.098
0
7.451
1.4602
2.9605
5.9609
11.9219
23.8438
47.6875
95.375
190.75
381.5
Dose (µg/mL)

Fig. 82-75


Lymphoma
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
-20
0
1.461
4.384
13.152
39.456
118.368
355.104
1,065.312
3,195.936
9,587.808
28.763.424
86.290.272
259.870.816
GZ 08.099
Dose (µg/mL)

Fig. 82-76


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.100
0
1.451
4.902
2.9605
5.9609
11.9219
23.8438
47.6875
95.375
190.75
381.5
Dose (µg/mL)

Fig. 82-77


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.101
0
1.953
3.906
7.813
15.625
31.25
62.5
125
250
500
1000
2000
4000
8000
16000
32000
Dose (µg/mL)

Fig. 82-78


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.102
0
1.953
3.906
7.812
15.625
31.250
62.500
125
250
500
1000
2000
4000
8000
16000
32000
64000
128000
256000
512000
1024000
2048000
4096000
8192000
16384000
32768000
65536000
131072000
262144000
524288000
1048576000
2097152000
4194304000
8388608000
16777216000
33554432000
67108864000
134217728000
268435456000
536870912000
1073741824000
2147483648000
4294967296000
8589934592000
17179869184000
34359738368000
68719476736000
137438953472000
274877906944000
549755813888000
1099511627776000
2199023255552000
4398046511104000
8796093022208000
17592186044416000
35184372088832000
70368744177664000
140737488355328000
281474976710656000
562949953421312000
1125899906842624000
2251799813685248000
4503599627370496000
9007199254740992000
18014398509481984000
36028797018963968000
72057594037927936000
144115188075855872000
288230376151711744000
576460752303423488000
1152921504606846976000
2305843009213693952000
4611686018427387904000
9223372036854775808000
Dose (µg/mL)

Fig. 82-79


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.103
0
.7451
1.4902
2.9805
5.9609
11.9219
23.8438
47.6875
95.375
190.75
381.5
Dose (µg/mL)

Fig. 82-80


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.104
0
1.5625
3.125
6.25
12.5
25
50
100
200
400
800
1600
3200
6400
12800
25600
51200
102400
204800
409600
819200
1638400
3276800
6553600
Dose (µg/mL)

Fig. 82-81


Lymphoma
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
GZ 08.105
0
1.5E-1
4.0E-1
2.0E-0
6.0E-0
1.5E+1
3.8E+1
9.5E+1
2.3E+2
5.7E+2
1.4E+3
3.6E+3
Dose (µg/mL)

Fig. 82-82


Leukemia
GZ 08.065
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)

Fig. 82-83


Leukemia
GZ 08.066
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
0.00
0.75
1.50
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)

Fig. 82-84


Leukemia
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)
GZ 08.067

Fig. 82-85


Leukemia
GZ 08.068
Cell Number (Percent of Baseline)
Dose (ug/mL)
140
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50

Fig. 82-86


Leukemia
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)
GZ 08.069

Fig. 82-87


Leukemia
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)
GZ 08.070

Fig. 82-88


Leukemia
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
0.00
0.15
0.30
0.61
1.22
2.44
4.88
9.76
19.53
39.06
78.13
156.25
312.50
GZ 08.071
Dose (ug/mL)

Fig. 82-89


Leukemia
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
0.00
0.75
1.50
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)
GZ 08.072

Fig. 82-90


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0.00
0.75
1.50
2.25
3.00
3.75
4.50
5.25
6.00
6.75
7.50
8.25
9.00
9.75
10.50
11.25
12.00
GZ 08.073
Dose (ug/mL)

Fig. 82-91


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.68
95.36
190.75
381.50
Dose (ug/mL)
GZ 08.074

Fig. 82-92


Leukemia
GZ 08.075
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)

Fig. 82-93


Leukemia
GZ 08.076
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0.00
0.75
1.49
1.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)

Fig. 82-94


Leukemia
GZ 08.077
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0.00
0.75
1.50
3.00
6.00
12.00
24.00
48.00
96.00
192.00
384.00
Dose (ug/mL)

Fig. 82-95


Leukemia
GZ 08.078
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)

Fig. 82-96


Leukemia
GZ 08.079
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)

Fig. 82-97


Leukemia
GZ 08.080
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
763.00
Dose (ug/mL)

Fig. 82-98


Leukemia
GZ 08.081
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0.00
0.15
0.30
0.60
1.20
2.40
4.80
9.60
19.20
38.50
76.80
153.50
307.00
614.00
1228.00
2457.00
4914.00
9828.00
19656.00
39312.00
78624.00
157248.00
Dose (ug/mL)

Fig. 82-99


Leukemia
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)
GZ 08.082

Fig. 82-100


Leukemia
GZ 08.083
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)

Fig. 82-101


Leukemia
GZ 08.084
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)

Fig. 82-102


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)
GZ 08.085

Fig. 82-103


Leukemia
GZ 08.086
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)

Fig. 82-104


Leukemia
GZ 08.087
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0.0
0.25
0.50
1.00
2.00
4.00
8.00
16.00
32.00
64.00
128.00
256.00
Dose (ug/mL)

Fig. 82-105


Leukemia
GZ 08.088
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)

Fig. 82-106


Leukemia
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)
GZ 08.089

Fig. 82-107


Leukemia
GZ 08.090
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
0.00
0.10
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)

Fig. 82-108


Leukemia
GZ 08.091
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
0.00
0.15
0.30
0.60
1.20
2.40
4.80
9.60
19.20
38.40
76.80
153.60
Dose (ug/mL)

Fig. 82-109


Leukemia
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
0.00
0.75
1.50
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)
GZ 08.092

Fig. 82-110


Leukemia
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
0.00
0.15
0.30
0.61
1.22
2.44
4.88
9.76
19.53
39.06
78.13
156.25
312.50
625.00
1250.00
2500.00
5000.00
Dose (ug/mL)
GZ 08.093

Fig. 82-111


Leukemia
GZ 08.094
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
0.00
0.15
0.39
1.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)

Fig. 82-112


Leukemia
GZ 08.095
Cell Number (Percent of Baseline)
Dose (ug/mL)
140
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50

Fig. 82-113


Leukemia
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)
GZ 08.096

Fig. 82-114


Leukemia
GZ 08.097
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)

Fig. 82-115


Leukemia
GZ 08.098
Cell Number (Percent of Baseline)
137
117
97
77
57
37
17
-3
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)

Fig. 82-116


Leukemia
GZ 08.099
Cell Number (Percent of Baseline)
Dose (ug/mL)
140
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50

Fig. 82-117


Leukemia
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)
GZ 08.100

Fig. 82-118


Leukemia
GZ 08.101
Cell Number (Percent of Baseline)
140
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)

Fig. 82-119


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)
GZ 08.102

Fig. 82-120


Leukemia
GZ 08.103
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
0.00
0.75
1.49
2.98
5.96
11.92
23.84
47.68
95.36
190.75
381.50
Dose (ug/mL)

Fig. 82-121


Leukemia
Cell Number (Percent of Baseline)
117
97
77
57
37
17
-3
0.0
0.75
1.49
2.98
5.96
11.92
23.84
47.69
95.38
190.75
381.50
Dose (ug/mL)
GZ 08.104

Fig. 82-122


Leukemia
Cell Number (Percent of Baseline)
120
100
80
60
40
20
0
-20
GZ 08.105
0
1,951
2,902
3,853
5,756
11,609
23,218
47,436
95,873
190,745
381,5
Dose (µg/mL)

Fig. 82-123


Lung Cancer
8.065 at 1.5 µg/mL
Cancer Lethality (% decline in viable cells)
30
25
20
15
10
5
0
I01
Curcumin
Harmine
Theoretical Additive Effect
8.065

Fig. 82-124


Lung Cancer
8.067 at 6.0 μg/mL
Cancer Lethality (% decline in cell viability)
40
30
20
10
0
103
Curcumin
Harmine
Theoretical Additive Effect
8.067

Fig. 82-125


Cell Lethality (% decline in cell viability)
30
25
20
15
10
5
0
8.068 at 1.5 µg/mL
Lung Cancer
i04
Curcumin
Harmine
Theoretical Additive Effect
8.068

Fig. 82-126


Lung Cancer
8.079 at 1.5 µg/mL
Cell Lethality (% decline in viable cells)
25
20
15
10
5
0
i015
Curcumin
Harmine
Theoretical Additive Effect
8.079

Fig. 82-127


Lung Cancer
8.080 at 1.5 µg/mL
Cell Lethality (% decline in cell viability)
20
18
16
14
12
10
8
6
4
2
0
h01
Isovanillin
Curcumin
Theoretical Additive Effect
8.080

Fig. 82-128


Lung Cancer
8.084 at 1.5 µg/mL
Cell Lethality (% decline in viable cells)
14
12
10
8
6
4
2
0
h05
Isovanillin
Curcumin
Theoretical Additive Effect
8.084

Fig. 82-129


Lung Cancer
8.085 at 1.5 µg/mL
Cancer Lethality (% decline in cell viability)
14
12
10
8
6
4
2
0
h06
Isovanillin
Curcumin
Theoretical Additive Effect
8.085

Fig. 82-130


Lung Cancer
8.086 at 24 µg/mL
Cancer Lethality (% decline in viable cells)
35
30
25
20
15
10
5
0
h07
Isovanillin
Curcumin
Theoretical Additive Effect
8.086

Fig. 82-131


Cancer Lethality (% decline in viable cells)
16
14
12
10
8
6
4
2
0
8.087 at 12 µg/mL
Lung Cancer
T
h08
Isovanillin
Curcumin
Theoretical Additive Effect
8.087

Fig. 82-132


Lung Cancer
8.088 at 1.5 µg/mL
Cancer Lethality (% decline in viable cells)
18
16
14
12
10
8
6
4
2
0
h09
Isovanillin
Curcumin
Theoretical Additive Effect
8.088

Fig. 82-133


Lung Cancer
8.089 at 1.5 µg/mL
Cancer Lethality (% decline in viable cells)
16
14
12
10
8
6
4
2
0
h10
Isovanillin
Curcumin
Theoretical Additive Effect
8.089

Fig. 82-134


Lung Cancer
8.090 at 1.5 µg/mL
Cancer Lethality (% decline in viable cells)
12
10
8
6
4
2
0
h11
Isovanillin
Curcumin
Theoretical Additive Effect
8.090

Fig. 82-135


Lung Cancer
8.091 at 1.5 µg/mL
Cancer Lethality (% decline in cell viability)
18
16
14
12
10
8
6
4
2
0
h12
Isovanillin
Curcumin
Theoretical Additive Effect
8.091

Fig. 82-136


Lung Cancer
8.092 at 12 µg/mL
Cancer Lethality (% decline in viable cells)
16
14
12
10
8
6
4
2
0
h13
Isovanillin
Curcumin
Theoretical Additive Effect
8.092

Fig. 82-137


Lung Cancer
8.093 at 6 µg/mL
Cancer Lethality (% decline in viable cells)
25
20
15
10
5
0
c01
Isovanillin
Harmine
Theoretical Additive Effect
8.093

Fig. 82-138


8.094 at 1.5 µg/mL
Lung Cancer
Cancer Lethality (% decline in viable cells)
35
30
25
20
15
10
5
0
c02
Isovanillin
Harmine
Theoretical Additive Effect
8.094

Fig. 82-139


Lung Cancer
0.8097 at 1.5 µg/mL
Cancer Lethality (% decline in viable cells)
25
20
15
10
5
0
c05
Isovanillin
Harmine
Theoretical Additive Effect
8.097

Fig. 82-140


Cancer Lethality (% decline in viable cells)
25
20
15
10
5
0
8.098 at 1.5 µg/mL
Lung Cancer
c06
Isovanillin
Harmine
Theoretical Additive Effect
8.098

Fig. 82-141


Cancer Lethality (% decline in viable cells)
20
15
10
5
0
8.100 at 1.5 µg/mL
Lung Cancer
c08
Isovanillin
Harmine
Theoretical Additive Effect
8.100

Fig. 82-142


Lung Cancer
8.101 at 1.5 µg/mL
Cancer Lethality (% decline in viable cells)
25
20
15
10
5
0
c09
Isovanillin
Harmine
Theoretical Additive Effect
8.101

Fig. 82-143


Lung Cancer
8.102 at 1.5 µg/mL
Cancer Lethality (% decline in viable cells)
25
20
15
10
5
0
c10
Isovanillin
Harmine
Theoretical Additive Effect
8.102

Fig. 82-144


Lung Cancer
8.103 at 1.5 µg/mL
Cancer Lethality (% decline in valable cells)
25
20
15
10
5
0
c11
Isovanillin
Harmine
Theoretical Additive Effect
8.103

Fig. 82-145


8.104 at 1.5 µg/mL
Lung Cancer
Cancer Lethality (% decline in viable cells)
30
25
20
15
10
5
0
c12
Isovanillin
Harmine
Theoretical Additive Effect
8.104

Fig. 82-146


Lung Cancer
8.105 at 1.5 µg/mL
Cancer Lethality (% decline in viable cells)
30
25
20
15
10
5
0
c13
Isovanillin
Harmine
Theoretical Additive Effect
8.105

Fig. 82-147


Lymphoma
08.067 at 2.98 µg/mL
Cancer Lethality (% decline in viable cells)
16
14
12
10
8
6
4
2
0
i03
Curcumin
Harmine
Theoretical Additive Effect
08.067

Fig. 82-148


Lymphoma
08.073 at 23.84 µg/mL
Cancer Lethality (% decline in viable cells)
35
30
25
20
15
10
5
0
i09
Curcumin
Harmine
Theoretical Additive Effect
08.073

Fig. 82-149


Lymphoma
08.076 at 95.37 µg/mL
Cancer Lethality (% decline in viable cells)
100
80
60
40
20
0
i12
Curcumin
Harmine
Theoretical Additive Effect
08.076

Fig. 82-150


Lymphoma
08.077 at 47.7 µg/mL
Cancer Lethality (% decline in viable cells)
50
40
30
20
10
0
i13
Curcumin
Harmine
Theoretical Additive Effect
08.077

Fig. 82-151


Lymphoma
08.080 at 47.68 µg/mL
Cancer Lethality (% decline in cell viability)
35
30
25
20
15
10
5
0
h01
Isovanillin
Curcumin
Theoretical Additive Effect
08.080

Fig. 82-152


Cancer Lethality (% decline in cell viability)
50
40
30
20
10
0
08.083 at 47.68 µg/mL
Lymphoma
h04
Isovanillin
Curcumin
Theoretical Additive Effect
08.083

Fig. 82-153


Lymphoma
08.086 at 47.68 µg/mL
Cancer Lethality (% decline in viable cells)
50
40
30
20
10
0
h07
Isovanillin
Curcumin
Theoretical Additive Effect
08.086

Fig. 82-154


Lymphoma
08.088 at 47.68 µg/mL
Cancer Lethality (% decline in viable cells)
35
30
25
20
15
10
5
0
h09
Isovanillin
Curcumin
Theoretical Additive Effect
08.088

Fig. 82-155


Lymphoma
08.092 at 47.68 µg/mL
Cancer Lethality (% decline in viable cells)
30
25
20
15
10
5
0
h13
Isovanillin
Curcumin
Theoretical Additive Effect
08.092

Fig. 82-156


Cancer Lethality (% decline in viable cells)
50
40
30
20
10
0
08.095 at 47.68 µg/mL
Lymphoma
c03
Isovanillin
Harmine
Theoretical Additive Effect
08.095

Fig. 82-157


Cancer Lethality (% decline in viable cells)
50
40
30
20
10
0
08.099 at 47.68 µg/mL
Lymphoma
c07
Isovanillin
Harmine
Theoretical Additive Effect
08.099

Fig. 82-158


Cancer Lethality (% decline in viable cells)
80
60
40
20
0
08.101 at 190.75 µg/mL
Lymphoma
c09
Isovanillin
Harmine
Theoretical Additive Effect
08.101

Fig. 82-159


Lymphoma
08.105 at 190.75 mg/mL
Cancer Lethality (% decline in viable cells)
100
80
60
40
20
0
c13
Isovanillin
Harmine
Theoretical Additive Effect
8.105

Fig. 82-160


Leukemia
08.086 at 11.92 µg/mL
Cancer Lethality (% decline in viable cells)
100
80
60
40
20
0
h07
Isovanillin
Curcumin
Theoretical Additive Effect
08.086

Fig. 82-161


Leukemia
08.087 at 11.92 µg/mL
Cancer Lethality (% decline in viable cells)
100
80
60
40
20
0
h08
Isovanillin
Curcumin
Theoretical Additive Effect
08.087

Fig. 82-162


Leukemia
08.090 at 11.92 µg/mL
Cancer Lethality (% decline in viable cells)
100
80
60
40
20
0
h11
Isovanillin
Curcumin
Theoretical Additive Effect
08.090

Fig. 82-163


Leukemia
08.094 at 11.92 µg/mL
Cancer Lethality (% decline in viable cells)
70
60
50
40
30
20
10
0
c02
Isovanillin
Harmine
Theoretical Additive Effect
08.094

Fig. 82-164


Cancer Lethality (% decline in cell viability)
80
60
40
20
0
08.098 at 190.75 µg/mL
Leukemia
c06
Isovanillin
Harmine
Theoretical Additive Effect
08.098

Fig. 82-165


Leukemia
08.104 at 23.84 µg/mL
Cancer Lethality (% decline in cell viability)
100
80
60
40
20
0
c12
Isovanillin
Harmine
Theoretical Additive Effect
08.104

Fig. 82-166


Leukemia
08.105 at 11.92 µg/mL
Cancer Lethality (% decline in viable cells)
80
60
40
20
0
c13
Isovanillin
Harmine
Theoretical Additive Effect
08.105

Fig. 82-167



FIG. 83A.



FIG. 83B.



FIG. 83C.



FIG. 83D.



FIG. 83E.



FIG. 83F.



FIG. 83G.



FIG. 83H.



FIG. 83I.



FIG. 83J.



FIG. 83K.



FIG. 83L.



Fig. 84A

Fig. 84C



Fig. 84B



Fig. 84D


GZ17-6.02
Spheroid Formation
CSC Markers:Dclk1,
LGR5, EpCam, Sox9
CSC
Other Cells
Bax-Bcl2 ratio
Caspase 3
Apoptosis
pEGFR/pAkt
PCNA
Cell Cycle Proteins: Cyclin B
Cyclin A1 and Cyclin D
Check Point Proteins: Cdc2
and Cdc25C
SHH
Stemness
Proliferation
Tumor size
reduced
(Inhibition of
Metastasis)
Metastasis Markers: MMP2 & MMP9

HUMAN THERAPEUTIC AGENTS

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation of U.S. application Ser. No. 18/629,507, filed Apr. 8, 2024, which is a continuation of U.S. application Ser. No. 17/589,060, filed Jan. 31, 2022 (issued as U.S. Pat. No. 11,951,099 on Apr. 9, 2024), which is a continuation of U.S. application Ser. No. 17/000,164 filed Aug. 21, 2020 (issued as U.S. Pat. No. 11,266,634 on Mar. 8, 2022), which is a continuation of U.S. application Ser. No. 16/724,979 filed Dec. 23, 2019 (issued as U.S. Pat. No. 10,751,330 on Aug. 25, 2020), which is a continuation of U.S. application Ser. No. 16/541,665 filed Aug. 15, 2019 (issued as U.S. Pat. No. 10,576,067 on Mar. 3, 2020), which is a continuation of US application SN 16,213,774 filed Dec. 7, 2018 (issued as U.S. Pat. No. 10,471,049 on Nov. 12, 2019), which is a continuation of U.S. application Ser. No. 15/826,101 filed Nov. 29, 2017, which is a continuation of U.S. application Ser. No. 15/337,987 filed Oct. 28, 2016 (issued as U.S. Pat. No. 9,907,786 on Mar. 6, 2018), which is a continuation-in-part of PCT application SN PCT/US2015/055968 filed Oct. 16, 2015, which is a continuation-in-part of U.S. utility application Ser. No. 14/721,011 filed May 26, 2015 (issued as U.S. Pat. No. 9,402,834 on Aug. 2, 2016), and which claims the benefit of U.S. Provisional Applications, Ser. 62/184,051 filed Jun. 24, 2015, Ser. 62/161,090 filed May 13, 2015, and Ser. 62/066,686 filed Oct. 21, 2014. U.S. application Ser. No. 15/337,987 filed Oct. 28, 2016, is also a continuation of PCT Application SN PCT/IB2016/000723 filed Apr. 20, 2016, which is a continuation-in-part of U.S. utility application Ser. No. 14/721,011 filed May 26, 2015 (issued as U.S. Pat. No. 9,402,834 on Aug. 2, 2016), and which claims the benefit of U.S. Provisional Application Ser. 62/184,051 filed Jun. 24, 2015, and Ser. 62/161,090 filed May 13, 2015. Each of the above provisional, non-provisional, and PCT applications is incorporated by reference herein in its entirety.

BACKGROUND OF THE INVENTION

Field of the Invention

[0002] The present invention relates to combination chemotherapeutics for treatment of humans, and especially for the treatment of human cancers, and corresponding methods for the treatment of humans suffering from cancers or other maladies. The invention further provides dosage forms and regimens for administration to human patients, and methods of formulating and administering such dosage forms to yield improvements in treatment outcomes. More particularly, the invention is concerned with the administration of specific chemotherapeutic dosage forms (e.g., liquid mixtures, capsules, pills, or tablets) containing one or more curcumin component(s), harmine component(s), and isovanillin component(s), and sub-combinations thereof.

Description of Related Art

[0003] Cancer is a generic term for a large group of diseases that can affect any part of the body. Other terms used are malignant tumors and neoplasms. One defining feature of cancer is the rapid creation of abnormal cells that grow beyond their usual boundaries, and which can then invade adjoining parts of the body and spread to other organs. This process is referred to as metastasis. Metastases are the major cause of death from cancer.

[0004] The transformation from a normal cell into a tumor cell is a multistage process, typically a progression from a pre-cancerous lesion to malignant tumors. These changes are the result of the interaction between a person's genetic factors and three categories of external agents, including:

- **[0005]** physical carcinogens, such as ultraviolet and ionizing radiation
- **[0006]** chemical carcinogens, such as asbestos, components of tobacco smoke, aflatoxin (a food contaminant) and arsenic (a drinking water contaminant)
- **[0007]** biological carcinogens, such as infections from certain viruses, bacteria or parasites.

[0008] Some examples of infections associated with certain cancers:

- **[0009]** Viruses: hepatitis B and liver cancer, Human Papilloma Virus (HPV) and cervical cancer, and human immunodeficiency virus (HIV) and Kaposi sarcoma.
- **[0010]** Bacteria: *Helicobacter pylori* and stomach cancer.
- **[0011]** Parasites: schistosomiasis and bladder cancer.

[0012] Aging is another fundamental factor for the development of cancer. The incidence of cancer rises dramatically with age, most likely due to a buildup of risks for specific cancers that increase with age. The overall risk accumulation is combined with the tendency for cellular repair mechanisms to be less effective as a person grows older.

[0013] Tobacco use, alcohol use, low fruit and vegetable intake, and chronic infections from hepatitis B (HBV), hepatitis C virus (HCV) and some types of Human Papilloma Virus (HPV) are leading risk factors for cancer in low- and middle-income countries. Cervical cancer, which is caused by HPV, is a leading cause of cancer death among women in low-income countries. In high-income countries, tobacco use, alcohol use, and being overweight or obese are major risk factors for cancer.

[0014] The most common cancer treatment modalities are surgery, chemotherapy, and radiation treatments. All of these techniques have significant drawbacks in terms of side effects and patient discomfort. For example, chemotherapy may result in significant decreases in white blood cell count (neutropenia), red blood cell count (anemia), and platelet count (thrombocytopenia). This can result in pain, diarrhea, constipation, mouth sores, hair loss, nausea, and vomiting.

[0015] Biological therapy (sometimes called immunotherapy, biotherapy, or biological response modifier therapy) is a relatively new addition to the family of cancer treatments. Biological therapies use the body's immune system, either directly or indirectly, to fight cancer or to lessen the side effects that may be caused by some cancer treatments.

[0016] During chemotherapies involving multiple-drug treatments, adverse drug events are common, and indeed toxicities related to drug-drug interactions are one of the leading causes of hospitalizations in the US. Obach, R. S. "Drug-Drug Interactions: An Important Negative Attribute in Drugs." *Drugs Today* 39.5 (2003): 308-338. In fact, in any single-month period, one-fifth of all surveyed adults in the USA reported an adverse drug response. Hakkarainen, K. M. et al. "Prevalence and Perceived Preventability of Self-Reported Adverse Drug Events—A Population-Based Survey of 7,099 Adults." *PLoS One* 8.9 (2013): e73166. A large-scale study of adults aged 57-85 found that 29% were

taking more than five prescription medications and nearly 5% were at risk of major adverse drug-drug interactions. In the field of oncology, a review of over 400 cancer patients determined that 77% were taking drugs that were considered to have a moderately severe potential for adverse drug interactions, and 9% had major adverse drug interactions. Ghalib, M. S. et al. "Alterations of Chemotherapeutic Pharmocokinetic Profiles by Drug-Drug Interactions." *Expert Opin. Drug Metabl. Toxicol* 5.2 (2009): 109-130.

[0017] Such interactions are a global health problem, and the WHO has determined that negative drug interactions are leading causes of morbidity and mortality around the world, with up to 7% of all hospitalizations in the US due to negative drug interactions. A recent survey of a single hospital shows that 83% of hospitalized patients were prescribed drug combinations with the potential to cause adverse reactions. Patel, P. S. et al. "A Study of Potential Adverse Drug-Drug Interactions Among Prescribed Drugs in a Medicine Outpatient Department of a Tertiary Care Teaching Hospital." *J. Basic Clin. Pharm.* 5.2 (2014): 44-48.

[0018] Examples of famous negative drug interactions include the development of rhabdomyolysis, a severe muscle disease, when taking Simvastatin with Amiodarone. As a result, the FDA introduced a warning on the drug label about the interaction. The calcium channel blocker Mibefradif, taken for high blood pressure, was removed from the market because of the harmful interaction with drugs that work on the electrical activity of the heart.

[0019] Cancer cells are cells that, by definition, grow and divide without normal limitations. The unrestricted cell growth results in tumors, comprised of a variety of cell types. Treatments to fight cancer are frequently successful in killing the typical, differentiated cancer cells that form the majority of a solid tumor, otherwise known as the bulk cells. However even with the best treatment, the cancer may return a few months to years later (Prince, M. E. et al., "Cancer stem cells in head and neck squamous cell cancer." *J. Clin. Oncol.* 26.17 (2008):2871-2875). For example, recurrence is frequently the case for pancreatic and head and neck cancer. It is now hypothesized that one of the key factors in the recurrence rate for cancers is the presence of cancer stem cells.

[0020] Cancer stem cells were not identified until the late 1990s and show two important properties of stem cells: 1) cancer stem cells can self-renew and, 2) cancer stem cells can differentiate into any other cell type (Bandhavkar, S. "Cancer stem cells: a metastasizing menace." *Cancer Med.* (2016) doi:10.1002/cam4.629; Dick, J. E. "Stem cell concepts renew cancer research." *Blood.* 112 (2008):4793-4807). While they make up only a small percentage of the total number of cells in a tumor, they compromise a unique category of cancer cells that are more likely to be resistant to chemotherapy or radiation therapy. In fact, it is now believed that the majority of cells in tumors are not cancer-causing and cannot initiate new tumors (Bandhavkar). Only cancer stem cells appear to be tumor-initiators (Visvader, J. E. et al. "Cancer stem cells: Current status and evolving complexities." *Cell Stem Cell.* 10 (2012):717-728). Cancer stem cells have been shown to coordinate tumor cell growth, metastases (migration and invasion), and drug resistance (Cammarota, F. et al. "Mesenchymal stem/stromal cells in stromal evolution and cancer progression." *Stem Cells Int.* (2016):4824573). These cancer stem cells behave differently than non-cancerous stem cells in the person (Cammarota et al.), and have been described as the "roots of aggressive tumors for which we have no effective treatment" (Doherty, M. R. et al. "Cancer stem cell plasticity drives therapeutic resistance." *Cancers* 8,8 (2016) doi:10.3390). In general stem cells are naturally resistant to chemotherapies and radiation therapy (Diehn, M. et al. "Cancer stem cells and radiotherapy: new insights into tumor radioresistance." *J. Natl. Cancer Inst.* 98 (2016):1775-1757; Mery, B. et al. "Targeting head and neck tumoral stem cells: From biological aspects to therapeutic perspectives." *World J Stem Cells* 8.1 (2016):13-21), because they have chemical pumps that remove the chemotherapies out of the cells, thus they can have no effect on the stem cells. They also have a slow rate of turnover, and most radiation and chemotherapies are designed to only kill cells that are rapidly dividing, such as the majority of the cells within the tumor. These characteristics explain, on a large scale, how stem cells associated with cancer are resistant to chemotherapy.

[0021] Current anticancer therapies may directly cause cancer cells to die or just inhibit their growth (Bandhavkar). If the anticancer therapy fails to target and remove the cancer stem cells, then relapse and drug resistance ensues. Selectively targeting and eliminating cancer stem cells would theoretically treat the primary tumors and halt any chance of recurrence (Mery et al.). Yet, the ability to kill cancer stem cells is currently considered a significant clinical challenge. Some recent evidence suggests that traditional chemotherapies can even induce the generation of new stem cells within tumors potentially making the cancer return faster (Doherty et. al).

[0022] Identification of the regulatory mechanisms and signaling pathways involved in cancer stem cells (CSCs) will help in designing novel agents to target this refractory cell population in pancreatic cancers. Cancer stem cells are capable of self-renewal and generating tumors resembling the primary tumor (Ponnurangam, S. et al. "Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells." *Oncotarget* 7.3 (2015):3217-3232). The sphere-forming assays have been widely used to identify stem cells based on their reported capacity to evaluate self-renewal and differentiation.

[0023] U.S. Pat. No. 8,039,025 describes cancer treatments in the form of extracts of *Arum palaestinum* Boiss, supplemented with individual amounts of β-sitosterol, isovanillin, and linoleic acid, and this patent is incorporated by reference herein in its entirety.

[0024] Despite the immense amount of worldwide research and efforts to stem the tide of cancer and its side effects, the disease in its many manifestations continues to be a huge problem. Therefore, any new cancer treatment having a curative affect and/or the ability to ameliorate cancer symptoms and improve the lifestyle of patients is highly significant and important.

SUMMARY OF THE INVENTION

[0025] The present invention provides improved chemotherapeutics for treatment of humans, and especially in the treatment of human cancers, with novel combinations of compounds, which are useful against a wide variety of different cancers with minimal or nonexistent adverse side effects. Generally speaking, the chemotherapeutics of the invention comprise respective quantities of at least two of, curcumin component(s), harmine component(s), and isovanillin component(s). The preferred chemotherapeutics

include all three of these components, but sub-combinations thereof are also useful, i.e., therapeutics comprising curcumin component(s) and harmine component(s), curcumin component(s) and isovanillin component(s), and harmine component(s) and isovanillin component(s). In particularly preferred embodiments, the active components of the compositions (i.e., those having a significant therapeutic effect) consist essentially of curcumin, harmine, and isovanillin components in the case of three-component compositions, and consist essentially of two of the three components in the case of the two-component compositions. Preferably, the at least one curcumin component comprises curcumin, the at least one harmine component comprises harmine, and the at least one isovanillin component comprises isovanillin or vanillin.

[0026] The invention also provides new methods for treatment of cancers by administration of appropriate quantities of the anti-cancer compositions hereof. Hence, the compositions are particularly designed for use in the treatment of cancers, and the compositions can be used for the manufacture of medicaments of anti-cancer therapeutic applications. In addition, the invention provides pharmaceutical compositions for the treatment of cancers comprising administering therapeutically effective amounts of the new compositions, prepared by processes known per se, with a pharmaceutically acceptable carrier.

[0027] Curcumin (CAS #458-37-7) is a diaryl heptanoid, and has the molecular formula C21H20O6. Curcumin occurs as a part of a curcuminoid plant extract containing curcumin, demethoxycurcumin, and bis-demethoxycurcumin. One commercially available effective curcuminoid is sold as "Curcumin from *Curcuma Longa* (Turmeric)," which contains greater than 65% by weight curcumin, as determined by HPLC analysis.

[0028] Harmine (CAS #442-51-3) is a methoxy methyl pyrido indole belonging to the O-carboline family of compounds, and has the molecular formula C13H12N2O. Harmine occurs in a number of different plants native to the Middle East and South America.

[0029] Isovanillin (CAS #621-59-0) is a phenolic aldehyde vanillin isomer, and has the molecular formula C8H8O3.

[0030] A "chemotherapeutic" or "chemotherapeutic agent" as used herein refers to the combinations of chemical compounds described herein as useful in the treatment of human conditions, especially human cancers. Chemotherapeutics may be cytostatic, selectively toxic or destructive of cancerous tissue and/or cells, but also include indiscriminately cytotoxic compounds used in cancer treatments.

[0031] The combination therapeutic agents of the invention have been found to be effective in the treatment of a broad spectrum of human cancers, and also to other conditions, such as elevated PSA counts in men. The broad scope of utility with the agents of the invention is in itself highly unusual. However, this feature, together with the nonexistent or minimal side effects induced by the agents, represents a startling development in the art.

BRIEF DESCRIPTION OF THE DRAWINGS

[0032] FIG. **1** is a graph of cell number versus dosage amounts of GZ17-6.02, illustrating the effect thereof in inducing the death of two different types of human head and neck cancer cells, as described in Example 1;

[0033] FIG. **2**A is a graph of cell number versus dosage amounts of GZ17-6.02, illustrating the effect thereof GZ17-6.02 in inducing the death of pediatric leukemia cells, as described in Example 2;

[0034] FIG. **2**B is a graph of cell number versus dosage amounts of GZ17-6.02, illustrating the effect thereof GZ17-6.02 in inducing the death of pediatric osteosarcoma cells, as described in Example 2;

[0035] FIG. **3**A is a graph of cell number versus dosage amounts of GZ17-6.02, illustrating the effect thereof GZ17-6.02 in inducing the death of lymphoma cells, as described in Example 3;

[0036] FIG. **3**B is a graph of cell number versus dosage amounts of GZ17-6.02, illustrating the effect thereof GZ17-6.02 in inducing the death of lung cancer cells, as described in Example 3;

[0037] FIG. **4**A is a graph of cell number versus dosage amounts of GZ17-6.02, illustrating the effect thereof GZ17-6.02 in inducing the death of ovarian cancer cells, as described in Example 4;

[0038] FIG. **4**B is a graph of cell number versus dosage amounts of GZ17-6.02, illustrating the effect thereof in inducing the death of prostate cancer cells, as described in Example 4;

[0039] FIG. **5**A is a graph of cell number versus dosage amounts of GZ17-6.02, illustrating the effect thereof in inducing the death of human breast cancer cells, as described in Example 5;

[0040] FIG. **5**B is a graph of cell number versus dosage amounts of GZ17-6.02, illustrating the effect thereof in inducing the death of pancreatic cancer cells, as described in Example 5;

[0041] FIG. **6** is a graph of cell number versus doses of GZ17-6.02 illustrating the relative effects thereof in inducing cell death in prostate cancer and ovarian cancer cells, as compared with non-cancerous fibroblasts, as described in Example 6;

[0042] FIG. **7**A is a graph illustrating the effect of GZ17-6.02 in preventing migration of head and neck cancer cells, as described in Example 7;

[0043] FIG. **7**B is a graph illustrating the effect of GZ17-6.02 in preventing invasion of head and neck cancer cells, as described in Example 7;

[0044] FIG. **8** is a graph of normalized cell number versus increasing doxorubicin doses alone and with the addition of two different concentrations of GZ17-6.02, as described in Example 8;

[0045] FIG. **9**A is a graph illustrating extent of apoptosis in a control test, as described in Example 9, and illustrating about 19.8% cell death via apoptosis;

[0046] FIG. **9**B is a graph illustrating extent of apoptosis in a test identical to the control test of FIG. **9**A, but including GZ17-6.02, as described in Example 9, and illustrating about 48.2% cell death via apoptosis;

[0047] FIG. **10**A is a graph illustrating that caspase 3 and 7 concentrations increased in response to GZ17-6.02, but caspase 9 levels did not change in response to GZ17-6.02 in lung cancer cells, as described in Example 10;

[0048] FIG. **10**B is a graph illustrating that caspase 6 concentrations increased in response to GZ17-6.02 in lung cancer cells, as described in Example 10;

[0049] FIG. **10**C is a graph illustrating that ATP levels, as a marker of mitochondrial toxicity, were not increased by GZ17-6.02 in lung cancer cells, as described in Example 10;

[0050] FIG. **11**A is a graph illustrating the mechanisms of ovarian cancer cells death by application of GZ17-6.02, as explained in Example 11;

[0051] FIG. **11**B is a graph illustrating the mechanisms of ovarian cancer cells death by application of GZ17-6.02, as explained in Example 11;

[0052] FIG. **11**C is a graph illustrating the mechanisms of ovarian cancer cells death by application of GZ17-6.02, as explained in Example 11;

[0053] FIG. **11**D is a graph illustrating the mechanisms of ovarian cancer cells death by application of GZ17-6.02, as explained in Example 11;

[0054] FIG. **11**E is a graph illustrating the mechanisms of ovarian cancer cells death by application of GZ17-6.02, as explained in Example 11;

[0055] FIG. **12**A is a graph illustrating the mechanisms of osteosarcoma cells death by application of GZ17-6.02, as explained in Example 12;

[0056] FIG. **12**B is a graph illustrating the mechanisms of osteosarcoma cells death by application of GZ17-6.02, as explained in Example 12;

[0057] FIG. **12**C is a graph illustrating the mechanisms of osteosarcoma cells death by application of GZ17-6.02, as explained in Example 12;

[0058] FIG. **12**D is a graph illustrating the mechanisms of osteosarcoma cells death by application of GZ17-6.02, as explained in Example 12;

[0059] FIG. **13** is a graph illustrating the mechanisms of human head and neck cancer cells death by application of GZ17-6.02, as explained in Example 13;

[0060] FIG. **14**A is a control quantitative dot-blot, which measures the relative amount of proteins, known to be involved in cell proliferation described in Example 14, where the proteins were epidermal growth factor receptor (EGFR), extracellular-signal-regulated kinase (ERK1/2), the catalytic subunit of AMP-activated kinase (AMPKα2), β-catenin, and Chk-2.

[0061] FIG. **14**B is a quantitative dot-block similar to that described in FIG. **14**A, but illustrating the amounts of the test proteins upon application of GZ17-6.02, as described in Example 14;

[0062] FIG. **15**A is a graph depicting the results of two independent scientists, each carrying out an identical induced cell death test with GZ17-6.02 on ovarian cancer cells, as described in Example 15;

[0063] FIG. **15**B is a graph depicting the results of two independent scientists, each carrying out an identical induced cell death test with GZ17-6.02 on lung cancer cells, as described in Example 4; and

[0064] FIG. **16**A is a comparative graph of tumor volume versus days after cancer cell inoculation in mice, between control inoculations (ethanol vehicle) and test inoculations containing the vehicle and GZ17-6.02, illustrating the dramatic reduction in tumor volumes in the test mice, as explained in Example 16;

[0065] FIG. **16**B is a comparative graph of contralateral tumor volume versus days after cancer cell inoculation in mice, indicating a systemic effect of use of GZ17-6.02, as explained in Example 16;

[0066] FIG. **16**C is a graph of fractional tumor volume versus days after treatment wherein one group of mice was implanted with human head and neck tumor cells using an implantation vehicle, and a control group of mice was implanted with only the vehicle, in order to determine tumor volume over time, as set forth in Example 16;

[0067] FIG. **17**A is a graph of cell number versus dosage amounts of GZ17-6.02 (open circles) versus a combined product including ⅓ by weight of each GZ17-6.02 component (filled circles), tested on ovarian cancer cells, as described in Example 4;

[0068] FIG. **17**B is a graph of cell number versus dosage amounts of GZ17-6.02 (open circles) versus a combined product including ⅓ by weight of each GZ17-6.02 component (filled circles), tested on lung cancer cells, as described in Example 3;

[0069] FIG. **17**C is a graph of cell number versus dosage amounts of GZ17-6.02 (open circles) versus a combined product including ⅓ by weight of each GZ17-6.02 component (filled circles), tested on prostate cancer cells, as described in Example 4;

[0070] FIG. **18**A is a graph of percent ovarian cancer cell death versus different component combinations of GZ17-6.02, illustrating results using isovanillin alone, and two-component products respectively including isovanillin plus curcumin, and isovanillin plus harmine, where the isovanillin concentration was held constant throughout;

[0071] FIG. **18**B is a graph of percent lung cancer cell death versus different component combinations of GZ17-6.02, illustrating results using isovanillin alone, and two-component products respectively including isovanillin plus curcumin, and isovanillin plus harmine, where the isovanillin concentration was held constant throughout;

[0072] FIG. **18**C is a graph of percent prostate cancer cell death versus different component combinations of GZ17-6.02, illustrating results using isovanillin alone, and two-component products respectively including isovanillin plus curcumin, and isovanillin plus harmine, where the isovanillin concentration was held constant throughout;

[0073] FIG. **18**D is a graph of percent lymphoma cancer cell death versus different component combinations of GZ17-6.02, illustrating results using isovanillin alone, and two-component products respectively including isovanillin plus curcumin, and isovanillin plus harmine, where the isovanillin concentration was held constant throughout;

[0074] FIG. **19**A is a graph of percent ovarian cancer cell death versus different component combinations of GZ17-6.02, illustrating results using curcumin alone, and two-component products respectively including curcumin plus isovanillin, and curcumin plus harmine, where the curcumin concentration was held constant throughout;

[0075] FIG. **19**B is a graph of percent lung cancer cell death versus different component combinations of GZ17-6.02, illustrating results using curcumin alone, and two-component products respectively including curcumin plus isovanillin, and curcumin plus harmine, where the curcumin concentration was held constant throughout;

[0076] FIG. **19**C is a graph of percent prostate cancer cell death versus different component combinations of GZ17-6.02, illustrating results using curcumin alone, and two-component products respectively including curcumin plus isovanillin, and curcumin plus harmine, where the curcumin concentration was held constant throughout;

[0077] FIG. **19**D is a graph of percent lymphoma cancer cell death versus different component combinations of GZ17-6.02, illustrating results using curcumin alone, and two-component products respectively including curcumin

plus isovanillin, and curcumin plus harmine, where the curcumin concentration was held constant throughout;

[0078] FIG. **20**A is a graph of percent ovarian cancer cell death versus different component combinations of GZ17-6.02, illustrating results using harmine alone, and two-component products respectively including harmine plus isovanillin, and harmine plus curcumin, where the harmine concentration was held constant throughout;

[0079] FIG. **20**B is a graph of percent lung cancer cell death versus different component combinations of GZ17-6.02, illustrating results using harmine alone, and two-component products respectively including harmine plus isovanillin, and harmine plus curcumin, where the harmine concentration was held constant throughout;

[0080] FIG. **20**C is a graph of percent prostate cancer cell death versus different component combinations of GZ17-6.02, illustrating results using harmine alone, and two-component products respectively including harmine plus isovanillin, and harmine plus curcumin, where the harmine concentration was held constant throughout;

[0081] FIG. **20**D is a graph of percent lymphoma cancer cell death versus different component combinations of GZ17-6.02, illustrating results using harmine alone, and two-component products respectively including harmine plus isovanillin, and harmine plus curcumin, where the harmine concentration was held constant throughout;

[0082] FIG. **21**A is a graph of lymphoma cancer cell lethality using GZ17-6.02 at a dosage rate of 12 μg/mL, and using the three components of GZ17-6.02 individually at the concentration present in GZ17-6.02, and further illustrating the theoretical additive effect of the three components versus GZ17-6.02;

[0083] FIG. **21**B is a graph of lymphoma cancer cell lethality using GZ17-6.02 at a dosage rate of 24 μg/mL, and using the three components of GZ17-6.02 individually at the concentration present in GZ17-6.02, and further illustrating the theoretical additive effect of the three components versus GZ17-6.02;

[0084] FIG. **21**C is a graph of lymphoma cancer cell lethality using GZ17-6.02 at a dosage rate of 48 μg/mL, and using the three components of GZ17-6.02 individually at the concentration present in GZ17-6.02, and further illustrating the theoretical additive effect of the three components versus GZ17-6.02;

[0085] FIG. **21**D is a graph of lymphoma cancer cell lethality using GZ17-6.02 at a dosage rate of 96 μg/mL, and using the three components of GZ17-6.02 individually at the concentration present in GZ17-6.02, and further illustrating the theoretical additive effect of the three components versus GZ17-6.02;

[0086] FIG. **22**A is a graph of ovarian cancer cell lethality using GZ17-6.02 at a dosage rate of 12 μg/mL, and using the three components of GZ17-6.02 individually at the concentration present in GZ17-6.02, and further illustrating the theoretical additive effect of the three components versus GZ17-6.02;

[0087] FIG. **22**B is a graph of ovarian cancer cell lethality using GZ17-6.02 at a dosage rate of 24 μg/mL, and using the three components of GZ17-6.02 individually at the concentration present in GZ17-6.02, and further illustrating the theoretical additive effect of the three components versus GZ17-6.02;

[0088] FIG. **22**C is a graph of breast cancer cell lethality using GZ17-6.02 at a dosage rate of 24 μg/mL, and using the three components of GZ17-6.02 individually at the concentration present in GZ17-6.02, and further illustrating the theoretical additive effect of the three components versus GZ17-6.02;

[0089] FIG. **23**A is a graph of lung cancer cell number versus increasing dosage amounts of vanillin alone, as described in Example 1;

[0090] FIG. **23**B is a graph of lung cancer cell number versus increasing dosage amounts of isovanillic acid alone, as described in Example 1;

[0091] FIG. **23**C is a graph of lung cancer cell number versus increasing dosage amounts of 0-vanillin alone, as described in Example 1;

[0092] FIG. **23**D is a graph of lung cancer cell number versus increasing dosage amounts of isovanillyl alcohol alone, as described in Example 1;

[0093] FIG. **23**E is a graph of ovarian cancer cell number versus increasing dosage amounts of vanillin alone, as described in Example 1;

[0094] FIG. **23**F is a graph of ovarian cancer cell number versus increasing dosage amounts of isovanillic acid alone, as described in Example 1;

[0095] FIG. **23**G is a graph of ovarian cancer cell number versus increasing dosage amounts of 0-vanillin alone, as described in Example 1;

[0096] FIG. **23**H is a graph of ovarian cancer cell number versus increasing dosage amounts of isovanillyl alcohol alone, as described in Example 1;

[0097] FIG. **23**I is a graph of prostate cancer cell number versus increasing dosage amounts of vanillin alone, as described in Example 1;

[0098] FIG. **23**J is a graph of prostate cancer cell number versus increasing dosage amounts of isovanillic acid alone, as described in Example 1;

[0099] FIG. **23**K is a graph of prostate cancer cell number versus increasing dosage amounts of 0-vanillin alone, as described in Example 1;

[0100] FIG. **23**L is a graph of prostate cancer cell number versus increasing dosage amounts of isovanillyl alcohol alone, as described in Example 1;

[0101] FIG. **24**A is a graph of lung cancer cell number versus increasing dosage amounts of harmaline alone, as described in Example 1;

[0102] FIG. **24**B is a graph of lung cancer cell number versus increasing dosage amounts of tetrahydro-harmine alone, as described in Example 1;

[0103] FIG. **24**C is a graph of lung cancer cell number versus increasing dosage amounts of harmol hydrochloride alone, as described in Example 1;

[0104] FIG. **24**D is a graph of lung cancer cell number versus increasing dosage amounts of harmalol hydrochloride dihydrate alone, as described in Example 1;

[0105] FIG. **24**E is a graph of lung cancer cell number versus increasing dosage amounts of harmane alone, as described in Example 1;

[0106] FIG. **24**F is a graph of ovarian cancer cell number versus increasing dosage amounts of harmaline alone, as described in Example 1;

[0107] FIG. **24**G is a graph of ovarian cancer cell number versus increasing dosage amounts of tetrahydro-harmine alone, as described in Example 1;

[0108] FIG. **24**H is a graph of ovarian cancer cell number versus increasing dosage amounts of harmol hydrochloride alone, as described in Example 1;

[0109] FIG. **24**I is a graph of ovarian cancer cell number versus increasing dosage amounts of harmalol hydrochloride dihydrate alone, as described in Example 1;

[0110] FIG. **24**J is a graph of ovarian cancer cell number versus increasing dosage amounts of harmane alone, as described in Example 1;

[0111] FIG. **24**K is a graph of prostate cancer cell number versus increasing dosage amounts of harmaline alone, as described in Example 1;

[0112] FIG. **24**L is a graph of prostate cancer cell number versus increasing dosage amounts of tetrahydro-harmine alone, as described in Example 1;

[0113] FIG. **24**M is a graph of prostate cancer cell number versus increasing dosage amounts of harmol hydrochloride alone, as described in Example 1;

[0114] FIG. **24**N is a graph of prostate cancer cell number versus increasing dosage amounts of harmalol hydrochloride dihydrate alone, as described in Example 1;

[0115] FIG. **24**O is a graph of prostate cancer cell number versus increasing dosage amounts of harmane alone, as described in Example 1;

[0116] FIG. **25**A is a graph of lung cancer cell number versus increasing dosage amounts of bisdemethoxy curcumin alone, as described in Example 1;

[0117] FIG. **25**B is a graph of ovarian cancer cell number versus increasing dosage amounts of bisdemethoxy curcumin alone, as described in Example 1;

[0118] FIG. **25**C is a graph of prostate cancer cell number versus increasing dosage amounts of bisdemethoxy curcumin alone, as described in Example 1;

[0119] FIG. **26** is a graph of ovarian cancer cell number versus dosage amounts of GZ17-6.02 where the product was stored at varying temperatures over two months, confirming that the product has long-term stability;

[0120] FIG. **27** is a graph of ovarian cancer cell number versus dosage amounts of GZ17-6.02, where the GZ17-6.02 was subjected to a series of successive freeze/thaw cycles, confirming that the product has excellent freeze/thaw stability;

[0121] FIG. **28**A is a graph of cell number versus dosage amounts of GZ17-8.02, illustrating the effect thereof in inducing the death of two different types ovarian cancer, lung cancer, prostate cancer, pancreatic cancer and fibroblast cells, as described in Example 28;

[0122] FIG. **28**B is a graph of cell number versus dosage amounts of GZ17-8.03, illustrating the effect thereof in inducing the death of ovarian cancer, lung cancer, prostate cancer, pancreatic cancer and fibroblast cells, as described in Example 28;

[0123] FIG. **28**C is a graph of cell number versus dosage amounts of GZ17-8.04, illustrating the effect thereof in inducing the death of ovarian cancer, lung cancer, prostate cancer, pancreatic cancer and fibroblast cells, as described in Example 28;

[0124] FIG. **28**D is a graph of cell number versus dosage amounts of GZ17-8.05, illustrating the effect thereof in inducing the death of ovarian cancer, lung cancer, prostate cancer, pancreatic cancer and fibroblast cells, as described in Example 28;

[0125] FIG. **28**E is a graph of cell number versus dosage amounts of GZ17-8.06, illustrating the effect thereof in inducing the death of ovarian cancer, lung cancer, prostate cancer, pancreatic cancer and fibroblast cells, as described in Example 28;

[0126] FIG. **28**F is a graph of cell number versus dosage amounts of GZ17-8.07, illustrating the effect thereof in inducing the death of ovarian cancer, lung cancer, prostate cancer, pancreatic cancer and fibroblast cells, as described in Example 28;

[0127] FIG. **28**G is a graph of cell number versus dosage amounts of GZ17-8.08, illustrating the effect thereof in inducing the death of ovarian cancer, lung cancer, prostate cancer, pancreatic cancer and fibroblast cells, as described in Example 28;

[0128] FIG. **28**H is a graph of cell number versus dosage amounts of GZ17-8.09, illustrating the effect thereof in inducing the death of ovarian cancer, lung cancer, prostate cancer, pancreatic cancer and fibroblast cells, as described in Example 28;

[0129] FIG. **28**I is a graph of cell number versus dosage amounts of GZ17-8.10, illustrating the effect thereof in inducing the death of ovarian cancer, lung cancer, prostate cancer, pancreatic cancer and fibroblast cells, as described in Example 28;

[0130] FIG. **29**A is a graph of cell number versus dosage amounts of GZ17-8.11, illustrating the effect thereof in inducing the death of ovarian cancer;

[0131] FIG. **29**B is a graph of cell number versus dosage amounts of GZ17-8.11, illustrating the effect thereof in inducing the death of lung cancer;

[0132] FIG. **29**C is a graph of cell number versus dosage amounts of GZ17-8.11, illustrating the effect thereof in inducing the death of prostate cancer;

[0133] FIG. **29**D is a graph of cell number versus dosage amounts of GZ17-8.11, illustrating the effect thereof in inducing the death of head and neck cancer;

[0134] FIG. **29**E is a graph of cell number versus dosage amounts of GZ17-8.11, illustrating the effect thereof in inducing the death of breast cancer;

[0135] FIG. **29**F is a graph of cell number versus dosage amounts of GZ17-8.11, illustrating the effect thereof in inducing the death of leukemia;

[0136] FIG. **29**G is a graph of cell number versus dosage amounts of GZ17-8.11, illustrating the effect thereof in inducing the death of lymphoma;

[0137] FIG. **30**A is a graph of cell number versus dosage amounts of GZ17-8.12, illustrating the effect thereof in inducing the death of ovarian cancer;

[0138] FIG. **30**B is a graph of cell number versus dosage amounts of GZ17-8.12, illustrating the effect thereof in inducing the death of lung cancer;

[0139] FIG. **30**C is a graph of cell number versus dosage amounts of GZ17-8.12, illustrating the effect thereof in inducing the death of prostate cancer;

[0140] FIG. **30**D is a graph of cell number versus dosage amounts of GZ17-8.12, illustrating the effect thereof in inducing the death of head and neck cancer;

[0141] FIG. **30**E is a graph of cell number versus dosage amounts of GZ17-8.12, illustrating the effect thereof in inducing the death of breast cancer;

[0142] FIG. **30**F is a graph of cell number versus dosage amounts of GZ17-8.12, illustrating the effect thereof in inducing the death of leukemia;

[0143] FIG. **30**G is a graph of cell number versus dosage amounts of GZ17-8.12, illustrating the effect thereof in inducing the death of lymphoma;

[0144] FIG. **31**A is a graph of cell number versus dosage amounts of GZ17-8.13, illustrating the effect thereof in inducing the death of ovarian cancer;

[0145] FIG. **31**B is a graph of cell number versus dosage amounts of GZ17-8.13, illustrating the effect thereof in inducing the death of lung cancer;

[0146] FIG. **31**C is a graph of cell number versus dosage amounts of GZ17-8.13, illustrating the effect thereof in inducing the death of prostate cancer;

[0147] FIG. **31**D is a graph of cell number versus dosage amounts of GZ17-8.13, illustrating the effect thereof in inducing the death of head and neck cancer;

[0148] FIG. **31**E is a graph of cell number versus dosage amounts of GZ17-8.13, illustrating the effect thereof in inducing the death of breast cancer;

[0149] FIG. **31**F is a graph of cell number versus dosage amounts of GZ17-8.13, illustrating the effect thereof in inducing the death of leukemia;

[0150] FIG. **31**G is a graph of cell number versus dosage amounts of GZ17-8.13, illustrating the effect thereof in inducing the death of lymphoma;

[0151] FIG. **32**A is a graph of cell number versus dosage amounts of GZ17-8.14, illustrating the effect thereof in inducing the death of ovarian cancer;

[0152] FIG. **32**B is a graph of cell number versus dosage amounts of GZ17-8.14, illustrating the effect thereof in inducing the death of lung cancer;

[0153] FIG. **32**C is a graph of cell number versus dosage amounts of GZ17-8.14, illustrating the effect thereof in inducing the death of prostate cancer;

[0154] FIG. **32**D is a graph of cell number versus dosage amounts of GZ17-8.14, illustrating the effect thereof in inducing the death of head and neck cancer;

[0155] FIG. **32**E is a graph of cell number versus dosage amounts of GZ17-8.14, illustrating the effect thereof in inducing the death of breast cancer;

[0156] FIG. **32**F is a graph of cell number versus dosage amounts of GZ17-8.14, illustrating the effect thereof in inducing the death of leukemia;

[0157] FIG. **32**G is a graph of cell number versus dosage amounts of GZ17-8.14, illustrating the effect thereof in inducing the death of lymphoma;

[0158] FIG. **33**A is a graph of cell number versus dosage amounts of GZ17-8.15, illustrating the effect thereof in inducing the death of ovarian cancer;

[0159] FIG. **33**B is a graph of cell number versus dosage amounts of GZ17-8.15, illustrating the effect thereof in inducing the death of lung cancer;

[0160] FIG. **33**C is a graph of cell number versus dosage amounts of GZ17-8.15, illustrating the effect thereof in inducing the death of prostate cancer;

[0161] FIG. **33**D is a graph of cell number versus dosage amounts of GZ17-8.15, illustrating the effect thereof in inducing the death of head and neck cancer;

[0162] FIG. **33**E is a graph of cell number versus dosage amounts of GZ17-8.15, illustrating the effect thereof in inducing the death of breast cancer;

[0163] FIG. **33**F is a graph of cell number versus dosage amounts of GZ17-8.15, illustrating the effect thereof in inducing the death of leukemia;

[0164] FIG. **33**G is a graph of cell number versus dosage amounts of GZ17-8.15, illustrating the effect thereof in inducing the death of lymphoma;

[0165] FIG. **34**A is a graph of cell number versus dosage amounts of GZ17-8.16, illustrating the effect thereof in inducing the death of ovarian cancer;

[0166] FIG. **34**B is a graph of cell number versus dosage amounts of GZ17-8.16, illustrating the effect thereof in inducing the death of lung cancer;

[0167] FIG. **34**C is a graph of cell number versus dosage amounts of GZ17-8.16, illustrating the effect thereof in inducing the death of prostate cancer;

[0168] FIG. **34**D is a graph of cell number versus dosage amounts of GZ17-8.16, illustrating the effect thereof in inducing the death of head and neck cancer;

[0169] FIG. **34**E is a graph of cell number versus dosage amounts of GZ17-8.16, illustrating the effect thereof in inducing the death of breast cancer;

[0170] FIG. **34**F is a graph of cell number versus dosage amounts of GZ17-8.16, illustrating the effect thereof in inducing the death of leukemia;

[0171] FIG. **34**G is a graph of cell number versus dosage amounts of GZ17-8.16, illustrating the effect thereof in inducing the death of lymphoma;

[0172] FIG. **35**A is a graph of cell number versus dosage amounts of GZ17-8.17, illustrating the effect thereof in inducing the death of ovarian cancer;

[0173] FIG. **35**B is a graph of cell number versus dosage amounts of GZ17-8.17, illustrating the effect thereof in inducing the death of lung cancer;

[0174] FIG. **35**C is a graph of cell number versus dosage amounts of GZ17-8.17, illustrating the effect thereof in inducing the death of prostate cancer;

[0175] FIG. **35**D is a graph of cell number versus dosage amounts of GZ17-8.17, illustrating the effect thereof in inducing the death of head and neck cancer;

[0176] FIG. **35**E is a graph of cell number versus dosage amounts of GZ17-8.17, illustrating the effect thereof in inducing the death of breast cancer;

[0177] FIG. **35**F is a graph of cell number versus dosage amounts of GZ17-8.17, illustrating the effect thereof in inducing the death of leukemia;

[0178] FIG. **35**G is a graph of cell number versus dosage amounts of GZ17-8.17, illustrating the effect thereof in inducing the death of lymphoma;

[0179] FIG. **36**A is a graph of cell number versus dosage amounts of GZ17-8.18, illustrating the effect thereof in inducing the death of ovarian cancer;

[0180] FIG. **36**B is a graph of cell number versus dosage amounts of GZ17-8.18, illustrating the effect thereof in inducing the death of lung cancer;

[0181] FIG. **36**C is a graph of cell number versus dosage amounts of GZ17-8.18, illustrating the effect thereof in inducing the death of prostate cancer;

[0182] FIG. **36**D is a graph of cell number versus dosage amounts of GZ17-8.18, illustrating the effect thereof in inducing the death of head and neck cancer;

[0183] FIG. **36**E is a graph of cell number versus dosage amounts of GZ17-8.18, illustrating the effect thereof in inducing the death of breast cancer;

[0184] FIG. **36**F is a graph of cell number versus dosage amounts of GZ17-8.18, illustrating the effect thereof in inducing the death of leukemia;

[0185] FIG. **36**G is a graph of cell number versus dosage amounts of GZ17-8.18, illustrating the effect thereof in inducing the death of lymphoma;

[0186] FIG. **37**A is a graph of cell number versus dosage amounts of GZ17-8.19, illustrating the effect thereof in inducing the death of ovarian cancer;

[0187] FIG. **37**B is a graph of cell number versus dosage amounts of GZ17-8.19, illustrating the effect thereof in inducing the death of lung cancer;

[0188] FIG. **37**C is a graph of cell number versus dosage amounts of GZ17-8.19, illustrating the effect thereof in inducing the death of prostate cancer;

[0189] FIG. **37**D is a graph of cell number versus dosage amounts of GZ17-8.19, illustrating the effect thereof in inducing the death of head and neck cancer;

[0190] FIG. **37**E is a graph of cell number versus dosage amounts of GZ17-8.19, illustrating the effect thereof in inducing the death of breast cancer;

[0191] FIG. **37**F is a graph of cell number versus dosage amounts of GZ17-8.19, illustrating the effect thereof in inducing the death of leukemia;

[0192] FIG. **37**G is a graph of cell number versus dosage amounts of GZ17-8.19, illustrating the effect thereof in inducing the death of lymphoma;

[0193] FIG. **38**A is a graph of cell number versus dosage amounts of GZ17-8.20, illustrating the effect thereof in inducing the death of ovarian cancer;

[0194] FIG. **38**B is a graph of cell number versus dosage amounts of GZ17-8.20, illustrating the effect thereof in inducing the death of lung cancer;

[0195] FIG. **38**C is a graph of cell number versus dosage amounts of GZ17-8.20, illustrating the effect thereof in inducing the death of prostate cancer;

[0196] FIG. **38**D is a graph of cell number versus dosage amounts of GZ17-8.20, illustrating the effect thereof in inducing the death of head and neck cancer;

[0197] FIG. **38**E is a graph of cell number versus dosage amounts of GZ17-8.20, illustrating the effect thereof in inducing the death of breast cancer;

[0198] FIG. **38**F is a graph of cell number versus dosage amounts of GZ17-8.20, illustrating the effect thereof in inducing the death of leukemia;

[0199] FIG. **38**G is a graph of cell number versus dosage amounts of GZ17-8.20, illustrating the effect thereof in inducing the death of lymphoma;

[0200] FIG. **39**A is a graph of cell number versus dosage amounts of GZ17-8.21, illustrating the effect thereof in inducing the death of ovarian cancer;

[0201] FIG. **39**B is a graph of cell number versus dosage amounts of GZ17-8.21, illustrating the effect thereof in inducing the death of lung cancer;

[0202] FIG. **39**C is a graph of cell number versus dosage amounts of GZ17-8.21, illustrating the effect thereof in inducing the death of prostate cancer;

[0203] FIG. **39**D is a graph of cell number versus dosage amounts of GZ17-8.21, illustrating the effect thereof in inducing the death of head and neck cancer;

[0204] FIG. **39**E is a graph of cell number versus dosage amounts of GZ17-8.21, illustrating the effect thereof in inducing the death of breast cancer;

[0205] FIG. **39**F is a graph of cell number versus dosage amounts of GZ17-8.21, illustrating the effect thereof in inducing the death of leukemia;

[0206] FIG. **39**G is a graph of cell number versus dosage amounts of GZ17-8.21, illustrating the effect thereof in inducing the death of lymphoma;

[0207] FIG. **40**A is a graph of cell number versus dosage amounts of GZ17-8.22, illustrating the effect thereof in inducing the death of ovarian cancer;

[0208] FIG. **40**B is a graph of cell number versus dosage amounts of GZ17-8.22, illustrating the effect thereof in inducing the death of lung cancer;

[0209] FIG. **40**C is a graph of cell number versus dosage amounts of GZ17-8.22, illustrating the effect thereof in inducing the death of prostate cancer;

[0210] FIG. **40**D is a graph of cell number versus dosage amounts of GZ17-8.22, illustrating the effect thereof in inducing the death of head and neck cancer;

[0211] FIG. **40**E is a graph of cell number versus dosage amounts of GZ17-8.22, illustrating the effect thereof in inducing the death of breast cancer;

[0212] FIG. **40**F is a graph of cell number versus dosage amounts of GZ17-8.22, illustrating the effect thereof in inducing the death of leukemia;

[0213] FIG. **40**G is a graph of cell number versus dosage amounts of GZ17-8.22, illustrating the effect thereof in inducing the death of lymphoma;

[0214] FIG. **41**A is a graph of cell number versus dosage amounts of GZ17-8.23, illustrating the effect thereof in inducing the death of ovarian cancer;

[0215] FIG. **41**B is a graph of cell number versus dosage amounts of GZ17-8.23, illustrating the effect thereof in inducing the death of lung cancer;

[0216] FIG. **41**C is a graph of cell number versus dosage amounts of GZ17-8.23, illustrating the effect thereof in inducing the death of prostate cancer;

[0217] FIG. **41**D is a graph of cell number versus dosage amounts of GZ17-8.23, illustrating the effect thereof in inducing the death of head and neck cancer;

[0218] FIG. **41**E is a graph of cell number versus dosage amounts of GZ17-8.23, illustrating the effect thereof in inducing the death of breast cancer;

[0219] FIG. **41**F is a graph of cell number versus dosage amounts of GZ17-8.23, illustrating the effect thereof in inducing the death of leukemia;

[0220] FIG. **41**G is a graph of cell number versus dosage amounts of GZ17-8.23, illustrating the effect thereof in inducing the death of lymphoma;

[0221] FIG. **42**A is a graph of cell number versus dosage amounts of GZ17-8.24, illustrating the effect thereof in inducing the death of ovarian cancer;

[0222] FIG. **42**B is a graph of cell number versus dosage amounts of GZ17-8.24, illustrating the effect thereof in inducing the death of lung cancer;

[0223] FIG. **42**C is a graph of cell number versus dosage amounts of GZ17-8.24, illustrating the effect thereof in inducing the death of prostate cancer;

[0224] FIG. **42**D is a graph of cell number versus dosage amounts of GZ17-8.24, illustrating the effect thereof in inducing the death of head and neck cancer;

[0225] FIG. **42**E is a graph of cell number versus dosage amounts of GZ17-8.24, illustrating the effect thereof in inducing the death of breast cancer;

[0226] FIG. **42**F is a graph of cell number versus dosage amounts of GZ17-8.24, illustrating the effect thereof in inducing the death of leukemia;

[0227] FIG. **42**G is a graph of cell number versus dosage amounts of GZ17-8.24, illustrating the effect thereof in inducing the death of lymphoma;

[0228] FIG. **43**A is a graph of cell number versus dosage amounts of GZ17-8.25, illustrating the effect thereof in inducing the death of ovarian cancer;

[0229] FIG. **43**B is a graph of cell number versus dosage amounts of GZ17-8.25, illustrating the effect thereof in inducing the death of lung cancer;

[0230] FIG. **43**C is a graph of cell number versus dosage amounts of GZ17-8.25, illustrating the effect thereof in inducing the death of prostate cancer;

[0231] FIG. **43**D is a graph of cell number versus dosage amounts of GZ17-8.25, illustrating the effect thereof in inducing the death of head and neck cancer;

[0232] FIG. **43**E is a graph of cell number versus dosage amounts of GZ17-8.25, illustrating the effect thereof in inducing the death of breast cancer;

[0233] FIG. **43**F is a graph of cell number versus dosage amounts of GZ17-8.25, illustrating the effect thereof in inducing the death of leukemia;

[0234] FIG. **43**G is a graph of cell number versus dosage amounts of GZ17-8.25, illustrating the effect thereof in inducing the death of lymphoma;

[0235] FIG. **44**A is a graph of cell number versus dosage amounts of GZ17-8.26, illustrating the effect thereof in inducing the death of ovarian cancer;

[0236] FIG. **44**B is a graph of cell number versus dosage amounts of GZ17-8.26, illustrating the effect thereof in inducing the death of lung cancer;

[0237] FIG. **44**C is a graph of cell number versus dosage amounts of GZ17-8.26, illustrating the effect thereof in inducing the death of prostate cancer;

[0238] FIG. **44**D is a graph of cell number versus dosage amounts of GZ17-8.26, illustrating the effect thereof in inducing the death of head and neck cancer;

[0239] FIG. **44**E is a graph of cell number versus dosage amounts of GZ17-8.26, illustrating the effect thereof in inducing the death of breast cancer;

[0240] FIG. **44**F is a graph of cell number versus dosage amounts of GZ17-8.26, illustrating the effect thereof in inducing the death of leukemia;

[0241] FIG. **44**G is a graph of cell number versus dosage amounts of GZ17-8.26, illustrating the effect thereof in inducing the death of lymphoma;

[0242] FIG. **45**A is a graph of cell number versus dosage amounts of GZ17-8.27, illustrating the effect thereof in inducing the death of ovarian cancer;

[0243] FIG. **45**B is a graph of cell number versus dosage amounts of GZ17-8.27, illustrating the effect thereof in inducing the death of lung cancer;

[0244] FIG. **45**C is a graph of cell number versus dosage amounts of GZ17-8.27, illustrating the effect thereof in inducing the death of prostate cancer;

[0245] FIG. **45**D is a graph of cell number versus dosage amounts of GZ17-8.27, illustrating the effect thereof in inducing the death of head and neck cancer;

[0246] FIG. **45**E is a graph of cell number versus dosage amounts of GZ17-8.27, illustrating the effect thereof in inducing the death of breast cancer;

[0247] FIG. **45**F is a graph of cell number versus dosage amounts of GZ17-8.27, illustrating the effect thereof in inducing the death of leukemia;

[0248] FIG. **45**G is a graph of cell number versus dosage amounts of GZ17-8.27, illustrating the effect thereof in inducing the death of lymphoma;

[0249] FIG. **46**A is a graph of cell number versus dosage amounts of GZ17-8.28, illustrating the effect thereof in inducing the death of ovarian cancer;

[0250] FIG. **46**B is a graph of cell number versus dosage amounts of GZ17-8.28, illustrating the effect thereof in inducing the death of lung cancer;

[0251] FIG. **46**C is a graph of cell number versus dosage amounts of GZ17-8.28, illustrating the effect thereof in inducing the death of prostate cancer;

[0252] FIG. **46**D is a graph of cell number versus dosage amounts of GZ17-8.28, illustrating the effect thereof in inducing the death of head and neck cancer;

[0253] FIG. **46**E is a graph of cell number versus dosage amounts of GZ17-8.28, illustrating the effect thereof in inducing the death of breast cancer;

[0254] FIG. **46**F is a graph of cell number versus dosage amounts of GZ17-8.28, illustrating the effect thereof in inducing the death of leukemia;

[0255] FIG. **46**G is a graph of cell number versus dosage amounts of GZ17-8.28, illustrating the effect thereof in inducing the death of lymphoma;

[0256] FIG. **47**A is a graph of cell number versus dosage amounts of GZ17-8.29, illustrating the effect thereof in inducing the death of ovarian cancer;

[0257] FIG. **47**B is a graph of cell number versus dosage amounts of GZ17-8.29, illustrating the effect thereof in inducing the death of lung cancer;

[0258] FIG. **47**C is a graph of cell number versus dosage amounts of GZ17-8.29, illustrating the effect thereof in inducing the death of prostate cancer;

[0259] FIG. **47**D is a graph of cell number versus dosage amounts of GZ17-8.29, illustrating the effect thereof in inducing the death of head and neck cancer;

[0260] FIG. **47**E is a graph of cell number versus dosage amounts of GZ17-8.29, illustrating the effect thereof in inducing the death of breast cancer;

[0261] FIG. **47**F is a graph of cell number versus dosage amounts of GZ17-8.29, illustrating the effect thereof in inducing the death of leukemia;

[0262] FIG. **47**G is a graph of cell number versus dosage amounts of GZ17-8.29, illustrating the effect thereof in inducing the death of lymphoma;

[0263] FIG. **48**A is a graph of cell number versus dosage amounts of GZ17-8.30, illustrating the effect thereof in inducing the death of ovarian cancer;

[0264] FIG. **48**B is a graph of cell number versus dosage amounts of GZ17-8.30, illustrating the effect thereof in inducing the death of lung cancer;

[0265] FIG. **48**C is a graph of cell number versus dosage amounts of GZ17-8.30, illustrating the effect thereof in inducing the death of prostate cancer;

[0266] FIG. **48**D is a graph of cell number versus dosage amounts of GZ17-8.30, illustrating the effect thereof in inducing the death of head and neck cancer;

[0267] FIG. **48**E is a graph of cell number versus dosage amounts of GZ17-8.30, illustrating the effect thereof in inducing the death of breast cancer;

[0268] FIG. **48**F is a graph of cell number versus dosage amounts of GZ17-8.30, illustrating the effect thereof in inducing the death of leukemia;

[0269] FIG. **48**G is a graph of cell number versus dosage amounts of GZ17-8.30, illustrating the effect thereof in inducing the death of lymphoma;

[0270] FIG. **49**A is a graph of cell number versus dosage amounts of GZ17-8.31, illustrating the effect thereof in inducing the death of ovarian cancer;

[0271] FIG. **49**B is a graph of cell number versus dosage amounts of GZ17-8.31, illustrating the effect thereof in inducing the death of lung cancer;

[0272] FIG. **49**C is a graph of cell number versus dosage amounts of GZ17-8.31, illustrating the effect thereof in inducing the death of lymphoma;

[0273] FIG. **49**D is a graph of cell number versus dosage amounts of GZ17-8.31, illustrating the effect thereof in inducing the death of leukemia;

[0274] FIG. **50**A is a graph of cell number versus dosage amounts of GZ17-8.32, illustrating the effect thereof in inducing the death of ovarian cancer;

[0275] FIG. **50**B is a graph of cell number versus dosage amounts of GZ17-8.32, illustrating the effect thereof in inducing the death of lung cancer;

[0276] FIG. **50**C is a graph of cell number versus dosage amounts of GZ17-8.32, illustrating the effect thereof in inducing the death of lymphoma;

[0277] FIG. **50**D is a graph of cell number versus dosage amounts of GZ17-8.32, illustrating the effect thereof in inducing the death of leukemia;

[0278] FIG. **51**A is a graph of cell number versus dosage amounts of GZ17-8.33, illustrating the effect thereof in inducing the death of ovarian cancer;

[0279] FIG. **51**B is a graph of cell number versus dosage amounts of GZ17-8.33, illustrating the effect thereof in inducing the death of lung cancer;

[0280] FIG. **51**C is a graph of cell number versus dosage amounts of GZ17-8.33, illustrating the effect thereof in inducing the death of lymphoma;

[0281] FIG. **51**D is a graph of cell number versus dosage amounts of GZ17-8.33, illustrating the effect thereof in inducing the death of leukemia;

[0282] FIG. **52**A is a graph of cell number versus dosage amounts of GZ17-8.34, illustrating the effect thereof in inducing the death of ovarian cancer;

[0283] FIG. **52**B is a graph of cell number versus dosage amounts of GZ17-8.34, illustrating the effect thereof in inducing the death of lung cancer;

[0284] FIG. **52**C is a graph of cell number versus dosage amounts of GZ17-8.34, illustrating the effect thereof in inducing the death of lymphoma;

[0285] FIG. **52**D is a graph of cell number versus dosage amounts of GZ17-8.34, illustrating the effect thereof in inducing the death of leukemia;

[0286] FIG. **53**A is a graph of cell number versus dosage amounts of GZ17-8.35, illustrating the effect thereof in inducing the death of ovarian cancer;

[0287] FIG. **53**B is a graph of cell number versus dosage amounts of GZ17-8.35, illustrating the effect thereof in inducing the death of lung cancer;

[0288] FIG. **53**C is a graph of cell number versus dosage amounts of GZ17-8.35, illustrating the effect thereof in inducing the death of lymphoma;

[0289] FIG. **53**D is a graph of cell number versus dosage amounts of GZ17-8.35, illustrating the effect thereof in inducing the death of leukemia;

[0290] FIG. **54**A is a graph of cell number versus dosage amounts of GZ17-8.36, illustrating the effect thereof in inducing the death of ovarian cancer;

[0291] FIG. **54**B is a graph of cell number versus dosage amounts of GZ17-8.36, illustrating the effect thereof in inducing the death of lung cancer;

[0292] FIG. **54**C is a graph of cell number versus dosage amounts of GZ17-8.36, illustrating the effect thereof in inducing the death of lymphoma;

[0293] FIG. **54**D is a graph of cell number versus dosage amounts of GZ17-8.36, illustrating the effect thereof in inducing the death of leukemia;

[0294] FIG. **55**A is a graph of cell number versus dosage amounts of GZ17-8.37, illustrating the effect thereof in inducing the death of ovarian cancer;

[0295] FIG. **55**B is a graph of cell number versus dosage amounts of GZ17-8.37, illustrating the effect thereof in inducing the death of lung cancer;

[0296] FIG. **55**C is a graph of cell number versus dosage amounts of GZ17-8.37, illustrating the effect thereof in inducing the death of lymphoma;

[0297] FIG. **55**D is a graph of cell number versus dosage amounts of GZ17-8.37, illustrating the effect thereof in inducing the death of leukemia;

[0298] FIG. **56**A is a graph of cell number versus dosage amounts of GZ17-8.38, illustrating the effect thereof in inducing the death of ovarian cancer;

[0299] FIG. **56**B is a graph of cell number versus dosage amounts of GZ17-8.38, illustrating the effect thereof in inducing the death of lung cancer;

[0300] FIG. **56**C is a graph of cell number versus dosage amounts of GZ17-8.38, illustrating the effect thereof in inducing the death of lymphoma;

[0301] FIG. **56**D is a graph of cell number versus dosage amounts of GZ17-8.38, illustrating the effect thereof in inducing the death of leukemia;

[0302] FIG. **57**A is a graph of cell number versus dosage amounts of GZ17-8.39, illustrating the effect thereof in inducing the death of ovarian cancer;

[0303] FIG. **57**B is a graph of cell number versus dosage amounts of GZ17-8.39, illustrating the effect thereof in inducing the death of lung cancer;

[0304] FIG. **57**C is a graph of cell number versus dosage amounts of GZ17-8.39, illustrating the effect thereof in inducing the death of lymphoma;

[0305] FIG. **57**D is a graph of cell number versus dosage amounts of GZ17-8.39, illustrating the effect thereof in inducing the death of leukemia;

[0306] FIG. **58**A is a graph of cell number versus dosage amounts of GZ17-8.40, illustrating the effect thereof in inducing the death of ovarian cancer;

[0307] FIG. **58**B is a graph of cell number versus dosage amounts of GZ17-8.40, illustrating the effect thereof in inducing the death of lung cancer;

[0308] FIG. **58**C is a graph of cell number versus dosage amounts of GZ17-8.40, illustrating the effect thereof in inducing the death of lymphoma;

[0309] FIG. **58**D is a graph of cell number versus dosage amounts of GZ17-8.40, illustrating the effect thereof in inducing the death of leukemia;

[0310] FIG. **59**A is a graph of cell number versus dosage amounts of GZ17-8.41, illustrating the effect thereof in inducing the death of ovarian cancer;

[0311] FIG. **59**B is a graph of cell number versus dosage amounts of GZ17-8.41, illustrating the effect thereof in inducing the death of lung cancer;

[0312] FIG. **59**C is a graph of cell number versus dosage amounts of GZ17-8.41, illustrating the effect thereof in inducing the death of lymphoma;

[0313] FIG. **59**D is a graph of cell number versus dosage amounts of GZ17-8.41, illustrating the effect thereof in inducing the death of leukemia;

[0314] FIG. **60**A is a graph of cell number versus dosage amounts of GZ17-8.42, illustrating the effect thereof in inducing the death of ovarian cancer;

[0315] FIG. **60**B is a graph of cell number versus dosage amounts of GZ17-8.42, illustrating the effect thereof in inducing the death of lung cancer;

[0316] FIG. **60**C is a graph of cell number versus dosage amounts of GZ17-8.42, illustrating the effect thereof in inducing the death of lymphoma;

[0317] FIG. **60**D is a graph of cell number versus dosage amounts of GZ17-8.42, illustrating the effect thereof in inducing the death of leukemia;

[0318] FIG. **61**A is a graph of cell number versus dosage amounts of GZ17-8.43, illustrating the effect thereof in inducing the death of ovarian cancer;

[0319] FIG. **61**B is a graph of cell number versus dosage amounts of GZ17-8.43, illustrating the effect thereof in inducing the death of lung cancer;

[0320] FIG. **61**C is a graph of cell number versus dosage amounts of GZ17-8.43, illustrating the effect thereof in inducing the death of lymphoma;

[0321] FIG. **61**D is a graph of cell number versus dosage amounts of GZ17-8.43, illustrating the effect thereof in inducing the death of leukemia;

[0322] FIG. **62**A is a graph of cell number versus dosage amounts of GZ17-8.44, illustrating the effect thereof in inducing the death of ovarian cancer;

[0323] FIG. **62**B is a graph of cell number versus dosage amounts of GZ17-8.44, illustrating the effect thereof in inducing the death of lung cancer;

[0324] FIG. **62**C is a graph of cell number versus dosage amounts of GZ17-8.44, illustrating the effect thereof in inducing the death of lymphoma;

[0325] FIG. **62**D is a graph of cell number versus dosage amounts of GZ17-8.44, illustrating the effect thereof in inducing the death of leukemia;

[0326] FIG. **63**A is a graph of cell number versus dosage amounts of GZ17-8.45, illustrating the effect thereof in inducing the death of ovarian cancer;

[0327] FIG. **63**B is a graph of cell number versus dosage amounts of GZ17-8.45, illustrating the effect thereof in inducing the death of lung cancer;

[0328] FIG. **63**C is a graph of cell number versus dosage amounts of GZ17-8.45, illustrating the effect thereof in inducing the death of lymphoma;

[0329] FIG. **63**D is a graph of cell number versus dosage amounts of GZ17-8.45, illustrating the effect thereof in inducing the death of leukemia;

[0330] FIG. **64**A is a graph of cell number versus dosage amounts of GZ17-8.46, illustrating the effect thereof in inducing the death of ovarian cancer;

[0331] FIG. **64**B is a graph of cell number versus dosage amounts of GZ17-8.46, illustrating the effect thereof in inducing the death of lung cancer;

[0332] FIG. **64**C is a graph of cell number versus dosage amounts of GZ17-8.46, illustrating the effect thereof in inducing the death of lymphoma;

[0333] FIG. **64**D is a graph of cell number versus dosage amounts of GZ17-8.46, illustrating the effect thereof in inducing the death of leukemia;

[0334] FIG. **65**A is a graph of cell number versus dosage amounts of GZ17-8.47, illustrating the effect thereof in inducing the death of ovarian cancer;

[0335] FIG. **65**B is a graph of cell number versus dosage amounts of GZ17-8.47, illustrating the effect thereof in inducing the death of lung cancer;

[0336] FIG. **65**C is a graph of cell number versus dosage amounts of GZ17-8.47, illustrating the effect thereof in inducing the death of lymphoma;

[0337] FIG. **65**D is a graph of cell number versus dosage amounts of GZ17-8.47, illustrating the effect thereof in inducing the death of leukemia;

[0338] FIG. **66**A is a graph of cell number versus dosage amounts of GZ17-8.48, illustrating the effect thereof in inducing the death of ovarian cancer;

[0339] FIG. **66**B is a graph of cell number versus dosage amounts of GZ17-8.48, illustrating the effect thereof in inducing the death of lung cancer;

[0340] FIG. **66**C is a graph of cell number versus dosage amounts of GZ17-8.48, illustrating the effect thereof in inducing the death of lymphoma;

[0341] FIG. **66**D is a graph of cell number versus dosage amounts of GZ17-8.48, illustrating the effect thereof in inducing the death of leukemia;

[0342] FIG. **67**A is a graph of cell number versus dosage amounts of GZ17-8.49, illustrating the effect thereof in inducing the death of ovarian cancer;

[0343] FIG. **67**B is a graph of cell number versus dosage amounts of GZ17-8.49, illustrating the effect thereof in inducing the death of lung cancer;

[0344] FIG. **67**C is a graph of cell number versus dosage amounts of GZ17-8.49, illustrating the effect thereof in inducing the death of lymphoma;

[0345] FIG. **67**D is a graph of cell number versus dosage amounts of GZ17-8.49, illustrating the effect thereof in inducing the death of leukemia;

[0346] FIG. **68**A is a graph of cell number versus dosage amounts of GZ17-8.50, illustrating the effect thereof in inducing the death of ovarian cancer;

[0347] FIG. **68**B is a graph of cell number versus dosage amounts of GZ17-8.50, illustrating the effect thereof in inducing the death of lung cancer;

[0348] FIG. **68**C is a graph of cell number versus dosage amounts of GZ17-8.50, illustrating the effect thereof in inducing the death of lymphoma;

[0349] FIG. **68**D is a graph of cell number versus dosage amounts of GZ17-8.50, illustrating the effect thereof in inducing the death of leukemia;

[0350] FIG. **69**A is a graph of cell number versus dosage amounts of GZ17-8.51, illustrating the effect thereof in inducing the death of ovarian cancer;

[0351] FIG. **69**B is a graph of cell number versus dosage amounts of GZ17-8.51, illustrating the effect thereof in inducing the death of lung cancer;

[0352] FIG. **69**C is a graph of cell number versus dosage amounts of GZ17-8.51, illustrating the effect thereof in inducing the death of lymphoma;

[0353] FIG. **69**D is a graph of cell number versus dosage amounts of GZ17-8.51, illustrating the effect thereof in inducing the death of leukemia;

[0354] FIG. **70**A is a graph of cell number versus dosage amounts of GZ17-8.52, illustrating the effect thereof in inducing the death of ovarian cancer;

[0355] FIG. **70**B is a graph of cell number versus dosage amounts of GZ17-8.52, illustrating the effect thereof in inducing the death of lung cancer;

[0356] FIG. **70**C is a graph of cell number versus dosage amounts of GZ17-8.52, illustrating the effect thereof in inducing the death of lymphoma;

[0357] FIG. **70**D is a graph of cell number versus dosage amounts of GZ17-8.52, illustrating the effect thereof in inducing the death of leukemia;

[0358] FIG. **71**A is a graph of cell number versus dosage amounts of GZ17-8.53, illustrating the effect thereof in inducing the death of ovarian cancer;

[0359] FIG. **71**B is a graph of cell number versus dosage amounts of GZ17-8.53, illustrating the effect thereof in inducing the death of lung cancer;

[0360] FIG. **71**C is a graph of cell number versus dosage amounts of GZ17-8.53, illustrating the effect thereof in inducing the death of lymphoma;

[0361] FIG. **71**D is a graph of cell number versus dosage amounts of GZ17-8.53, illustrating the effect thereof in inducing the death of leukemia;

[0362] FIG. **72**A is a graph of cell number versus dosage amounts of GZ17-8.54, illustrating the effect thereof in inducing the death of ovarian cancer;

[0363] FIG. **72**B is a graph of cell number versus dosage amounts of GZ17-8.54, illustrating the effect thereof in inducing the death of lung cancer;

[0364] FIG. **72**C is a graph of cell number versus dosage amounts of GZ17-8.54, illustrating the effect thereof in inducing the death of lymphoma;

[0365] FIG. **72**D is a graph of cell number versus dosage amounts of GZ17-8.54, illustrating the effect thereof in inducing the death of leukemia;

[0366] FIG. **73**A is a graph of cell number versus dosage amounts of GZ17-8.55, illustrating the effect thereof in inducing the death of ovarian cancer;

[0367] FIG. **73**B is a graph of cell number versus dosage amounts of GZ17-8.55, illustrating the effect thereof in inducing the death of lung cancer;

[0368] FIG. **73**C is a graph of cell number versus dosage amounts of GZ17-8.55, illustrating the effect thereof in inducing the death of lymphoma;

[0369] FIG. **73**D is a graph of cell number versus dosage amounts of GZ17-8.55, illustrating the effect thereof in inducing the death of leukemia;

[0370] FIG. **74**A is a graph of cell number versus dosage amounts of GZ17-8.56, illustrating the effect thereof in inducing the death of ovarian cancer;

[0371] FIG. **74**B is a graph of cell number versus dosage amounts of GZ17-8.56, illustrating the effect thereof in inducing the death of lung cancer;

[0372] FIG. **74**C is a graph of cell number versus dosage amounts of GZ17-8.56, illustrating the effect thereof in inducing the death of lymphoma;

[0373] FIG. **74**D is a graph of cell number versus dosage amounts of GZ17-8.56, illustrating the effect thereof in inducing the death of leukemia;

[0374] FIG. **75**A is a graph of cell number versus dosage amounts of GZ17-8.57, illustrating the effect thereof in inducing the death of ovarian cancer;

[0375] FIG. **75**B is a graph of cell number versus dosage amounts of GZ17-8.57, illustrating the effect thereof in inducing the death of lung cancer;

[0376] FIG. **75**C is a graph of cell number versus dosage amounts of GZ17-8.57, illustrating the effect thereof in inducing the death of lymphoma;

[0377] FIG. **75**D is a graph of cell number versus dosage amounts of GZ17-8.57, illustrating the effect thereof in inducing the death of leukemia;

[0378] FIG. **76**A is a graph of cell number versus dosage amounts of GZ17-8.58, illustrating the effect thereof in inducing the death of ovarian cancer;

[0379] FIG. **76**B is a graph of cell number versus dosage amounts of GZ17-8.58, illustrating the effect thereof in inducing the death of lung cancer;

[0380] FIG. **76**C is a graph of cell number versus dosage amounts of GZ17-8.58, illustrating the effect thereof in inducing the death of lymphoma;

[0381] FIG. **76**D is a graph of cell number versus dosage amounts of GZ17-8.58, illustrating the effect thereof in inducing the death of leukemia;

[0382] FIG. **77**A is a graph of cell number versus dosage amounts of GZ17-8.59, illustrating the effect thereof in inducing the death of ovarian cancer;

[0383] FIG. **77**B is a graph of cell number versus dosage amounts of GZ17-8.59, illustrating the effect thereof in inducing the death of lung cancer;

[0384] FIG. **77**C is a graph of cell number versus dosage amounts of GZ17-8.59, illustrating the effect thereof in inducing the death of lymphoma;

[0385] FIG. **77**D is a graph of cell number versus dosage amounts of GZ17-8.59, illustrating the effect thereof in inducing the death of leukemia;

[0386] FIG. **78**A is a graph of cell number versus dosage amounts of GZ17-8.60, illustrating the effect thereof in inducing the death of ovarian cancer;

[0387] FIG. **78**B is a graph of cell number versus dosage amounts of GZ17-8.60, illustrating the effect thereof in inducing the death of lung cancer;

[0388] FIG. **78**C is a graph of cell number versus dosage amounts of GZ17-8.60, illustrating the effect thereof in inducing the death of lymphoma;

[0389] FIG. **78**D is a graph of cell number versus dosage amounts of GZ17-8.60, illustrating the effect thereof in inducing the death of leukemia;

[0390] FIG. **79**A is a graph of cell number versus dosage amounts of GZ17-8.61, illustrating the effect thereof in inducing the death of ovarian cancer;

[0391] FIG. **79**B is a graph of cell number versus dosage amounts of GZ17-8.61, illustrating the effect thereof in inducing the death of lung cancer;

[0392] FIG. **79**C is a graph of cell number versus dosage amounts of GZ17-8.61, illustrating the effect thereof in inducing the death of lymphoma;

[0393] FIG. **79**D is a graph of cell number versus dosage amounts of GZ17-8.61, illustrating the effect thereof in inducing the death of leukemia;

[0394] FIG. **80**A is a graph of cell number versus dosage amounts of GZ17-10.04, illustrating the effect thereof in inducing the death of ovarian cancer;

[0395] FIG. **80**B is a graph of cell number versus dosage amounts of GZ17-10.05, illustrating the effect thereof in inducing the death of ovarian cancer;

[0396] FIG. **80**C is a graph of cell number versus dosage amounts of GZ17-10.06, illustrating the effect thereof in inducing the death of ovarian cancer;

[0397] FIG. **80**D is a graph of cell number versus dosage amounts of GZ17-10.04, illustrating the effect thereof in inducing the death of lymphoma;

[0398] FIG. **80**E is a graph of cell number versus dosage amounts of GZ17-10.05, illustrating the effect thereof in inducing the death of lymphoma;

[0399] FIG. **80**F is a graph of cell number versus dosage amounts of GZ17-10.06, illustrating the effect thereof in inducing the death of lymphoma;

[0400] FIG. **80**G is a comparative bar graph illustrating the comparative lymphoma cell-killing effect of the individual components, GZ17-10.04-10.06, versus the theoretical additive effect of these components, and the actual effect thereof, demonstrating the synergism of the three-component composition;

[0401] FIG. **80**H is a comparative bar graph illustrating the comparative lymphoma cell-killing effect of the individual components, GZ17-10.04 and 10.06, versus the theoretical additive effect of these components, and the actual effect thereof, demonstrating the synergism of the three-component composition;

[0402] FIG. **80**I is a graph of cell number versus dosage amounts of GZ17-10.04, illustrating the effect thereof in inducing the death of leukemia;

[0403] FIG. **80**J is a graph of cell number versus dosage amounts of GZ17-10.05, illustrating the effect thereof in inducing the death of leukemia;

[0404] FIG. **80**K is a graph of cell number versus dosage amounts of GZ17-10.06, illustrating the effect thereof in inducing the death of leukemia;

[0405] FIG. **80**L is a comparative bar graph illustrating the comparative leukemia cell-killing effect of the individual components, GZ17-10.04-10.06, versus the theoretical additive effect of these components, and the actual effect thereof, demonstrating the synergism of the three-component composition;

[0406] FIG. **80**M is a comparative bar graph illustrating the comparative leukemia cell-killing effect of the individual components, GZ17-10.04 and 10.06, versus the theoretical additive effect of these components, and the actual effect thereof, demonstrating the synergism of the three-component composition;

[0407] FIG. **80**N is a graph of cell number versus dosage amounts of GZ17-10.04, illustrating the effect thereof in inducing the death of breast cancer;

[0408] FIG. **80**O is a graph of cell number versus dosage amounts of GZ17-10.05, illustrating the effect thereof in inducing the death of breast cancer;

[0409] FIG. **80**P is a graph of cell number versus dosage amounts of GZ17-10.06, illustrating the effect thereof in inducing the death of breast cancer;

[0410] FIG. **80**Q is a comparative bar graph illustrating the comparative breast cancer cell-killing effect of the individual components, GZ17-10.04-10.06, versus the theoretical additive effect of these components, and the actual effect thereof, demonstrating the synergism of the three-component composition;

[0411] FIG. **80**R is a comparative bar graph illustrating the comparative breast cancer cell-killing effect of the individual components, GZ17-10.04 and 10.06, versus the theoretical additive effect of these components, and the actual effect thereof, demonstrating the synergism of the three-component composition;

[0412] FIG. **81**A is a graph of cell number versus dosage amounts of GZ17-08.512, illustrating the effect thereof in inducing the death of ovarian cancer;

[0413] FIG. **81**B is a graph of cell number versus dosage amounts of GZ17-08.512, illustrating the effect thereof in inducing the death of lymphoma;

[0414] FIG. **81**C is a graph of cell number versus dosage amounts of GZ17-08.512, illustrating the effect thereof in inducing the death of head and neck cancer;

[0415] FIG. **81**D is a graph of cell number versus dosage amounts of GZ17-08.513, illustrating the effect thereof in inducing the death of ovarian cancer;

[0416] FIG. **81**E is a graph of cell number versus dosage amounts of GZ17-08.513, illustrating the effect thereof in inducing the death of lymphoma;

[0417] FIG. **81**F is a graph of cell number versus dosage amounts of GZ17-08.513, illustrating the effect thereof in inducing the death of head and neck cancer;

[0418] FIG. **81**G is a graph of cell number versus dosage amounts of GZ17-08.514, illustrating the effect thereof in inducing the death of ovarian cancer;

[0419] FIG. **81**H is a graph of cell number versus dosage amounts of GZ17-08.514, illustrating the effect thereof in inducing the death of lymphoma;

[0420] FIG. **81**I is a graph of cell number versus dosage amounts of GZ17-08.514, illustrating the effect thereof in inducing the death of head and neck cancer;

[0421] FIG. **81**J is a graph of cell number versus dosage amounts of GZ17-08.515, illustrating the effect thereof in inducing the death of ovarian cancer;

[0422] FIG. **81**K is a graph of cell number versus dosage amounts of GZ17-08.515, illustrating the effect thereof in inducing the death of lymphoma;

[0423] FIG. **81**L is a graph of cell number versus dosage amounts of GZ17-08.515, illustrating the effect thereof in inducing the death of head and neck cancer;

[0424] FIG. **81**M is a graph of cell number versus dosage amounts of GZ17-08.516, illustrating the effect thereof in inducing the death of ovarian cancer;

[0425] FIG. **81**N is a graph of cell number versus dosage amounts of GZ17-08.516, illustrating the effect thereof in inducing the death of lymphoma;

[0426] FIG. **81**O is a graph of cell number versus dosage amounts of GZ17-08.516, illustrating the effect thereof in inducing the death of head and neck cancer;

[0427] FIG. **81**P is a graph of cell number versus dosage amounts of GZ17-08.517, illustrating the effect thereof in inducing the death of ovarian cancer;

[0428] FIG. **81**Q is a graph of cell number versus dosage amounts of GZ17-08.517, illustrating the effect thereof in inducing the death of lymphoma;

[0429] FIG. **81**R is a graph of cell number versus dosage amounts of GZ17-08.517, illustrating the effect thereof in inducing the death of head and neck cancer;

[0430] FIG. **81**S is a graph of cell number versus dosage amounts of GZ17-08.518, illustrating the effect thereof in inducing the death of ovarian cancer;

[0431] FIG. **81**T is a graph of cell number versus dosage amounts of GZ17-08.518, illustrating the effect thereof in inducing the death of lymphoma;

[0432] FIG. **81**U is a graph of cell number versus dosage amounts of GZ17-08.518, illustrating the effect thereof in inducing the death of head and neck cancer;

[0433] FIG. **81**V is a graph of cell number versus dosage amounts of GZ17-08.519, illustrating the effect thereof in inducing the death of ovarian cancer;

[0434] FIG. **81**W is a graph of cell number versus dosage amounts of GZ17-08.519, illustrating the effect thereof in inducing the death of lymphoma;

[0435] FIG. **81**X is a graph of cell number versus dosage amounts of GZ17-08.519, illustrating the effect thereof in inducing the death of head and neck cancer;

[0436] FIG. **81**Y is a graph of cell number versus dosage amounts of GZ17-08.520, illustrating the effect thereof in inducing the death of ovarian cancer;

[0437] FIG. **81**Z is a graph of cell number versus dosage amounts of GZ17-08.520, illustrating the effect thereof in inducing the death of lymphoma;

[0438] FIG. **81**AA is a graph of cell number versus dosage amounts of GZ17-08.520, illustrating the effect thereof in inducing the death of head and neck cancer;

[0439] FIG. **81**BB is a graph of cell number versus dosage amounts of GZ17-08.521, illustrating the effect thereof in inducing the death of ovarian cancer;

[0440] FIG. **81**CC is a graph of cell number versus dosage amounts of GZ17-08.521, illustrating the effect thereof in inducing the death of lymphoma;

[0441] FIG. **81**DD is a graph of cell number versus dosage amounts of GZ17-08.521, illustrating the effect thereof in inducing the death of head and neck cancer;

[0442] FIG. **82-1** is a graph of cell number versus dosage amounts of GZ08.065, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0443] FIG. **82-2** is a graph of cell number versus dosage amounts of GZ08.066, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0444] FIG. **82-3** is a graph of cell number versus dosage amounts of GZ08.067, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0445] FIG. **82-4** is a graph of cell number versus dosage amounts of GZ08.068, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0446] FIG. **82-5** is a graph of cell number versus dosage amounts of GZ08.069, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0447] FIG. **82-6** is a graph of cell number versus dosage amounts of GZ08.070, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0448] FIG. **82-7** is a graph of cell number versus dosage amounts of GZ08.071, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0449] FIG. **82-8** is a graph of cell number versus dosage amounts of GZ08.072, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0450] FIG. **82-9** is a graph of cell number versus dosage amounts of GZ08.073, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0451] FIG. **82-10** is a graph of cell number versus dosage amounts of GZ08.074, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0452] FIG. **82-11** is a graph of cell number versus dosage amounts of GZ08.075, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0453] FIG. **82-12** is a graph of cell number versus dosage amounts of GZ08.076, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0454] FIG. **82-13** is a graph of cell number versus dosage amounts of GZ08.077, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0455] FIG. **82-14** is a graph of cell number versus dosage amounts of GZ08.078, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0456] FIG. **82-15** is a graph of cell number versus dosage amounts of GZ08.079, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0457] FIG. **82-16** is a graph of cell number versus dosage amounts of GZ08.080, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0458] FIG. **82-17** is a graph of cell number versus dosage amounts of GZ08.081, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0459] FIG. **82-18** is a graph of cell number versus dosage amounts of GZ08.082, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0460] FIG. **82-19** is a graph of cell number versus dosage amounts of GZ08.083, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0461] FIG. **82-20** is a graph of cell number versus dosage amounts of GZ08.084, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0462] FIG. **82-21** is a graph of cell number versus dosage amounts of GZ08.085, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0463] FIG. **82-22** is a graph of cell number versus dosage amounts of GZ08.086, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0464] FIG. **82-23** is a graph of cell number versus dosage amounts of GZ08.087, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0465] FIG. **82-24** is a graph of cell number versus dosage amounts of GZ08.088, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0466] FIG. **82-25** is a graph of cell number versus dosage amounts of GZ08.089, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0467] FIG. **82-26** is a graph of cell number versus dosage amounts of GZ08.090, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0468] FIG. **82-27** is a graph of cell number versus dosage amounts of GZ08.091, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0469] FIG. **82-28** is a graph of cell number versus dosage amounts of GZ08.092, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0470] FIG. **82-29** is a graph of cell number versus dosage amounts of GZ08.093, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0471] FIG. **82-30** is a graph of cell number versus dosage amounts of GZ08.094, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0472] FIG. **82-31** is a graph of cell number versus dosage amounts of GZ08.095, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0473] FIG. **82-32** is a graph of cell number versus dosage amounts of GZ08.096, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0474] FIG. **82-33** is a graph of cell number versus dosage amounts of GZ08.097, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0475] FIG. **82-34** is a graph of cell number versus dosage amounts of GZ08.098, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0476] FIG. **82-35** is a graph of cell number versus dosage amounts of GZ08.099, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0477] FIG. **82-36** is a graph of cell number versus dosage amounts of GZ08.100, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0478] FIG. **82-37** is a graph of cell number versus dosage amounts of GZ08.101, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0479] FIG. **82-38** is a graph of cell number versus dosage amounts of GZ08.102, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0480] FIG. **82-39** is a graph of cell number versus dosage amounts of GZ08.103, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0481] FIG. **82-40** is a graph of cell number versus dosage amounts of GZ08.104, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0482] FIG. **82-41** is a graph of cell number versus dosage amounts of GZ08.105, illustrating the effect thereof in inducing the death of lung cancer, as described in Example 82;

[0483] FIG. **82-42** is a graph of cell number versus dosage amounts of GZ08.065, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0484] FIG. **82-43** is a graph of cell number versus dosage amounts of GZ08.066, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0485] FIG. **82-44** is a graph of cell number versus dosage amounts of GZ08.067, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0486] FIG. **82-45** is a graph of cell number versus dosage amounts of GZ08.068, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0487] FIG. **82-46** is a graph of cell number versus dosage amounts of GZ08.069, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0488] FIG. **82-47** is a graph of cell number versus dosage amounts of GZ08.070, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0489] FIG. **82-48** is a graph of cell number versus dosage amounts of GZ08.071, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0490] FIG. **82-49** is a graph of cell number versus dosage amounts of GZ08.072, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0491] FIG. **82-50** is a graph of cell number versus dosage amounts of GZ08.073, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0492] FIG. **82-51** is a graph of cell number versus dosage amounts of GZ08.074, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0493] FIG. **82-52** is a graph of cell number versus dosage amounts of GZ08.075, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0494] FIG. **82-53** is a graph of cell number versus dosage amounts of GZ08.076, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0495] FIG. **82-54** is a graph of cell number versus dosage amounts of GZ08.077, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0496] FIG. **82-55** is a graph of cell number versus dosage amounts of GZ08.078, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0497] FIG. **82-56** is a graph of cell number versus dosage amounts of GZ08.079, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0498] FIG. **82-57** is a graph of cell number versus dosage amounts of GZ08.080, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0499] FIG. **82-58** is a graph of cell number versus dosage amounts of GZ08.081, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0500] FIG. **82-59** is a graph of cell number versus dosage amounts of GZ08.082, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0501] FIG. **82-60** is a graph of cell number versus dosage amounts of GZ08.083, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0502] FIG. **82-61** is a graph of cell number versus dosage amounts of GZ08.084, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0503] FIG. **82-62** is a graph of cell number versus dosage amounts of GZ08.085, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0504] FIG. **82-63** is a graph of cell number versus dosage amounts of GZ08.086, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0505] FIG. **82-64** is a graph of cell number versus dosage amounts of GZ08.087, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0506] FIG. **82-65** is a graph of cell number versus dosage amounts of GZ08.088, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0507] FIG. **82-66** is a graph of cell number versus dosage amounts of GZ08.089, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0508] FIG. **82-67** is a graph of cell number versus dosage amounts of GZ08.090, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0509] FIG. **82-68** is a graph of cell number versus dosage amounts of GZ08.091, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0510] FIG. **82-69** is a graph of cell number versus dosage amounts of GZ08.092, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0511] FIG. **82-70** is a graph of cell number versus dosage amounts of GZ08.093, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0512] FIG. **82-71** is a graph of cell number versus dosage amounts of GZ08.094, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0513] FIG. **82-72** is a graph of cell number versus dosage amounts of GZ08.095, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0514] FIG. **82-73** is a graph of cell number versus dosage amounts of GZ08.096, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0515] FIG. **82-74** is a graph of cell number versus dosage amounts of GZ08.097, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0516] FIG. **82-75** is a graph of cell number versus dosage amounts of GZ08.098, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0517] FIG. **82-76** is a graph of cell number versus dosage amounts of GZ08.099, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0518] FIG. **82-77** is a graph of cell number versus dosage amounts of GZ08.100, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0519] FIG. **82-78** is a graph of cell number versus dosage amounts of GZ08.101, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0520] FIG. **82-79** is a graph of cell number versus dosage amounts of GZ08.102, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0521] FIG. **82-80** is a graph of cell number versus dosage amounts of GZ08.103, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0522] FIG. **82-81** is a graph of cell number versus dosage amounts of GZ08.104, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0523] FIG. **82-82** is a graph of cell number versus dosage amounts of GZ08.105, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 82;

[0524] FIG. **82-83** is a graph of cell number versus dosage amounts of GZ08.065, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0525] FIG. **82-84** is a graph of cell number versus dosage amounts of GZ08.066, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0526] FIG. **82-85** is a graph of cell number versus dosage amounts of GZ08.067, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0527] FIG. **82-86** is a graph of cell number versus dosage amounts of GZ08.068, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0528] FIG. **82-87** is a graph of cell number versus dosage amounts of GZ08.069, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0529] FIG. **82-88** is a graph of cell number versus dosage amounts of GZ08.070, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0530] FIG. **82-89** is a graph of cell number versus dosage amounts of GZ08.071, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0531] FIG. **82-90** is a graph of cell number versus dosage amounts of GZ08.072, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0532] FIG. **82-91** is a graph of cell number versus dosage amounts of GZ08.073, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0533] FIG. **82-92** is a graph of cell number versus dosage amounts of GZ08.074, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0534] FIG. **82-93** is a graph of cell number versus dosage amounts of GZ08.075, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0535] FIG. **82-94** is a graph of cell number versus dosage amounts of GZ08.076, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0536] FIG. **82-95** is a graph of cell number versus dosage amounts of GZ08.077, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0537] FIG. **82-96** is a graph of cell number versus dosage amounts of GZ08.078, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0538] FIG. **82-97** is a graph of cell number versus dosage amounts of GZ08.079, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0539] FIG. **82-98** is a graph of cell number versus dosage amounts of GZ08.080, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0540] FIG. **82-99** is a graph of cell number versus dosage amounts of GZ08.081, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0541] FIG. **82-100** is a graph of cell number versus dosage amounts of GZ08.082, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0542] FIG. **82-101** is a graph of cell number versus dosage amounts of GZ08.083, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0543] FIG. **82-102** is a graph of cell number versus dosage amounts of GZ08.084, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0544] FIG. **82-103** is a graph of cell number versus dosage amounts of GZ08.085, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0545] FIG. **82-104** is a graph of cell number versus dosage amounts of GZ08.086, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0546] FIG. **82-105** is a graph of cell number versus dosage amounts of GZ08.087, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0547] FIG. **82-106** is a graph of cell number versus dosage amounts of GZ08.088, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0548] FIG. **82-107** is a graph of cell number versus dosage amounts of GZ08.089, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0549] FIG. **82-108** is a graph of cell number versus dosage amounts of GZ08.090, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0550] FIG. **82-109** is a graph of cell number versus dosage amounts of GZ08.091, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0551] FIG. **82-110** is a graph of cell number versus dosage amounts of GZ08.092, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0552] FIG. **82-111** is a graph of cell number versus dosage amounts of GZ08.093, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0553] FIG. **82-112** is a graph of cell number versus dosage amounts of GZ08.094, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0554] FIG. **82-113** is a graph of cell number versus dosage amounts of GZ08.095, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0555] FIG. **82-114** is a graph of cell number versus dosage amounts of GZ08.096, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0556] FIG. **82-115** is a graph of cell number versus dosage amounts of GZ08.097, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0557] FIG. **82-116** is a graph of cell number versus dosage amounts of GZ08.098, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0558] FIG. **82-117** is a graph of cell number versus dosage amounts of GZ08.099, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0559] FIG. **82-118** is a graph of cell number versus dosage amounts of GZ08.100, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0560] FIG. **82-119** is a graph of cell number versus dosage amounts of GZ08.101, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0561] FIG. **82-120** is a graph of cell number versus dosage amounts of GZ08.102, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0562] FIG. **82-121** is a graph of cell number versus dosage amounts of GZ08.103, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0563] FIG. **82-122** is a graph of cell number versus dosage amounts of GZ08.104, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0564] FIG. **82-123** is a graph of cell number versus dosage amounts of GZ08.105, illustrating the effect thereof in inducing the death of leukemia, as described in Example 82;

[0565] FIG. **82-124** is a comparative bar graph illustrating the comparative lung cancer cell-killing effect of the individual components of GZ08.065, versus the theoretical additive effect of these components, and the actual effect

thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0566] FIG. **82-125** is a comparative bar graph illustrating the comparative lung cancer cell-killing effect of the individual components of GZ08.067, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0567] FIG. **82-126** is a comparative bar graph illustrating the comparative lung cancer cell-killing effect of the individual components of GZ08.068, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0568] FIG. **82-127** is a comparative bar graph illustrating the comparative lung cancer cell-killing effect of the individual components of GZ08.079, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0569] FIG. **82-128** is a comparative bar graph illustrating the comparative lung cancer cell-killing effect of the individual components of GZ08.080, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition;

[0570] FIG. **82-129** is a comparative bar graph illustrating the comparative lung cancer cell-killing effect of the individual components of GZ08.084, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0571] FIG. **82-130** is a comparative bar graph illustrating the comparative lung cancer cell-killing effect of the individual components of GZ08.085, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0572] FIG. **82-131** is a comparative bar graph illustrating the comparative lung cancer cell-killing effect of the individual components of GZ08.086, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0573] FIG. **82-132** is a comparative bar graph illustrating the comparative lung cancer cell-killing effect of the individual components of GZ08.087, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0574] FIG. **82-133** is a comparative bar graph illustrating the comparative lung cancer cell-killing effect of the individual components of GZ08.088, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0575] FIG. **82-134** is a comparative bar graph illustrating the comparative lung cancer cell-killing effect of the individual components of GZ08.089, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0576] FIG. **82-135** is a comparative bar graph illustrating the comparative lung cancer cell-killing effect of the individual components of GZ08.090, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0577] FIG. **82-136** is a comparative bar graph illustrating the comparative lung cancer cell-killing effect of the individual components of GZ08.091, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0578] FIG. **82-137** is a comparative bar graph illustrating the comparative lung cancer cell-killing effect of the individual components of GZ08.092, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0579] FIG. **82-138** is a comparative bar graph illustrating the comparative lung cancer cell-killing effect of the individual components of GZ08.093, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0580] FIG. **82-139** is a comparative bar graph illustrating the comparative lung cancer cell-killing effect of the individual components of GZ08.094, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0581] FIG. **82-140** is a comparative bar graph illustrating the comparative lung cancer cell-killing effect of the individual components of GZ08.097, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0582] FIG. **82-141** is a comparative bar graph illustrating the comparative lung cancer cell-killing effect of the individual components of GZ08.098, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0583] FIG. **82-142** is a comparative bar graph illustrating the comparative lung cancer cell-killing effect of the individual components of GZ08.100, versus the theoretical additive effect of these components, and the actual effect

thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0584] FIG. **82-143** is a comparative bar graph illustrating the comparative lung cancer cell-killing effect of the individual components of GZ08.101, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0585] FIG. **82-144** is a comparative bar graph illustrating the comparative lung cancer cell-killing effect of the individual components of GZ08.102, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0586] FIG. **82-145** is a comparative bar graph illustrating the comparative lung cancer cell-killing effect of the individual components of GZ08.103, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0587] FIG. **82-146** is a comparative bar graph illustrating the comparative lung cancer cell-killing effect of the individual components of GZ08.104, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0588] FIG. **82-147** is a comparative bar graph illustrating the comparative lung cancer cell-killing effect of the individual components of GZ08.105, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0589] FIG. **82-148** is a comparative bar graph illustrating the comparative lymphoma cell-killing effect of the individual components of GZ08.067, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0590] FIG. **82-149** is a comparative bar graph illustrating the comparative lymphoma cell-killing effect of the individual components of GZ08.073, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0591] FIG. **82-150** is a comparative bar graph illustrating the comparative lymphoma cell-killing effect of the individual components of GZ08.076, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0592] FIG. **82-151** is a comparative bar graph illustrating the comparative lymphoma cell-killing effect of the individual components of GZ08.077, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0593] FIG. **82-152** is a comparative bar graph illustrating the comparative lymphoma cell-killing effect of the individual components of GZ08.080, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0594] FIG. **82-153** is a comparative bar graph illustrating the comparative lymphoma cell-killing effect of the individual components of GZ08.083, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0595] FIG. **82-154** is a comparative bar graph illustrating the comparative lymphoma cell-killing effect of the individual components of GZ08.086, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0596] FIG. **82-155** is a comparative bar graph illustrating the comparative lymphoma cell-killing effect of the individual components of GZ08.088, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0597] FIG. **82-156** is a comparative bar graph illustrating the comparative lymphoma cell-killing effect of the individual components of GZ08.092, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0598] FIG. **82-157** is a comparative bar graph illustrating the comparative lymphoma cell-killing effect of the individual components of GZ08.095, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0599] FIG. **82-158** is a comparative bar graph illustrating the comparative lymphoma cell-killing effect of the individual components of GZ08.099, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0600] FIG. **82-159** is a comparative bar graph illustrating the comparative lymphoma cell-killing effect of the individual components of GZ08.101, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0601] FIG. **82-160** is a comparative bar graph illustrating the comparative lymphoma cell-killing effect of the individual components of GZ08.105, versus the theoretical additive effect of these components, and the actual effect

thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0602] FIG. **82-161** is a comparative bar graph illustrating the comparative leukemia cell-killing effect of the individual components of GZ08.086, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0603] FIG. **82-162** is a comparative bar graph illustrating the comparative leukemia cell-killing effect of the individual components of GZ08.087, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0604] FIG. **82-163** is a comparative bar graph illustrating the comparative leukemia cell-killing effect of the individual components of GZ08.090, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0605] FIG. **82-164** is a comparative bar graph illustrating the comparative leukemia cell-killing effect of the individual components of GZ08.094, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0606] FIG. **82-165** is a comparative bar graph illustrating the comparative leukemia cell-killing effect of the individual components of GZ08.098, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0607] FIG. **82-166** is a comparative bar graph illustrating the comparative leukemia cell-killing effect of the individual components of GZ08.104, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0608] FIG. **82-167** is a comparative bar graph illustrating the comparative leukemia cell-killing effect of the individual components of GZ08.105, versus the theoretical additive effect of these components, and the actual effect thereof at the indicted concentration, demonstrating the synergism of the three-component composition, as described in Example 82;

[0609] FIG. **83**A is a graph of cell number versus dosage amounts of orthovanillin, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 83;

[0610] FIG. **83**B is a graph of cell number versus dosage amounts of curcumin, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 83;

[0611] FIG. **83**C is a graph of cell number versus dosage amounts of harmaline, illustrating the effect thereof in inducing the death of lymphoma, as described in Example 83;

[0612] FIG. **83**D is a comparative bar graph illustrating the comparative lymphoma cell-killing effect of the individual components, orthovanillin, curcumin, and harmaline, as shown in FIGS. **83**A-**83**C, versus the theoretical additive effect of these components, and the actual effect thereof, demonstrating the synergism of the three-component composition;

[0613] FIG. **83**E is a graph of cell number versus dosage amounts of orthovanillin, illustrating the effect thereof in inducing the death of leukemia, as described in Example 83;

[0614] FIG. **83**F is a graph of cell number versus dosage amounts of curcumin, illustrating the effect thereof in inducing the death of leukemia, as described in Example 83;

[0615] FIG. **83**G is a graph of cell number versus dosage amounts of harmaline, illustrating the effect thereof in inducing the death of leukemia, as described in Example 83;

[0616] FIG. **83**H is a comparative bar graph illustrating the comparative leukemia cell-killing effect of the individual components, orthovanillin, curcumin, and harmaline, as shown in FIGS. **83**E-**83**G, versus the theoretical additive effect of these components, and the actual effect thereof, demonstrating the synergism of the three-component composition;

[0617] FIG. **83**I is a graph of cell number versus dosage amounts of orthovanillin, illustrating the effect thereof in inducing the death of breast cancer, as described in Example 83;

[0618] FIG. **83**J is a graph of cell number versus dosage amounts of curcumin, illustrating the effect thereof in inducing the death of breast cancer, as described in Example 83;

[0619] FIG. **83**K is a graph of cell number versus dosage amounts of harmaline, illustrating the effect thereof in inducing the death of breast cancer, as described in Example 83;

[0620] FIG. **83**L is a comparative bar graph illustrating the comparative breast cancer cell-killing effect of the individual components, orthovanillin, curcumin, and harmaline, as shown in FIGS. **83**I-**83**K, versus the theoretical additive effect of these components, and the actual effect thereof, demonstrating the synergism of the three-component composition;

[0621] FIG. **84**A is series of photographs of pancreatic cancer spheres including a control, treatment of the spheres with GZ17-6.02 at levels of $0.5IC_{50}$ and IC_{50}, illustrating the effect of GZ17-6.02 in reducing the number and size of pancreatic cancer spheres, as set forth in Example 84;

[0622] FIG. **84**B is a series of blots illustrating in vitro pancreatic cell treatment with GZ17-6.02 at levels of $0.5IC_{50}$ and IC_{50}, and depicting decreases in cancer stem cell markers owing to the treatment with GZ17-6.02, as set forth in Example 84;

[0623] FIG. **84**C is a series of blots illustrating the treatment of mouse pancreatic cancer cells with GZ17-6.02, and depicting the decrease in cancer stem cell markers owing to the treatment with GZ17-6.02, as set forth in Example 84; and

[0624] FIG. **84**D is a possible pathway diagram illustrating the action of GZ17-6.02 on both cancer stem cells (CSC) and other cancer cells within a tumor, as set forth in Example 84.

DETAILED DESCRIPTION

[0625] The therapeutic agents of the invention are used in therapeutically effective amounts, i.e., amounts that will

elicit the biological or medical response of a tissue, system, or subject that is being sought, and in particular to elicit some desired therapeutic effect against a variety of human diseases, and especially cancers; in the case of cancers, the agents operate by preventing and/or inhibiting proliferation and/or survival of cancerous cells, and/or by slowing the progression of cancers. Those skilled in the art recognize that an amount may be considered therapeutically effective even if the condition is not totally eradicated or prevented, but it or its symptoms and/or effects are improved or alleviated partially in the subject. Of course, the appropriate makeup of the agents hereof and dosing regimens using such agents will depend on the particular cancer being treated, the extent of the disease, and other factors related to the patient as determined by those skilled in the art. Hence, the terms "therapeutic" or "treat," as used herein, refer to products or processes in accordance with the invention that are intended to produce a beneficial change in an existing condition (e.g., cancerous tissue, tumor size, metastases, etc.) of a subject, such as by reducing the severity of the clinical symptoms and/or effects of the condition, and/or reducing the duration of the symptoms/effects of a subject.

[0626] Additional ingredients may be included with the chemotherapeutic agents of the invention for administration to the subject. Such additional ingredients include, other active agents, preservatives, buffering agents, salts, carriers, excipients, diluents, or other pharmaceutically-acceptable ingredients. The active agents that could be included in the compositions include antiviral, antibiotic, or other anticancer compounds.

[0627] The combined therapeutic agents of the invention preferably give synergistic results, which are entirely unexpected. Moreover, the lack of side effects when the agents are administered to patients is quite surprising and essentially unique. As used herein, the terms "combination" or "in combination" are intended to embrace compositions wherein the components are physically intermixed as dosage forms, and to situations where the individual components are separately administered to a subject over relatively short periods of time, which would have the same therapeutic effects as a single dosage form.

[0628] In use, a therapeutically effective amount of an agent in accordance with the invention is administered to a subject in need thereof. Such may comprise a single unit dosage or, more usually, periodic (e.g., daily) administration of lower dosages over time. Advantageously, administration of such therapeutically effective amounts achieves an unexpected therapeutic synergy. This means that the therapeutic two- or three-component compositions of the invention exhibit a joint action where one or more of the components supplements or enhances the action of at least one of the other components to produce an effect greater than that which may be obtained by use of individual components in equivalent quantities, or produce effects that could not be obtained with safe quantities of the other components, individually or in combination. Generally, one or more of the components working together produce an effect greater than the sum of their individual effects.

[0629] The dosages may be administered in any convenient manner, such as by oral, rectal, nasal, ophthalmic, parenteral (including intraperitoneal, gastrointestinal, intrathecal, intravenous, cutaneous (e.g., dermal patch), subcutaneous (e.g. injection or implant), or intramuscular) administrations. The dosage forms of the invention may be in the form of liquids, gels, suspensions, solutions, or solids (e.g., tablets, pills, or capsules). Moreover, therapeutically effective amounts of the agents of the invention may be co-administered with other chemotherapeutic agent(s), where the two products are administered substantially simultaneously or in any sequential manner.

[0630] Additional advantages of the various embodiments of the invention will be apparent to those skilled in the art upon review of the disclosure herein and the working examples below. It will be appreciated that the various embodiments described herein are not necessarily mutually exclusive unless otherwise indicated herein. For example, a feature described or depicted in one embodiment may also be included in other embodiments, but is not necessarily included. Thus, the present invention encompasses a variety of combinations and/or integrations of the specific embodiments described herein.

[0631] As used herein, the phrase "and/or," when used in a list of two or more items, means that any one of the listed items can be employed by itself or any combination of two or more of the listed items can be employed. For example, if a composition is described as containing or excluding components A, B, and/or C, the composition can contain or exclude A alone; B alone; C alone; A and B in combination; A and C in combination; B and C in combination; or A, B, and C in combination.

[0632] The present description also uses numerical ranges to quantify certain parameters relating to various embodiments of the invention. It should be understood that when numerical ranges are provided, such ranges are to be construed as providing literal support for claim limitations that only recite the lower value of the range as well as claim limitations that only recite the upper value of the range. For example, a disclosed numerical range of about 10 to about 100 provides literal support for a claim reciting "greater than about 10" (with no upper bounds) and a claim reciting "less than about 100" (with no lower bounds).

[0633] In the ensuing discussion, the curcumin, harmine, and isovanillin component(s) will be individually described. In such discussions, where terms are used which specify or imply the presence of carbon-carbon chains (e.g., alkyl, alkenyl, alkoxy, alkyl amine, alkenyl amine, aldehyde, carboxylate, or the like), these disclosures should be understood to refer to primary (straight), branched chain, or cyclic carbon chain groups. Moreover, unless indicated otherwise, reference to aryl groups means phenyl, substituted phenyl, naphthyl, substituted naphthyl; and heteroatom aryl groups refers to aryl groups containing a nitrogen, oxygen, boron, or sulfur atom, such as pyridine; heterocyclic groups refers to cyclic groups containing from 3-7 atoms, one or more of which is a nitrogen, oxygen, boron, or sulfur heteroatom; and amine refers to primary, secondary, tertiary, or quaternary amines.

[0634] As used herein, pharmaceutically acceptable salts with reference to the components means salts of the component compounds of the present invention which are pharmaceutically acceptable, i.e., salts which are useful in preparing pharmaceutical compositions that are generally safe, non-toxic, and neither biologically nor otherwise undesirable and are acceptable for human pharmaceutical use, and which possess the desired degree of pharmacological activity. Such pharmaceutically acceptable salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,

phosphoric acid, and the like; or with organic acids such as 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, 2-naphthalenesulfonic acid, 3-phenylpropionic acid, 4,4'-methylenebis(3-hydroxy-2-ene-1-carboxylic acid), 4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, acetic acid, aliphatic mono- and dicarboxylic acids, aliphatic sulfuric acids, aromatic sulfuric acids, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, carbonic acid, cinnamic acid, citric acid, cyclopentanepropionic acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, heptanoic acid, hexanoic acid, hydroxynaphthoic acid, lactic acid, laurylsulfuric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, muconic acid, o-(4-hydroxybenzoyl)benzoic acid, oxalic acid, p-chlorobenzenesulfonic acid, phenyl-substituted alkanoic acids, propionic acid, p-toluenesulfonic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, tartaric acid, tertiarybutylacetic acid, trimethylacetic acid, and the like. Pharmaceutically acceptable salts also include base addition salts which may be formed when acidic protons present are capable of reacting with inorganic or organic bases. Acceptable inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide and calcium hydroxide. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine and the like. It should be recognized that the particular anion or cation forming a part of any salt of this invention is not critical, so long as the salt, as a whole, is pharmacologically acceptable. Additional examples of pharmaceutically acceptable salts and their methods of preparation and use are presented in *Handbook of Pharmaceutical Salts Properties, and Use*, P. H. Stahl & C. G. Wermuth eds., ISBN 978-3-90639-058-1 (2008).

[0635] As noted below, the curcumin, harmine, and isovanillin component(s) may be obtained as synthetic compounds of high purity, or from modified naturally occurring sources. In either case, however, it is preferred that the component(s) be purified to a level of at least about 50% by weight, more preferably at least about 70% by weight, still more preferably at least about 90% by weight, and most preferably at least about 98% by weight.

[0636] The individual discussions of the component(s) contain structural formulas. In order to be entirely clear, curcumin-based formulas are indicated "C-number," (not to be confused with carbon chain numbers, which are indicated as "Cnumber," without an intervening hyphen), harmine-based formulas are indicated as "H-number," and isovanillin-based formulas are indicated as "I-number."



[0637] Before discussing the individual components of the invention, it should be understood that use of unmodified, naturally occurring sources of the components is generally not appropriate or desirable, because these naturally occurring products contain relatively small amounts of the desired components and/or have potentially interfering compounds therein. For example, naturally occurring turmeric has only approximately 2-3% by weight curcumin therein and accordingly the straightforward use of unmodified turmeric would not be suitable for the invention. In like manner, naturally occurring harmala seed contains only a very minor amount of harmine and such a product would also be inappropriate.

[0638] Thus, the preferred components of the invention are either synthetically derived or derived from one or more naturally occurring product(s) which have been significantly modified so as to contain at least about 25% by weight (more preferably at least about 50% by weight, and still more preferably about 70% by weight) of the desired component. As used herein, "synthetically derived" means that the component in question was synthesized using specific starting ingredients and one or more chemical and/or biological reactions to obtain substantially pure compounds. Modification of naturally occurring products may involve extractions, or any other physical or chemical steps to achieve the desired end product, e.g., harmine components may be obtained from treatment of harmala seed, or curcumin components may be obtained from treatment of turmeric.

[0639] For example, curcumin can be synthetically derived to a high degree of purity. Alternately, curcumin can be obtained by extraction or other treatment of naturally occurring turmeric so that the curcumin content of the modified turmeric has the above-noted levels of curcumin therein.

The Curcumin Component(s)

[0640] As used herein, "curcumin component(s)" shall mean curcumin, its metabolites and derivatives, isomers and tautomers thereof, esters, metal complexes (e.g., Cu, Fe, Zn, Pt, V), and pharmaceutically acceptable salts of any of the foregoing. Curcumin derivatives include both naturally occurring and synthetic derivatives, e.g., the spontaneous degradation products of curcumin, curcumin metabolites, and synthetic curcumin derivative compounds.

1. Curcumin.

[0641] Curcumin (diferuloylmethane, 1,7-bis(4-hydroxy3-methoxyphenyl)-1,6-heptadiene-3,5-dione) is a symmetrical diphenolic dienone, see structure C-I below. It exists in solution as an equilibrium mixture of the symmetrical dienone (diketo) and the keto-enol tautomer; the keto-enol form is strongly favored by intramolecular hydrogen bonding. Curcumin contains two aryl rings separated by an unsaturated 7-carbon linker having a symmetrical β-diketone group (as used herein, "β-diketone" embraces both tautomeric forms, namely the diketo and enol forms). The aryl rings of curcumin contain a hydroxyl group in the para position and a methoxy group in the meta position.

2. Degradation Products of Curcumin.

[0642] It is known that, under certain pH and other conditions, curcumin will spontaneously form degradation products, and especially one or more of the following:

C-2



Trans-6-(4′-hydroxy-3′-methoxyphenyl)-2,4-dioxo-5-hexenal

C-3



Ferulic aldehyde

C-4



Ferulic acid

C-5



Feruloyl methane

-continued

C-6



Vanillin

C-47



Deketene curcumin

3. Curcumin Metabolites

[0643] It has been determined that curcumin is differently metabolized in vivo depending upon the route of administration, see, Shen et al. *The Pharmacology of Curcumin: Is it the Degradation Products*? Trends in Molecular Medicine, March 2012 Vol. 18, No. 2, incorporated by reference herein it its entirety. Thus, when curcumin is orally administered, the metabolites normally include one or more of the following:

C-7



Curcumin glucuronide

C-8



Curcuminsulfate

[0644] On the other hand, where the route of administration is intravenous/intraperitoneal, the metabolites generally include the following:

C-9



Tetrahydrocurcumin

C-10



Hexahydrocurcumin

C-11



Octahydrocurcumin

[0645] Other naturally occurring curcumin derivatives include cyclocurcumin, bisdemethoxycurcumin, demethoxycurcumin, dihydrocurcumin, caffeic acid, cinnamic acid, isoeugenol, dibenzoylmethane, dehydrozingerone, capsaicin, [6]-gingerol, [6]-paradol, chlorogenic acid, yakuchinone A, oregonin, cassumuin A, and cassumuin B.

4. Synthetic Curcumin Derivatives.

[0646] Curcumin derivatives are expected to be beneficial for use in the treatment methods of the invention. The term "curcumin derivative" is used interchangeably with the term "curcumin analog" and "curcumin analogue" (alternative spelling) and includes, for example, curcumin derivatives, analogs, curcuminoids and chalcones. In one embodiment the curcumin derivative includes first and second aryl groups covalently attached by way of a linker or a linking group. In another embodiment, the second aryl group is absent, such that the curcumin derivative contains a first aryl group and the linker but no second aryl group at the distal end of the linker. Optionally, the first and/or second aryl group is a heteroaryl group. The first and second aryl groups may be independently substituted or unsubstituted.

[0647] Curcumin derivatives that exhibit improved pharmacokinetic properties and/or reduced toxicity are preferred. For example, curcumin derivatives that include heteroaryl groups and/or unsaturated linkers are expected to impart improved pharmacokinetic properties and/or reduced toxicity to the compounds, because they are expected to be less chemically reactive in vivo. One example of preferred curcumin derivatives includes those including one or two carbonyl groups in the linker region, including those derivatives that preserve the enone functionality of curcumin. Derivatives that include heteroaryl groups and/or unsaturated linkers are expected to be less likely to be degraded and/or form toxic adducts or intermediates under physiological conditions.

[0648] Thus, in one aspect, curcumin derivatives of the invention are generally encompassed by the formula:

Ar1-L-Ar2 C-12

where Ar1 and Ar2 are independently aryl groups, and L is a divalent linking group that includes between 3 and 7 backbone carbon atoms, wherein one or more of the backbone carbon atoms include a carbonyl or hydroxyl moiety.

a. Aryl Groups

[0649] Preferred aryl groups include phenyl, naphthyl, thienyl, pyridinium, and pyridyl groups.

[0650] Aryl groups Ar1 and Ar2 may be substituted or unsubstituted, and one or more of the ring carbons may be substituted with a heteroatom, and especially N, S, B, or O.

[0651] For example, in one embodiment of the invention, Ar1 can be an aryl group according to the formula:

C-13



and Ar2 can be an aryl group according to the formula:

C-14



where one or more of the aryl ring carbons of Ar1 and Ar2 may be independently substituted with a heteroatom selected from N, S, B, or O, and R1-R10 are independently selected from the group consisting of H, hydroxyl, halogen, amine, nitro, sulfonate, sulfoxide, thio, ester, carboxylate, amide, borate, C1-C4 boronate, C1-C8 alkyl, C2-C8 alkenyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 amine, C2-C8 carboxyl, C2-C8 ester, C1-C4 aldehyde, and glucuronide groups; L is a divalent linker including from 3-7 backbone carbon atoms that form a chain connecting the Ar1, Ar2, and R11 groups as the case may be, where L includes at least one of a carbonyl or hydroxyl group. In further embodiments, Ar1 and Ar2 are phenyl groups; R1-R10 are independently selected from the group consisting of H, hydroxyl, halogen, amine, nitro, sulfonate, thio, borate, C1-C2 boronate, sulfoxide, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamine, C2-C6 alkenylamine, C1-C6 acetoxy, C1-C4 carboxyl, with at least one of R1-R5 and R6-R10 being hydroxyl.

b. Divalent Linking Groups

[0652] The linker L is a spacer that preferably includes 3, 4, 5, 6 or 7 carbon atoms that form a linear carbon chain connecting the first and second aryl groups. The carbons atoms in the carbon chain that trace out shortest path between the first and optional second aryl groups are referred to herein as the "backbone" carbon atoms. The

number of backbone carbon atoms is readily determined in straight chain alkyl groups. In linkers that include a cyclic alkyl group as a constituent of the linear chain, the backbone carbon atoms include the least number of ring carbons possible. The number of backbone carbon atoms is used herein as a shorthand way to designate the length of the linker being used. For example, a 7-carbon linker is a divalent linker that includes 7 backbone carbon atoms.

[0653] Preferably at least one of the backbone carbon atoms is included in a carbonyl (C═O) or thio carbonyl (C═S) moiety. The linker may be substituted or unsubstituted. The linker may further be saturated or unsaturated. In a preferred embodiment, the linker contains an odd number of carbon atoms (i.e., 3, 5, or 7 carbon atoms), and at least one unsaturated carbon-carbon bond. In additional embodiments, the linker may include a hydroxyl moiety in place of, or in addition to, the at least one carbonyl moiety.

[0654] Curcumin derivatives of the invention include a linking group L that is preferably covalently attached at one end to aryl group Ar1. Optionally, the linking group L may also be covalently attached at the other end to a second aryl group, Ar2, which is selected independently from Ar1. The linking group L is a divalent linking group that preferably includes an alkylene or an alkenylene group having between 3 and 7 backbone carbon atoms, and more advantageously an odd number of backbone carbon atoms (i.e., 3, 5, or 7 carbon atoms). The linker also preferably has at least one carbonyl moiety, and may further include a hydroxyl moiety in place of, or in addition to, the at least one carbonyl moiety. The linking group may be substituted or unsubstituted, and may be saturated or unsaturated. Preferably, the linking group has a carbon-carbon double bond between the a and p carbons relative to Ar1 and/or Ar2 (e.g., see formulas C-1 and C-19 through C-33, which illustrate such a double bond. Still more preferably, the linking group includes conjugated double bonds. Table 1 shows compounds with 7-carbon linkers; Table 2 shows compounds with 5-carbon linkers; and Table 3 shows compounds with 3-carbon linkers.

[0655] A divalent linking group includes two carbons with unfilled valencies that provide valence points where a covalent bond can be formed to an adjacent alkyl or aryl group that also includes a carbon with an unfilled valency. Generally, a valence point is represented in a chemical formula by a bond that is shown as not being attached to another group (e.g., CH3-, wherein — represents the valence point).

[0656] In embodiments wherein the curcumin derivative lacks the second aryl group Ar2, the distal valence point on the linking group can be filled with any substituent of interest, preferably a short chain alkyl group (e.g., C1-C6, more preferably C1-C4) or a hydrogen (H). Compounds lacking a second aryl group may be represented by formula:

Ar1-L-R11 C-15

R11 can be, for example, a heterocyclic group or an alkyl group, preferably an alkyl group having four or fewer carbon atoms, e.g., a methyl group. R11 can alternately be an amine, a hydroxyl, a hydrogen, nitro, sulfonate, sulfoxide, thio, ester, carboxylate, amide, borate, or a C1-C4 boronate.

i. Curcumin Derivatives Including 7-Carbon Linking Groups

[0657] In one embodiment of the invention, the curcumin derivatives include one or two aryl groups (Ar1 and optionally Ar2) and a linking group L that is a 7-carbon linking group (i.e., a linking group that includes 7 backbone carbon atoms). Preferably, the 7-carbon linking group includes at least one unsaturated carbon-carbon bond. Examples of 7-carbon linking groups include

—CH═CH—(CO)—CR12=C(OH)—CH═CH—, C-16

—CH═CH—(CO)—C(R12)2-(CO)—CH═CH—, and C-17

—CH═CH—(CO)—CH═C(OH)—CH═CH C-18

where R12 includes substituent alkyl, arylalkyl, or aryl groups comprising 10 carbon atoms or less. In some embodiments, R12 may be a methyl, ethyl, or benzyl group. These linking groups are the divalent forms of 4-alkyl-1,6 heptadiene-3,5-dione; 4,4-dialkyl-1,6 heptadiene-3,5-dione; and heptane-3,5-dione.

[0658] Table 1 shows a number of examples of curcumin derivatives that include a 7-carbon linker. The compounds shown contain two aryl rings separated by a 7-carbon linker having two carbonyls (or the equivalent keto-enol tautomer). In many, but not all, of the compounds, the linker is unsaturated. "Bn" refers to a benzyl group.

TABLE 1

7-Carbon Linker Analogs.	
	C-19
	C-20
	C-21
	C-22
	C-23
	C-24

TABLE 1-continued

7-Carbon Linker Analogs.	
	C-25
	C-26
	C-27
	C-28
	C-29
	C-30
	C-31
	C-32
	C-33
	C-34

TABLE 1-continued

7-Carbon Linker Analogs.	
	C-35
	C-36
	C-37
	C-38
	C-39
	C-40
	C-41

ii. Curcumin Derivatives Including 5-Carbon Linking Groups

[0659] In a further embodiment of the invention, the curcumin derivatives include one or two aryl groups (Ar1 and optionally Ar2) that are linked by a linking group L that is a 5-carbon linking group (i.e., a linking group that includes 5 backbone carbon atoms). Preferably, the 5-carbon linking group includes at least one unsaturated carbon-carbon bond. Examples of 5-carbon linking groups include:

—CH═CH—(CO)—CH═CH— , C^{-42}

—CH2—CH2—(CO)—CH2—CH2— , C^{-43}

-continued

C-44

—CH2—CH2—CH(OH)—CH2—CH2— ,

C-45



, and

C-46



[0660] These linking groups are the divalent forms of 1,4-pentadiene-3-one; pentan-3-one; pentan-3-ol, 2,6; bis (methylene)cyclohexanone; and 1,2,4,5-diepoxy pentan-3-one. As noted herein, curcumin derivatives may include a cyclic linking group. For example, 1-methyl-2,6-diphenyl-4-piperidone provides a compound with a 5-carbon linking group that is bridged by a tertiary amine to form a cyclic alkylene linking group including the heteroatom nitrogen.

[0661] Table 2 shows a number of examples of curcumin derivatives that include a 5-carbon linker. The compounds shown contain two aryl rings separated by a 5-carbon linker having a single carbonyl or hydroxyl. In many, but not all, of the compounds, the linker is unsaturated.

TABLE 2

5-Carbon Linker Analogs.	
	C-47
	C-48
	C-49
	C-50
	C-51

TABLE 2-continued

5-Carbon Linker Analogs.	
	C-52
	C-53
	C-54
	C-55
	C-56
	C-57
	C-58
	C-59
	C-60

TABLE 2-continued

5-Carbon Linker Analogs.

C-61



C-62



C-63



C-64



C-65



C-66



C-67



C-68



C-69



TABLE 2-continued

5-Carbon Linker Analogs.

C-70



C-71



C-72



C-73



C-74



C-75



C-76



C-77



C-78



TABLE 2-continued

5-Carbon Linker Analogs.	
	C-79
	C-80
	C-81
	C-82
	C-83
	C-84
	C-85
	C-86
	C-87
	C-88

TABLE 2-continued

5-Carbon Linker Analogs.	
	C-89
	C-90

iii. Curcumin Derivatives Including 3-Carbon Linking Groups

[0662] In a further embodiment of the invention, the curcumin derivatives include one or two aryl groups (Ar1 and optionally Ar2) that are linked by a linking group L that is a 3-carbon linking group (i.e., a linking group that includes 3 backbone carbon atoms). Preferably, the 3-carbon linking group includes at least one unsaturated carbon-carbon bond. An example of a 3-carbon linking group is —CH═CH—(CO)—; i.e., a divalent form of propenone.

[0663] Table 3 shows a number of examples of curcumin derivatives that include a 3-carbon linker. The compounds shown generally have an unsaturated 3-carbon linker having a single carbonyl. While most of the examples shown have two aryl groups separated by the linker, several of the embodiments include only a single aryl group. In the examples that include only a single aryl group, a methyl group is provided at the other end of the linking group. One compound includes the heteroatom N in place of one of the backbone carbon atoms; however, this is still considered a 3-C linker in that 3 atoms (C, N, and C) are present along the shortest bridge between the two aryl groups.

TABLE 3

3-Carbon Linker Analogs.	
	C-91
	C-92
	C-93

TABLE 3-continued

3-Carbon Linker Analogs.	
	C-94
	C-95
	C-96
	C-97
	C-98
	C-99
	C-100
	C-101
	C-102

TABLE 3-continued

3-Carbon Linker Analogs.	
	C-103

iv. Additional Curcumin Derivatives

[0664] Curcumin derivatives of the invention may include a variety of linking groups and Ar groups while retaining the necessary activity. Accordingly, additional curcumin analogs are contemplated. These include curcumin analogs containing central methylene substituents such as ethyl, propyl, butyl, isopropyl and substituted benzyl groups according to the formula:

C-104



R13 = CH_2CH_3, $CH(CH_3)_2$, $CH_2CH_2CH_3$, $CH_2CH_2CH_2CH_3$ $CH_2C_6H_4X$; X = OH, OCH_3, $N(CH_3)_2$, CH_3

Central Methylene Substituent Analogs

[0665] Additional analogs that are contemplated are those having a pyridine ring with and without a central methylene substituent on the 7-carbon linker such as those shown in the formulas:

C-105



C-106



[0666] each T, U, V is independently selected from N, CH, such that each Ar ring is a pyridine; R14=CH_2CH_3, $CH(CH_3)_2$, $CH_2CH_2CH_3$, $CH_2CH_2CH_2CH_3$, $CH_2C_6H_4X$; X=OH, OCH_3, $N(CH_3)_2$, CH_3 Pyridine aryl ring analogs

[0667] Many curcumin analogs which have a 5-carbon linker possess significant activity. Additional active analogs

in this series may contain substituents such as hydroxy and methoxy groups on the aryl rings. Examples of these analogs are shown in the formula:

C-107



[0668] each R15 is independently selected from CH_2CH_3, $CH(CH_3)_2$, $CH_2CH_2CH_3$, $CH_2CH_2CH_2CH_3$

Aryl Substituent Analogs

[0669] Other analogs include heterocyclic moieties, which may be substituted or unsubstituted, as shown in the formulas:

C-108



each R16 is independently selected from Cl, F, CF_3, OH

C-109



R17 = Ph, CH_2CH_3

Heterocyclic Analogs

v. Synthetic Curcumin Derivatives Via Different Reaction Schemes

[0670] A large number of naturally occurring and synthetic curcumin derivatives, the latter explicated by reference to the methods of synthesis thereof, are disclosed in Anand et al. "Biological Activities of Curcumin and Its Analogues (Congeners) Made By Man and Mother Nature." *Biochemical Pharmacology* 76 (2008):1590-1611, which is incorporated by reference herein its entirety. Representative synthetic curcumin derivatives are set forth below.

C-110



C-111



C-112



C-113



C-114



C-115



C-116



C-117



-continued

C-118



C-119



C-120



C-121



C-122



C-123



C-124



C-125



C-126



-continued

C-127



C-128



C-129



C-130



C-131



C-132



C-133



C-134



-continued

C-135



C-136



C-137



C-138



C-139



C-140



C-141



C-142



-continued

C-143



C-144



C-145



C-146



C-147



where R18, R19, and R20 are each independently selected from the group consisting of H, C1-C4 alkyl, and C1-C4 amine groups.

vi. Miscellaneous Curcumin Components



	R21	R22	R23
C-148	OCH_3	OH	OCH_3
C-149	OCH_3	OH	H
C-149	H	OH	H

-continued

C-151



C-152



C-153



C-154



C-155



C-156



C-157



C-158



-continued

C-159



where R24 and R25 are independently selected from the group consisting of OH, C1-C4 alkoxy, and C1-C4 alkylcarbonyloxy; R26 and R27 are independently selected from the group consisting of H, OH, C1-C4 alkoxy, and C1-C4 alkylcarbonyloxy; R28 is selected from the group consisting of H, OH, and C1-C4 alkylcarbonyloxy; and R29 is selected from the group consisting of H and C1-C4 alkoxy.

C-160



C-161



where R30, R31, R32, R33, R34, R35, and R36 are independently selected from the group consisting of H, OH, C1-C4 alkoxy, and C1-C4 alkylcarbonyloxy.

C-162



where R37 and R38 are independently selected from the group consisting of methoxy and OH, and the center benzene ring may be substituted in the 1,3- or the 1,4-position with the acryloyl groups.

[0671] Additionally, some or all of the carbonyl (C═O) moieties of formulae C-148 through C-162 may be substituted with thio carbonyl (C═S) moieties.

vii. Presently Preferred Curcumin Components

[0672] Based upon the structure activity relationships of curcumin and curcumin derivatives, curcumin components of formula C-13A are preferred:

C-13A



where R1-R5 are as previously defined, and the * denotes the valence point where the additional portion of the compounds are attached. That is, the preferred components have the moiety depicted in C-13A and additional portion exemplified by the foregoing disclosure, e.g., the remaining structure of the linker L and Ar2 or R11.

[0673] The most preferred curcumin components are exemplified by formula C-12 where:

[0674] Ar1 and Ar2 are each aryl groups, and especially phenyl, naphthyl, thienyl, pyridinium, and pyridyl groups, and most preferably phenyl groups, wherein all of the foregoing may be substituted or unsubstituted;

[0675] L contains either 5 or 7 backbone carbon atoms and at least one of a carbonyl or hydroxyl group;

[0676] at least one of R1-R5 and R6-R10 is hydroxyl.

[0677] Still more preferably, the curcumin components should have:

[0678] the R2 and R7, or R3 and R7, substituents of formulas C-13 and C-14 as hydroxyl;

[0679] the R3 and R8 substituents of formulas C-13 and C-14 as methoxy or ethoxy (most preferably methoxy);

[0680] a β-diketone group in the linker L of formula C-12; and/or

[0681] at least one, and preferably two, carbon-carbon double bonds in the linker L of formula C-12, where at least one of the double bonds is located between the a and p carbons relative to Ar1 and/or Ar2;

[0682] where the curcumin component is not apocynin.

[0683] In other embodiments, the curcumin component is taken from compounds of the general formula

Ar1-L-Ar2 C-12

where Ar1 and Ar2 are independently selected form the group consisting phenyl and naphthyl groups, where the phenyl groups may be substituted with one or more substituents selected from the group consisting of OH, C1-C4 alkoxys (more preferably C1-C2 alkoxys), C1-C4 haloalkyls (more preferably C1-C2 haloalkyls), halo, and L has from 3-7 backbone carbon atoms including at least one carbonyl group therein.

[0684] Use has also been made of a commercially available, proprietary curcumin product sold under the designation "ResCu" by Davospharma, and which is asserted to be a more bioavailable form of standard curcumin. This commercial product has been tested in connection with the invention and found to be a suitable curcumin component.

The Harmine Component(s)

[0685] As used herein, "harmine component(s)" shall mean harmine, its metabolites and derivatives, isomers and tautomers thereof, and esters and pharmaceutically acceptable salts of any of the foregoing.

[0686] Harmine belongs to the family of β-carboline alkaloids, its chemical name is 7-methoxy-1-methyl 9H-pyrrole [3,4-b]indole, and its molecular formula is C13H12N2O. The base structure of 3-carboline is shown in H-0.

H-0



β-Carboline

[0687] Harmine has a molecular weight of 212.25 and a melting point of 261° C. Harmine was originally isolated from *Peganum harmala*, which is widely used as a traditional herbal drug in the Middle East and North Africa. The chemical structure of harmine, 1-methyl-7-methoxy-β-carboline, is shown as follows:

H-1



[0688] Harmine derivatives, which are variously substituted β-carbolines, are illustrated in the following formulas, which differ in that H-2 has a quaternary ammonium group at the 2-position, whereas H-3 has a tertiary nitrogen at the 2-position.

H-2



H-3



With reference to formulas H-2 and H-3:

[0689] Z1 is hydrogen; a C1-C6 alkyl or haloalkyl, a C2-C6 alkenyl or haloalkenyl; an aryl group or an arylalkyl group, wherein the aryl group is optionally substituted at any position with halogen, nitro, hydroxyl, C1-C3 alkoxy, amino, sulfonate, sulfoxide, thio, ester, carboxylate, amide, borate, or C1-C4 boronate and wherein the alkyl group is selected from C1-C4 alkyl; or a heterocyclic group;

[0690] Z2 is hydrogen; a C1-C6 carboxyl, ester, carboxylate, acylamino, acyl halide, sulfonate, sulfoxide, thio, amide or alkoxycarbonyl group; an aryloxycarbonyl group; alkyl group optionally substituted with hydroxyl or alkoxycarbonyl; carbamate; acylhydrazine; or a heterocyclic oxycarbonyl group, where the heterocyclic portion contains from 3-7 atoms and a nitrogen, oxygen, boron, or sulfur heteroatom;

[0691] Z3 is hydrogen; a C1-C6 alkyl or haloalkyl; sulfonate, sulfoxide, thio, carboxylate, amide, C2-C6 alkenyl group; hydroxyl; a C1-C6 alkoxy group; a C1-C6 carboxylic ester group; an arylalkoxy group where the alkoxy portion contains from 1-6 carbon atoms; or a heterocyclic group containing from 3-7 atoms and a nitrogen, oxygen, boron, or sulfur heteroatom;

[0692] Z4 is hydrogen; a C1-C6 alkyl, haloalkyl; C2-C6 alkenyl group; a hydroxyalkyl group where the alkyl portion contains from 1-6 carbon atoms; an arylalkyl group wherein the aryl group is optionally substituted at any position with halogen, nitro, hydroxyl, C1-C3 alkoxy, borate, C1-C4 boronate, sulfonate, sulfoxide, thio, ester, carboxylate, amide or amino, and wherein the alkyl group is selected from C1-C4 alkyl group; an arylalkanone; or a heterocyclic group containing from 3-7 atoms and a nitrogen, oxygen, boron or sulfur heteroatom;

[0693] Z5 is hydrogen; a C1-C6 alkyl group; an aryl group substituted at any position with one or more of (1)-(2), where (1) is a C1-C4 alkyl group, and (2) is a C1-C6 carbonyl, hydroxycarbonyl, ester, sulfonate, sulfoxide, thio, ester, carboxylate, amide or amino group; arylalkyl where the alkyl group is a C1-C6 alkyl; 1-5 substituted arylalkyl; arylhydrocarbyl; arylcarboxyl; aryl ester group; arylamino group; or a heterocyclic group containing from 3-7 atoms and a nitrogen, oxygen, boron or sulfur heteroatom; X is a halogen; a sulfonic group, a sulfuric group, a nitric acid group or a carboxylate, in the compounds of the above formulas H-2 and H-3:

[0694] Z1 is preferably hydrogen, a C1-C4 alkyl group, or an arylalkyl group; more preferably hydrogen, or a C1-C2 alkyl group; and most preferably methyl;

[0695] Z2 is preferably hydrogen or a C1-C4 alkoxycarbonyl group; more preferably a C1-C2 alkoxycarbonyl group; and most preferably hydrogen;

[0696] Z3 is preferably hydrogen, hydroxyl, or a C1-C4 alkyloxy group; more preferably methoxy;

[0697] Z4 is preferably hydrogen, a C1-C4 alkyl group, a C1-C4 hydroxyalkyl group, or an optionally substituted arylalkyl group; more preferably hydrogen, a C1-C2 alkyl group, or a C1-C2 hydroxyalkyl group; still more preferably ethyl or benzyl; and most preferably hydrogen.

[0698] In certain embodiments where Z1 is hydrogen, a C1-C4 alkyl group, or an arylalkyl group, Z2 is hydrogen, hydroxyl, a C1-C4 carboxyl group, a C1-C4 ester group, a carboxylate group, a halogen, or a C1-C4 alkoxycarbonyl group; Z3 is hydrogen, hydroxyl, or a C1-4 alkoxy group; Z4 is hydrogen, a C1-C2 alkyl group, a C1-C2 hydroxyalkyl group, or an optionally substituted arylalkyl group; and Z5 is hydrogen, a C1-C6 alkyl group, or an optionally substituted aryl-alkyl group.

[0699] In certain embodiments where Z1 is hydrogen, Z2 is a C1-C2 alkoxycarbonyl group, Z3 is hydrogen, and Z4 is C1-C2 alkyl group, or an optionally substituted arylalkyl group.

[0700] In certain embodiments where Z1 is hydrogen, Z2 is ethoxycarbonyl, Z3 is hydrogen, and Z4 is ethyl or benzyl.

[0701] In certain embodiments where Z1 is methyl, Z2 is ethoxycarbonyl, Z3 is hydrogen, Z4 is pentafluorobenzyl, and Z5 is hydrogen.

[0702] In certain embodiments where Z1 is hydrogen, Z2 is hydrogen, Z3 is hydrogen, Z4 is benzyl, Z5 is benzyl, and X is bromine.

[0703] Certain preferred harmine components include β-carboline, tryptoline, pinoline, harmine, harmalol, harmalol hydrochloride hydrate, tetrahydroharmine, harmane, harmol, vasicine, and vasicinone.

[0704] Other harmine derivatives include:

H-4



H-5



where Z1, Z2, and Z9 are set forth below, and X1 is a halogen preferably Cl, Br, and F or carboxylate anion.

[0705] Based upon the structure-activity relationships of harmine and harmine derivatives, preferred components are illustrated by formula H-6:

H-6



where the three * denote valence points where respective additional atoms or portions of the components are attached to give complete compounds; the dotted lines in the right-hand six-membered ring of H-6 indicate that the ring may optionally be aromatic; Z1 and Z4 are independently H or a C1-C6 alkyl group, more preferably a C1-C4 alkyl group, and most preferably methyl for Z1 and hydrogen for Z4; and the remaining unoccupied positions on the six-membered rings (i.e., the left-hand phenyl group and the right-hand six-membered ring) are each independently selected from

the group consisting of Z1, as previously defined. That is, the preferred harmine components have the moiety depicted in H-1 and additional portions exemplified by the foregoing disclosure. N+ is optionally substituted with Z5, as previously defined. In some cases, X^- as previously defined is present. One of ordinary skill in the art would understand that ----- indicates a double or single bond is present. For example, where one of the -* substituents is OCH3 and is located at the No. 7 position as illustrated in formula H-1, the other -* substituents on the remaining unoccupied positions on the terminal 6-membered rings are all H, Z4 is H and Z1 is methyl, and Z5 and X^- not existing, the resulting compound is harmine.

[0706] One class of preferred harmine components are shown in formula H-3, where Z3 is a methoxy or ethoxy group and Z4 is a benzyl group. A second preferred class of harmine components is shown in formula H-2, where Z1 is a methyl group, Z2 is hydrogen, Z3 is a benzyloxy group, Z4 and Z5 are benzyl groups.

Z6	Z7	Z8
	$CH_3CH_2CH_2CH_2$—	
CH_3—		
		$CH_3CH_2CH_2CH_2$—
		$CH_3CH_2CH_2CH_2$—
H—		
		$CH_3CH_2CH_2CH_2$—
		$CH_3CH_2CH_2CH_2$—
		$CH_3CH_2CH_2CH_2$—
		

-continued

Z6	Z7	Z8
		
		
H—	$CH_3CH_2CH_2CH_2$—	

[0707] In other embodiments, preferred harmine components include compounds of the formula

H-7



R39 is selected from the group consisting of H, C1-C4 alkoxys (more preferably C1-C2 alkoxys), O, and OH substituents, R40 is selected from the group consisting of H, C1-C4 alkyls (more preferably C1-C2 alkyls), C1-C4 haloalkyls (more preferably C1-C2 haloalkyls), C1-C4 alkoxys (more preferably C1-C2 alkoxys), nitrophenyls, C1-C4 organic acids (more preferably C1-C2 organic acids), C1-C4 alkylalcohols (more preferably C1-C2 alkylalcohols), and C1-C6 alkyl esters (more preferably C2-C4 alkyl esters), and R41 is selected from the group consisting of nothing, H, and nitrophenyls.

The Isovanillin Component(s)

[0708] As used herein, "isovanillin component(s)" refers to isovanillin, its metabolites and derivatives, isomers and tautomers thereof, and esters and pharmaceutically acceptable salts of any of the foregoing.

[0709] Isovanillin is a phenolic aldehyde having a hydroxyl group at the meta position and a methoxy group at the para position. Isovanillin is illustrated in the following structure:

I-1



[0710] Isovanillin is metabolized in vivo to vanillin, which is the same as structure I-1, except that the hydroxyl and methoxy substituents are exchanged, i.e., in vanillin, the hydroxyl group is in the para position, and the methoxy group is in the meta position.

[0711] Useful derivatives of isovanillin have the following general formula:

I-2



where at least one of Q1-Q6 is an alkoxy group and/or an aldehyde group, especially where the alkoxy and/or aldehyde groups contain from 1-6 carbon atoms; more preferably, where Q1 is an aldehyde, alcohol, amine, carbonyl, carboxylate, C1-C6 alkylhydroxy, ester, imidazole, nitro, sulfonate, sulfoxide, thio, amide, oxime, borate, or boronate, or semicarbazone group; the Q2-Q6 groups are independently selected from hydrogen, hydroxyl, halo, nitro, C1-C6 alkoxy, C1-C6 alkyl or alkenyl groups, with the proviso that at least one of the Q2-Q6 groups is an alkoxy group. In more preferred forms, the aldehyde, alcohol, amine, carbonyl, carboxylate, and ester groups should have a C1-C6 carbon chain length, the boronate is a C1-C4 boronate, and at least one of the Q2-Q6 groups is an alkoxy group (most preferably methoxy), and another is a hydroxyl group; advantageously, the alkoxy and hydroxyl groups are adjacent each other. In particularly preferred forms, the remainder of the Q2-Q6 groups, apart from the alkoxy and hydroxyl groups, are all H. Advantageously, the isovanillin components of the invention should include only one phenyl group and are free

of any fused ring structures (as used herein, "fused ring structures" refer to structures such as found in naphthalene or anthracene where two rings share common atoms).

[0712] Some preferred isovanillin components are selected from isovanillin, vanillin, ethyl vanillin, ortho-vanillin, vanillic acid, isovanillic acid, vanillic alcohol, isovanillic alcohol, 6-bromine-5-hydroxy-4-methoxybenzaldehyde, 4-hydroxy-3,5-dimethoxybenzaldehyde, 4,5-dihydroxy-3-methoxybenzaldehyde, 5-hydroxy-4-methoxybenazldehyde, 2-Benzyloxy-3-methoxybenzaldehyde, 2-(2-benzyloxy-3-methoxyphenyl)-1H-benzimidazole, N-1-(2-benzyloxy-3-methoxybenzyl)-2-(2-benzyloxy-3-methoxyphenyl)-1H-benzimidazole, and (S)-1-(2-benzyloxy-3-methoxyphenyl)-2, 2, 2-trichloroethyl benzenesulfonate (regarding the last four compounds, see Al-Mudaris et al., *Anticancer Properties of Novel Synthetic Vanillin Derivatives* (2012)).

[0713] Certain imidazole derivatives (such as nitro-imidazoles) have been shown to have significant anticancer activity, see, e.g., Sharma et al., "Imidazole Derivatives Show Anticancer Potential by Inducing Apoptosis and Cellular Senescence," *Med.Chem.Commun.* 2014, 5, 1751, incorporated by reference herein. Representative imidazole derivatives include:

I-3



I-4



I-5



-continued

I-6



I-7



I-8



I-9



I-10



-continued

I-11



I-12



Additional isovanillin derivatives of interest are:

I-14



I-15



I-16



I-17



-continued

I-18



[0714] It will be appreciated that the aryl group substituents in formulas I-14-I18 can be at any desired position on the on the aryl rings, e.g., the —OH need not be adjacent and the heteroatom substituents may be at any desired location.

[0715] Based upon the structure-activity relationships of isovanillin and isovanillin derivatives, preferred components are illustrated by formula I-13:

I-13



where the two * denote valence points where respective additional atoms or portions of the components are attached to form complete compounds, the remaining phenyl ring positions not taken by the two depicted moieties are independently R1 as previously defined with reference to formula C-13, and Q7 is H or a C1-C6 alkyl group, more preferably a C1-C4 alkyl group, and most preferably methyl. That is, the preferred isovanillin components have the moiety depicted in I-13 and additional portions exemplified by the foregoing disclosure. For example, where * is CHO, the substituent —O-Q7 is located at the para position, Q7 is a methyl group, and the —O—* group is located at the meta position, the * of the —O—* moiety is H, and the remaining unoccupied positions on the phenyl ring are all H, the resulting compound is isovanillin. In preferred forms, the isovanillin component is not apocynin.

[0716] In other embodiments, the isovanillin components are selected from the compounds of the formula

I-19



where Q9 is selected from the group consisting of C1-C4 aldehydes (more preferably C1-C2 aldehydes), C1-C4 alkylalcohols (more preferably C1-C2 alkylalcohols), C1-C4 alkyl esters (more preferably C1-C2 alkyl esters), and C1-C4 organic acids (more preferably C1-C2 organic acids), Q10 is selected from the group consisting of OH, H, C1-C6 alkyl esters (more preferably C1-C4 alkyl esters), C1-C4 alkoxys (more preferably C1-C2 alkoxys), and benzyloxy, and Q11 is selected from the group consisting of H, C1-C4 alkoxys (more preferably C1-C2 alkoxys), and OH.

The Complete Compositions of the Invention

[0717] In the case of the preferred three-component compositions of the invention, made by combining individual quantities of normally highly purified curcumin component(s), harmine component(s), and isovanillin component(s), the as-added amounts should give weight ratios of about 10:1.7:0.85 (isovanillin component(s):harmine component(s):curcumin component(s)), but more broadly, the ratios are approximately 0.1-25:0.1-5:0.1-5 (isovanillin component(s):harmine component(s):curcumin component(s)). In this respect, it will be seen that the isovanillin component(s) of the preferred GZ17-6.02 product is/are the preponderant component(s) in the compositions on a weight basis, with the harmine and curcumin component(s) being present in lesser amounts on a weight basis. Generally, the isovanillin component(s) in the most preferred product should be present at a level at least three times (more preferably at least five times) greater than that of each of the harmine and curcumin component(s), again on a weight basis. However, the invention is not limited to such weight ratios. As noted in Example 17, an isovanillin component:harmine component:curcumin component weight ratio of 1:1:1 is also effective. In terms of amounts of the three components, the isovanillin component(s) should be present at a level of from about 25-85% by weight, the harmine component(s) should be present at a level of from about 7-50% by weight, and the curcumin component(s) should be present at a level of from about 5-40% by weight, based upon the total weight of the three components taken as 100% by weight.

[0718] In the case of two-component compositions in accordance with the invention made up of curcumin component(s) plus harmine component(s), the weight ratio of the curcumin component(s):harmine component(s) should range from about 0.01:1 to 10:1; and the weight amounts of the curcumin component(s) should range from about 20% to 75% by weight (more preferably from about 30-55% by weight, and most preferably about 45% by weight), and the weight amounts of the harmine component(s) should range from about 25% to 80% by weight (more preferably from about 45% to 70% by weight, and most preferably about 55% by weight), based upon the total weight of the two components in the compositions taken as 100% by weight. Generally, the amount of the harmine component should be greater than the amount of the curcumin component in these two-component compositions.

[0719] Two-component compositions made up of isovanillin component(s) plus curcumin component(s) should have a weight ratio of the isovanillin component(s):curcumin component(s) ranging from about 0.5:1 to 25:1; and the weight amounts of the isovanillin component(s) should range from about 25% to 95% by weight (more preferably from about 75% to 95% by weight, and most preferably about 88% by weight), and the weight amounts of the curcumin component(s) should range from about 5% to 75% by weight (more preferably from about 5% to 25% by weight, and most preferably about 12% by weight), based upon the total weight of the two components in the compositions taken as 100% by weight.

[0720] Finally, two-component compositions made up of isovanillin component(s) plus harmine component(s) should have a weight ratio of the isovanillin component(s):harmine component(s) should range from about 0.5:1 to 15:1; and the weight amounts of the isovanillin component(s) should range from about 25% to 95% by weight (more preferably from about 75% to 95% by weight, and most preferably about 85% by weight), and the weight amounts of the harmine component(s) should range from about 5% to 75% by weight (more preferably from about 5% to 25% by weight, and most preferably about 15% by weight) by weight, based upon the total weight of the two components in the compositions taken as 100% by weight.

[0721] In this connection, it should be understood that the isovanillin component(s) of any of the foregoing two- or three-component compositions containing isovanillin component(s) may be made up of initially added isovanillin component(s) plus any degradation products of the other component(s) yielding products within the ambit of the isovanillin component(s); for example, it is known that under certain circumstances curcumin will spontaneously degrade to give quantities of vanillin, and, in such circumstances, the total amount of the isovanillin component(s) would be the initially added amounts together with these degradation products. More broadly, the ultimate amounts of the curcumin, harmine, and isovanillin component(s) in the compositions of the invention should be determined based upon the actual contents of the component(s) in question, regardless of whether these component(s) are derived from the originally added component(s) or as degradation products of some or all of these originally added component(s).

[0722] As indicated previously, levels of dosing using the compositions of the invention is quite variable owing to factors such as the patient's age, patient's physical condition, the type of condition(s) being treated (e.g., specific cancer(s)), and the severity of the conditions. In general, however, regardless of the dosage form or route of administration employed, such as liquid solutions or suspensions, capsules, pills, or tablets, via oral, parenteral, or injection, the compositions should be dosed of from about 5 to 2000 mg per day, and more usually from about 100-800 mg per day. Such dosages may be based on a single administration per day, but more usually multiple administrations per day.

[0723] Finally, the invention also embraces compositions and methods where the individual components are provided and administered separately to subjects, so long as the therapeutic effects of the invention are substantially preserved.

Examples 1-28

[0724] The following Examples set forth preferred therapeutic agents and methods in accordance with the invention, but it is to be understood that these examples are given by way of illustration only, and nothing therein should be taken as a limitation upon the overall scope of the invention. A number of the Examples set forth various tests using the preferred drug of the invention, GZ17-6.02, which is sometimes referred to as GZ17Syn-6.02.

[0725] The GZ17-6.02 product of the Examples was made by dispersing quantities of solid synthetic isovanillin (771 mg, 98% by weight purity), synthetic harmine (130.3 mg, 99% by weight purity), and a commercially available curcumin product derived by the treatment of turmeric (98.7 mg, containing 99.76% by weight curcuminoids, namely 71.38% curcumin, 15.68% demethoxycurcumin, and 12.70% bisdemethoxycurcumin), in a 1 mL ethanol at a weight ratio of 771:130.3:98.7 (isovanillin:harmine:curcumin product) in ethanol followed by sonication of the

dispersion. Aliquots of this stock solution were then used to create the different GZ17-6.02 dilutions using stock media of the cells in question.

[0726] The two-component products described in Example 23 were made in the same fashion as the GZ17-6.02 agent, and the weight ratios of the two components were as set forth immediately above, e.g., the isovanillin/harmine sub-combinations contained a weight ratio of 771:130.3, and so forth.

Example 1

[0727] In this example, the preferred GZ17-6.02 product was tested with two different human head and neck cancers (HN5 and OSC19), in order to determine the extent of cell death induced by the product.

Methods

[0728] The respective cells were individually cultured in a growth medium prepared using RPMI-1640 medium containing 11.1 mM D-glucose with 10% fetal bovine serum, 10 mM HEPES, 2 mM L-glutamine, 1 mM sodium pyruvate, 0.05 mM 2-mercaptoethanol, and Antibiotic-Antimycotic. These cells were maintained in T75 tissue culture flasks in a humidified incubator at 37° C. and 5% CO_2. The media were changed on a third day after cell plating, and the cells were passaged on day 5 by trypsinization.

Formation of Cancer Spheroids

[0729] Custom-made micromolds with 100 m diameter wells were loaded with the cells (U.S. Pat. No. 8,735,154, incorporated by reference herein). The media were changed every day by partial replacement. Cell aggregates were allowed to form in the micromolds for 72 hours and then were transferred to a 100 mm non-treated tissue culture dishes for 3 additional days. The spheroids were passed through 70 m and 100 m cell strainers (#3431751 and #43152, Corning, Tewksbury, MA) and maintained in HEPES Balanced Salt Solution comprised of: 20 mM HEPES, 114 mM NaCl, 4.7 mM KCl, 1.2 mM KH_2PO_4, 1.16 mM $MgSO_4$, 2.5 mM $CaCl_2$), 25.5 mM $NaHCO_3$ and 0.2% bovine serum albumin (fatty acid free), pH 7.2.

Testing of GZ17-6.02 on Head and Neck Cancer Spheroids

[0730] Individual wells of a 96 well plate were manually loaded with 15-20 cancer spheroids each, and exposed to selected doses of GZ17-6.02. Each trial was run with at least 4 replicates at each dose. After a 24 hour exposure to the selected dosages of GZ17-6.02, PrestoBlue (Life Technologies, Inc) was added to each well and fluorescence readings were taken 4-6 hours later with an excitation wavelength of 485 nm and an emission wavelength of 560 nm, using a microplate reader (Enspire Multimode, PerkinElmer). Results were averaged following background subtraction and normalized to untreated cell controls.

[0731] FIG. **1** demonstrated that GZ17-6.02 dramatically kills HN5 and OSC19 cancer cells in a dose-dependent manner. The X axis is the increasing dose of GZ17-6.02 and the Y axis is the average number of live cells in each well at the end of a 24 hour exposure to the stated dose of GZ17-6.02.

Example 2

[0732] In this example, GZ17-6.02 was found to induce significant cancer cell death in human pediatric leukemia cells and pediatric osteosarcoma in a dose-dependent manner.

[0733] Jurkat leukemia cells were grown in suspension in media (RPMI supplemented with 10% FBS), maintained at approximately 500,000 cells/mL. The cells were plated in 96-well plates, and each well was exposed to a selected dose of GZ17-6.02 for 24 hours (a minimum of 4 replicates for each dosage). These cells were not treated to generate spheroids, but were directly plated onto the well plates. After a 24 hour exposure to the selected dosages of GZ17-6.02, PrestoBlue (Life Technologies, Inc) was added to each well and fluorescence readings were taken 4-6 hours later with an excitation wavelength of 485 nm and an emission wavelength of 560 nm, using a microplate reader (Enspire Multimode, PerkinElmer). Results were averaged following background subtraction and normalized to untreated cell controls.

[0734] Human osteosarcoma cells (HOS) also had a significant dose-dependent increase in cell death when exposed to GZ17-6.02 for 24 hours. The methods to create and test osteosarcoma spheroids were the same as the methods described in Example 1.

[0735] As illustrated in FIGS. **2**A and **2**B, increasing doses of GZ17-6.02 induced significant cell death in both leukemia and osteosarcoma cell types tested.

Example 3

[0736] In this example, the effect of increasing doses of GZ17-6.02 in killing human lymphoma cells (mo205) and human lung cancer cells (H358) was tested.

[0737] The lymphomas treatment methods used were identical to those described in Example 2 relative to the pediatric leukemia cells, whereas the lung cancer treatment method was the same as described in Example 1.

[0738] FIGS. **3**A and **3**B set forth the results of these tests, and demonstrate the effectiveness of GZ17-6.02 in inducing lymphoma and lung cancer cell death.

Example 4

[0739] In this example, the effect of increasing doses of GZ17-6.02 in killing human ovarian cancer cells (A1847) and human prostate cancer cells (22rv1) was tested.

[0740] The cells were treated and tested as set forth in Example 1.

[0741] This test confirmed that both types of cells experienced dose-dependent death when exposed to GZ17-6.02, see FIGS. **4**A and **4**B.

Example 5

[0742] In this example, the effect of increasing doses of GZ17-6.02 in killing human breast cancer cells (du4475) and human pancreatic cancer cells (panc-1) was tested.

[0743] The cells were treated and tested as set forth in Example 1, except that a different growth medium was used, namely Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine serum, and 1% penicillin/streptomycin mix (Sigma-Aldrich).

[0744] This test confirmed that both types of cells experienced dose-dependent death when exposed to GZ17-6.02, see FIGS. **5**A and **5**B.

[0745] As is evident from Examples 1-5, ten different cancer types were tested with GZ17-6.02 and they all were sensitive to the therapeutic agent. In most of the cancers (head and neck cancer (OSC19), leukemia, osteosarcoma (bone cancer), lymphoma, lung cancer, ovarian, prostate, breast, and pancreatic cancer), the compound killed nearly all of the cells in the dish at a dose of 3.13-6.25 mg/mL. This array of cancer types represents a substantial portion of human cancers. Moreover, the results confirm that the therapeutic agent is effective in both solid tumor cancers and blood cancers.

Example 6

[0746] In this test, non-cancerous integumental (dermal) fibroblasts (hgf-1) were tested with GZ17-6.02 and compared with prostate cancer (22rv1) and ovarian cancer cells (A1847), to determine the effect of GZ17-6.02 on the non-cancerous cells versus the prostate cancer and ovarian cancer cells.

[0747] The fibroblasts were treated as follows: The cells were grown to confluence in the DMEM medium of Example 5, and then placed in 96-well plates where they adhered to the bottom of the plates. Each well was then exposed to a selected dose of GZ17-6.02 for 24 hours (a minimum of 4 replicates each), and tested according to Example 1. The prostate cancer and ovarian cancer results were taken from the previous Example 4.

[0748] As illustrated in FIG. **6**, the cancer cells begin to die at lower GZ17-6.02 doses than the non-cancerous fibroblast cells, demonstrating that GZ17-6.02 is more toxic to cancer cells versus the non-cancerous fibroblasts.

Example 7

[0749] Migration of cells away from a primary tumor, followed by invasion of those tumor cells first into the blood vessels and later out of the blood vessels and into other tissues, are the two steps essential for metastases to form from a primary tumor. The cells were grown in the DMEM media of Example 5.

[0750] Head and neck cancer cells (OSC19) were tested using a commercially available migration assay kit, Cultrex 96 Well Migration Assay (R&D Systems). The cell movement from the upper compartment to the lower compartment was measured as representative of cell migration. A negative control migration was also measured, using the GZ17-6.02 vehicle, namely a dilution of ethanol in the growth media to the same concentration as GZ17-6.02 in the growth media.

[0751] The head and neck cancer cells were also assayed for migration using a Cultrex Cell Invasion Assay (R&D Systems). The ability of the head and neck cancer cells to invade a collagen matrix was measured by counting cells that exited the upper chamber and passed through a collagen-surrounded lower chamber. Similarly, a negative control for invasion was also measured, using the same ethanol vehicle employed in the migration assay.

[0752] As illustrated in FIG. **7**A, the GZ17-6.02 significantly inhibited migration so that almost no head and neck cancer cells could migrate from the site of origin. Likewise, GZ17-6.02 significantly inhibited invasion (FIG. **7**B) by more than 60%.

Example 8

[0753] In this test, the synergism of GZ17-6.02 with doxorubicin (a common chemotherapy drug) was tested on ovarian cancer cells. In this test, increasing doses of doxorubicin were administered to ovarian cancer spheroids and cell deaths were measured, as described in Example 1. The protocol involved testing doxorubicin alone at various dosages (FIG. **8**, doxorubicin alone—closed circles), with comparative tests using the various dosages of doxorubicin in combination with either 0.2 mg/mL (FIG. **8** open circles) or 0.4 mg/mL (FIG. **8** closed triangles) GZ17-6.02. Additionally, the induced cell death results from use of 0.2 mg/mL GZ17-6.02 alone (FIG. **8**, line A) and 0.4 mg/mL GZ17-6.02 alone (FIG. **8**, line B) were determined.

[0754] As is evident from FIG. **8**, even at the lowest dose of doxorubicin (0.002 μM), the addition of GZ17-6.02 at 0.2 and 0.4 mg/mL increased cell death significantly below the level of either compound alone. At low doses of doxorubicin alone (up to 0.158 μM), doxorubicin was ineffective. GZ17-6.02 administered alone at a dose of 0.2 mg/mL resulted in cell death at a level represented by the upper horizontal dotted line in FIG. **8**. Moreover, GZ17-6.02 administered alone at a dose of 0.4 mg/mL resulted in cell death at a level represented by the lower horizontal dotted line in FIG. **8**. Thus, even at these low dosages, addition of GZ17-6.02 significantly increased cell death (see data points under both of the horizontal dotted lines in FIG. **8**). This demonstrates the synergy of the combination of GZ17-6.02 and doxorubicin, even at low dosages of both GZ17-6.02 and doxorubicin. This trend is confirmed at higher dosages of doxorubicin, where the combined products were always more effective than doxorubicin alone.

Example 9

[0755] There are multiple general ways in which cancer (blood or solid tumors) can be blocked by chemotherapy. One is to actually induce death in the cancer cells (apoptosis), and a second is to block the ability of cells to receive nutrients, basically starving them to death (necrosis). This test demonstrates that at the ED_{50} of GZ17-6.02 on head and neck cancer cells (OSC19) caused cell death via apoptosis. In the test, head and neck cancer cells were stained with an apoptotic fluorophore and sorted by flow cytometry, which allows a single cell to be counted and measured for fluorescence simultaneously. This histograms in FIGS. **9**A and **9**B illustrate the shift in fluorescence intensity to a lower level, indicating apoptotic cell death. While the control (FIG. **9**A, head and neck cancer cells without GZ17-6.02) had little apoptotic cell death (19.8%), 48.2% of the cells exposed to GZ17-6.02 died of apoptosis (FIG. **9**B). This indicates one type of mechanism of action of GZ17-6.02.

Example 10

[0756] Caspase proteins are intracellular proteins involved in the apoptotic programmed cell death pathway. In instances where live lung cancer cell number decrease while a caspase protein increases, it can be inferred by association that the caspase was activated, and was thus associated with the molecular pathway of the cell death.

[0757] In these tests, the lung cancer cells (H358) were assayed using caspase testing kits (Promega Caspase-Glo 3/7, -Glo 2, -Glo 6, -Glo 8, and -Glo 9). Sample lung cancer cells were homogenized on ice in the provided preparation

buffer and agitated on a plate shaker at low speeds (around 300 rpm). The supernatants were exposed to the provided assay solutions and read on a microplate reader for luminescent output (Enspire Multimode, PerkinElmer).

[0758] The test results indicated that caspases 3 and 7 (FIG. **10**A, filled triangles) increased dramatically in association with cell death (filled circles). In addition, results indicated that caspase 6 (FIG. **10**B, open circles) increased in association with cell death (filled circles). In contrast, caspase 9 was not activated (FIG. **10**A, open circles). This implies a receptor-mediated cell death pathway and not a mitochondrial cell death pathway. In order to confirm this, an ATP assay (CellTiter-Glo, Promega) was conducted in which toxicity of the mitochondria were measured at the same time as cell death, based upon ATP concentrations. If a mitochondrial toxicity were responsible for cell death, it would happen at lower doses or prior in time to the cell death. FIG. **10**C confirms that there was no significant mitochondrial toxicity (filled circles) while there was cell death (open circles).

Example 11

[0759] The procedures of Example 10 were followed, with testing of GZ17-6.02 on ovarian cancer cells (A1847). Caspases 3 and 7 were activated at low doses of GZ17-6.02, indicating a receptor-mediated cell death (FIG. **11**A, filled circles). Caspase 6 was active at low doses of GZ17-6.02 (FIG. **11**B, filled circles). However, caspase 8 was activated, which typically signals cell death via the mitochondria (FIGS. **11**C, filled circles) and caspase 9 was also activated (FIG. **11**D, filled circles). In order to confirm the mitochondrial cell death pathway, mitochondrial toxicity was monitored in comparison to cell death (FIG. **11**E, filled circles), indicating that the mitochondrial toxicity was at least partially involved in the subsequent cell death.

Example 12

[0760] The procedures of Example 10 were followed, with testing of GZ17-6.02 on osteosarcoma cells (HOS). These tests indicated that levels of caspases 3 and 7 were significantly higher when exposed to doses of GZ17-6.02 over 0.4 mg/mL before or during cell death (FIG. **12**A, filled circles). Caspase 6 was activated at high doses of GZ17-6.02 (FIG. **12**B, filled circles). In contrast, caspase 2 (FIG. **12**C, filled circles) and caspase 9 (FIG. **12**D, filled circles) showed no activation that would indicate that they were involved in the cell death pathways induced by GZ17-6.02.

Example 13

[0761] The procedures of Example 10 were followed, with testing of GZ17-6.02 on human head and neck cancer cells (OSC19). FIG. **13** (filled circles) indicates that there is no mitochondrial toxicity involved in GZ17-6.02 induced cell death in the head and neck cancer cells.

Example 14

[0762] In addition to directly killing cancer cells, chemotherapeutic agents can work by blocking the rapid proliferation of cancer cells, thus eventually halting the progression of the cancer.

[0763] In this test, a multiplex dot-based Western assay for proliferative proteins was used to measure the relative amounts of proteins known to be involved in cell proliferation signaling, in both a control test (no GZ17-6.02) and an inactivation test (with GZ17-6.02, at the ED_{50} for head and neck cancer cells).

[0764] Following a 24 hour exposure to GZ17-6.02 or vehicle head and neck cancer cells (OSC19) were homogenized and the lysate loaded onto the Human Phospho-Kinase Array Kit (R&D Systems) using the following procedure. The antibody-attached membranes were incubated overnight at 4° C. with the respective cell lysates, followed by repeated washing and incubation in the detection antibodies for 24 hours. After subsequent repeated washes, streptavidin-TRP was applied for 30 minutes. Membranes were washed and exposed to film after applying chemiluminescence reagent mix.

[0765] Cellular proteins specific to a pathway of cell proliferation were tested in duplicate (resulting in 2 side-by-side dots for each protein in FIG. **14**A). The darker the dot, the more relative protein was present in the homogenate. As shown in FIG. **14**B, cell proliferation proteins showed a dramatic reduction in amount when exposed to the head and neck cancer cell ED_{50} dose of GZ17-6.02. The proteins showing the greatest reduction included epidermal growth factor receptor (block a compared to block a'), extracellular-signal-regulated kinase (block b compared to block b'), the catalytic subunit of AMP-activated kinase (block c compared to block c'), 0-catenin (block d compared to block d'), STAT2 (block e compared to block e') and Chk-2 (block f compared to block f').

Example 15

[0766] In this example, two independent scientists conducted identical tests with ovarian cancer and lung cancer cells (A1847 and H358) using the techniques described in Example 1, in order to determine induced cell death upon application of GZ17-6.02. The nearly identical results (filled circles versus open circles) confirm the reliability of the testing as a determination of GZ17-6.02 effectiveness. FIG. **15**A sets forth the ovarian cancer results, whereas FIG. **15**B gives the lung cancer cell results.

Example 16

[0767] Six-week old FOXN1 mice were inoculated with human head and neck cancer cells (OSC19) bilaterally into the flank region, in order to induce the formation of palpable tumors. The bilateral tumors were measured at one week after cell injection, and had each grown to an average volume of approximately 9 mm^3. Half of the mice were injected daily with 15 mg/kg body weight GZ17-6.02 stock solution into the right side tumors, starting on day 7 after inoculation of the tumor cells. The other half of the mice were injected with the same volume of the ethanol carrier of the stock solution into the right side tumors. Thus, each mouse had 2 palpable tumors, one on either flank, but only one side was injected with GZ17-6.02. Every 2-4 days, the tumors on both sides of each mouse were measured with vernier calipers in 2 perpendicular dimensions and the volumes calculated.

[0768] FIG. **16**A shows that GZ17-6.02 dramatically halted tumor growth in the treated mice, so that by 3 weeks there was a distinct and statistically significant difference between the vehicle-treated controls and the GZ17-6.02 treated mice. Further, the trend in the GZ17-6.02 treated mice was that the tumors began to decrease in volume from

day 21 (although the decrease was not statistically significant) from tumor size at day 28. FIG. **16**A shows the decline in tumor volume in the tumors that were directly injected with GZ17-6.02. FIG. **16**B shows the halt in tumor growth that occurred in the non-injected tumors on the contralateral side of the neck of the treated mice. FIG. **16**B demonstrates that GZ17-6.02 has a systemic anticancer effect, i.e., the contralateral tumor size decrease without direct injection of GZ17-6.02 indicates that the agent traveled through the bloodstream of the mice.

[0769] Throughout the study, the animals showed no signs of complications, distress, or toxicity. Thus, none of the over 30 mice in the study exhibited any observable adverse reactions. Daily observation of the mice documented that none suffered any weight loss, new tumor formation, loss of appetite, change in fur appearance or grooming behavior, or change in activity owing to lethargy. Moreover, there were no gross abnormalities of any of the internal organs of the mice upon necropsy. It was thus concluded that there were no drug-drug interactions, which are common with multiple-drug anti-cancer compositions.

[0770] In another mice study, a head and neck tumor was surgically removed from a human patient, and approximate 35 mg-portions of the tumor were implanted in a first randomized group of ten nude-FOXN1 mice using a 5% ethanol in saline vehicle via oral gavage. A second randomized group of ten mice was treated only with the vehicle as a control, in the same manner as the first group. The first mice group was treated with 30 mg/kg/day doses of GZ17-6.02 five days/week, and the doses were increased to 50 mg/kg/day during the second week of treatment. The two groups of mice were treated for a total of three weeks, and tumor volumes were measured twice a week using a Vernier caliper. The results of this study are set forth in FIG. **16**C, which illustrates that the fractional tumor volumes relative to the pretreatment tumor size were reduced in the first group of mice, while the control mice exhibited gradually increasing tumor burdens.

Example 17

[0771] In this Example, a different ratio of isovanillin, harmine, and curcumin was used, as compared with GZ17-6.02, namely ⅓ by weight of each component. This formulation was prepared by mixing the three GZ17-6.02 components in 1 mL of ethanol to obtain a secondary stock solution. FIG. **17**A shows that the original stock solution (filled circles) and the secondary stock solution (open circles) are bioequivalent in terms of ovarian cancer cell (A1847) kill rate. FIGS. **17**B and **17**C show the same general effect for lung cancer cells (H358) and prostate cancer cells (22rv1).

Example 18

[0772] In this Example, a known ovarian cancer cell kill rate for GZ17-6.02 was selected, and the amount of isovanillin in this dosage (0.78 mg/mL) was tested against GZ17-6.02. Additionally, sub-combinations of isovanillin:curcumin and isovanillin:harmine were tested, where the concentrations of the two ingredients were identical to those in the GZ17-6.02. Thus, the concentration of the isovanillin:curcumin product was 0.78 mg/mL isovanillin and 0.13 mg/mL curcumin, and the concentration of the isovanillin:harmine product was 0.78 mg/mL isovanillin and 0.099 mg/mL harmine. FIGS. **18**A-**18**D illustrate these results with ovarian cancer cells (A1847), lung cancer cells (H358), prostate cancer cells (22rv1), and lymphoma cells (M0205). As is evident, the two-component products each exhibited greater kill rates as compared with isovanillin alone.

Example 19

[0773] The procedures of Example 18 were followed, except that curcumin was tested alone versus GZ17-6.02, together with curcumin:isovanillin and curcumin:harmine two-component products. In this test, the curcumin was present at a level of 0.78 mg/mL and the concentrations in the curcumin:isovanillin product were 0.78 mg/mL curcumin and 3.59 mg/mL isovanillin, and in the curcumin:harmine product the concentrations were 0.78 mg/mL curcumin and 0.59 mg/mL harmine. FIGS. **19**A-**19**D illustrate the results of this test, and confirm that the two-component products give better results than curcumin alone.

Example 20

[0774] The procedures of Example 18 were followed, except that harmine was tested alone versus GZ17-6.02, together with harmine:isovanillin and harmine:curcumin two-component products. In this test, the harmine was present at a level of 0.78 mg/mL and the concentrations in the harmine:isovanillin product were 0.78 mg/mL harmine and 6.09 mg/mL isovanillin, and in the harmine:curcumin product the concentrations were 0.78 mg/mL curcumin and 1.03 mg/mL curcumin. FIGS. **20**A-**20**D illustrate the results of this test, and confirm that the two-component products give better results than harmine alone.

Example 21

[0775] In this example, the individual components of GZ17-6.02 were tested against lymphoma cancer cells (M0205) at the component concentrations found in GZ17-6.02, at dosage rates of 12, 24, 48, and 96 μg/mL. The theoretical additive effect (black bar) of the 3 components was also calculated in each case and shown versus the actual test results found using GZ17-6.02. FIGS. **21**A-**21**D illustrate the results of these tests, and confirm that, at the tested dosages, the GZ17-6.02 product had a greater effect than the individual components and the theoretical additive effect thereof, thus establishing synergistic effects. In this regard, those skilled in the art understand that dosages of anticancer products actually administered to patients depend on a number of factors, including age, weight, sex, physical conditions, types of cancers, and stages of cancers. By the same token, it should also be understood that at some dosage levels and/or specific concentrations of components, the results of FIGS. **21**A-**21**D may not be duplicated. These same considerations apply to the tests set forth in Examples 22 and 23 below. In most cases, however, compositions giving therapeutic synergies at the selected dosages are preferred.

Example 22

[0776] In this example, the individual components of GZ17-6.02 were tested against ovarian cancer cells (A1847) and breast cancer cells (du4475) at the component concentrations found in GZ17-6.02, at dosage rates of 12 and 24 μg/mL. The theoretical additive effect (black bar) of the 3 components was also calculated in each case and shown

versus the actual test results found using GZ17-6.02. FIGS. **22**A and **22**B illustrate the results of these ovarian cancer tests, and confirm that, at the tested dosages, the GZ17-6.02 product had a greater effect than the individual components and the theoretical additive effect thereof. In an additional test at 48 μg/mL dosage rate, this effect was not observed. FIG. **22**C sets forth the results using breast cancer cells.

Example 23

[0777] In this example, increasing concentrations of different isovanillin derivatives or metabolites were tested using lung cancer cells (H358), ovarian cancer cells (A1847), and prostate cancer cells (22rv1), to determine the anticancer effects of the derivatives/metabolites, using the techniques of Example 1. Each of the derivatives/metabolites (vanillin, isovanillic acid, 0-vanillin, and isovanillyl alcohol) demonstrated anticancer effects (see FIGS. **23**A-**23**L).

Example 24

[0778] In this example, increasing concentrations of different harmine derivatives or metabolites were tested using lung cancer cells (H358), ovarian cancer cells (A1847), and prostate cancer cells (22rv1), to determine the anticancer effects of the derivatives/metabolites, using the techniques of Example 1. Each of the derivatives/metabolites (harmaline, tetrahydro-harmine, harmole hydrochloride, harmalol hydrochloride, and harmane) demonstrated anticancer effects (see FIGS. **24**A-**24**O).

Example 25

[0779] In this example, increasing concentrations of a curcumin derivative, bisdemethoxy curcumin, were tested using lung cancer cells (H358), ovarian cancer cells (A1847), and prostate cancer cells (22rv1), to determine the anticancer effects of the derivative, using the techniques of Example 1. The results confirmed the anticancer effects of this derivative (see FIGS. **25**A-**25**C).

Example 26

[0780] In this test, the preferred GZ17-6.02 product was stored at various temperatures over a two-month period, and then tested against ovarian cancer cells (A1847). The results are set forth in FIG. **26**, which illustrates that at storage temperatures of −20° C. and 4° C., the product maintained its potency.

Example 27

[0781] In this test, the GZ17-6.02 product was subjected to successive freeze/thaw cycles. In each cycle, the product was frozen at −20° C., followed by allowing the product temperature to equilibrate at room temperature. At the end of each cycle, the product was tested against ovarian cancer cells (A1847) using the methods of Example 1. A total of 10 successive freeze/thaw cycles were performed on the same sample. FIG. **27** illustrates that there was no significant change in the efficacy of the GZ17-6.02 against ovarian cancer cells.

Example 28

[0782] In this series of tests, GZ17-8.02 (which is identical with the preferred GZ17-6.02 composition), and several different combinations of curcumin, harmine, and isovanillin derivatives were tested against ovarian cancer (A1847), lung cancer (H358), prostate cancer (22rv1), pancreatic cancer, and fibroblast cells (hgf-1), in order to confirm that such derivative combinations were effective. In each case, the weight ratio of the isovanillin component:curcumin component:harmine component was 7.7:1:1.3, and the compositions were prepared as described above and the tests were carried out as described in Examples 1, 2, and 6. The compositions are identified below, including the respective graphs giving the results of the tests:

[0783] GZI7-8.02 (FIG. **28**A)

[0784] GZI7-8.03 contained vanillin, turmeric-derived curcumin, and harmine (FIG. **28**B)

[0785] GZI7-8.04 contained orthovanillin, turmeric-derived curcumin, and harmine, and (FIG. **28**C)

[0786] GZI7-8.05 contained isovanillyl alcohol, turmeric-derived curcumin, and harmine (FIG. **28**D)

[0787] GZI7-8.06 contained isovanillic acid, turmeric-derived curcumin, and harmine (FIG. **28**E)

[0788] GZI7-8.07 contained isovanillin, turmeric-derived curcumin, and harmaline (FIG. **28**F)

[0789] GZI7-8.08 contained isovanillin, turmeric-derived curcumin, and harmane (FIG. **28**G)

[0790] GZI7-8.09 contained isovanillin, 100% synthetic curcumin, and harmine (FIG. **28**H)

[0791] GZI7-8.10 contained isovanillin, bisdemethoxy curcumin, and harmine (FIG. **28**I)

Examples 29-79

[0792] In each of the following examples, respective compositions having different combinations of isovanillin, curcumin, and harmine components were tested as set forth in Examples 1-6, against cancer cells to determine the anticancer effectiveness thereof. The specific cancer cell lines used in each case were those previously described. In all cases, the weight ratio of the isovanillin component:curcumin component:harmine component was 7.7:1:1.3, and the compositions were prepared as described above in connection with the preparation of GZ17-6.02. A separate graph is provided for each test, which identifies the cancer cells tested.

[0793] The following Table sets forth the Example numbers, composition designation, components, and corresponding Figure numbers for this series of tests. Where "curcumin" is specified, this refers to turmeric-derived curcumin, and where "curcumin (syn)" is specified, this refers to essentially pure synthetically-derived curcumin.

Example No.	Composition	Isovanillin Component	Curcumin Component	Harmine Component	FIG. Nos.
29	GZ17-08.11	isovanillin	bisdemethoxy curcumin	harmaline	29 A-G
30	GZ17-08.12	isovanillin	bisdemethoxy curcumin	harmane	30 A-G

-continued

Example No.	Composition	Isovanillin Component	Curcumin Component	Harmine Component	FIG. Nos.
31	GZ17-08.13	isovanillin	bisdemethoxy curcumin	harmalol	31 A-G
32	GZ17-08.14	isovanillin	bisdemethoxy curcumin	harmol	32 A-G
33	GZ17-08.15	vanillin	bisdemethoxy curcumin	harmine	33 A-G
34	GZ17-08.16	vanillin	bisdemethoxy curcumin	harmaline	34 A-G
35	GZ17-08.17	vanillin	bisdemethoxy curcumin	harmane	35 A-G
36	GZ17-08.18	vanillin	bisdemethoxy curcumin	harmalol	36 A-G
37	GZ17-08.19	vanillin	bisdemethoxy curcumin	harmol	37 A-G
38	GZ17-08.20	isovanillin	curcumin (syn)	harmalol	38 A-G
39	GZ17-08.21	isovanillin	curcumin (syn)	harmol	39 A-G
40	GZ17-08.22	vanillin	curcumin (syn)	harmaline	40 A-G
41	GZ17-08.23	vanillin	curcumin (syn)	harmane	41 A-G
42	GZ17-08.24	vanillin	curcumin (syn)	harmalol	42 A-G
43	GZ17-08.25	vanillin	curcumin (syn)	harmol	43 A-G
44	GZ17-08.26	orthovanillin	bisdemethoxy curcumin	harmine	44 A-G
45	GZ17-08.27	orthovanillin	bisdemethoxy curcumin	harmaline	45 A-G
46	GZ17-08.28	orthovanillin	bisdemethoxy curcumin	harmane	46 A-G
47	GZ17-08.29	orthovanillin	bisdemethoxy curcumin	harmalol	47 A-G
48	GZ17-08.30	orthovanillin	bisdemethoxy curcumin	harmol	48 A-G
49	GZ17-08.31	isovanillyl alcohol	bisdemethoxy curcumin	harmine	49 A-D
50	GZ17-08.32	isovanillyl alcohol	bisdemethoxy curcumin	harmaline	50 A-D
51	GZ17-08.33	isovanillyl alcohol	bisdemethoxy curcumin	harmane	51 A-D
52	GZ17-08.34	isovanillyl alcohol	bisdemethoxy curcumin	harmalol	52 A-D
53	GZ17-08.35	isovanillyl alcohol	bisdemethoxy curcumin	harmol	53 A-D
54	GZ17-08.36	orthovanillin	curcumin (syn)	harmaline	54 A-D
55	GZ17-08.37	orthovanillin	curcumin (syn)	harmane	55 A-D
56	GZ17-08.38	orthovanillin	curcumin (syn)	harmalol	56 A-D
57	GZ17-08.39	orthovanillin	curcumin (syn)	harmol	57 A-D
58	GZ17-08.40	isovanillyl alcohol	curcumin (syn)	harmaline	58 A-D
59	GZ17-08.41	isovanillyl alcohol	curcumin (syn)	harmane	59 A-D
60	GZ17-08.42	isovanillyl alcohol	curcumin (syn)	harmalol	60 A-D
61	GZ17-08.43	isovanillyl alcohol	curcumin (syn)	harmol	61 A-D
62	GZ17-08.44	isovanillic acid	bisdemethoxy curcumin	harmine	62 A-D
63	GZ17-08.45	isovanillic acid	bisdemethoxy curcumin	harmaline	63 A-D
64	GZ17-08.46	isovanillic acid	bisdemethoxy curcumin	harmane	64 A-D
65	GZ17-08.47	isovanillic acid	bisdemethoxy curcumin	harmalol	65 A-D
66	GZ17-08.48	isovanillic acid	bisdemethoxy curcumin	harmol	66 A-D
67	GZ17-08.49	isovanillic acid	curcumin (syn)	harmaline	67 A-D
68	GZ17-08.50	isovanillic acid	curcumin (syn)	harmane	68 A-D
69	GZ17-08.51	isovanillic acid	curcumin (syn)	harmalol	69 A-D
70	GZ17-08.52	isovanillic acid	curcumin (syn)	harmol	70 A-D

-continued

Example No.	Composition	Isovanillin Component	Curcumin Component	Harmine Component	FIG. Nos.
71	GZ17-08.53	5-bromovanillin	curcumin	harmine	71 A-D
72	GZ17-08.54	2-bromo-3-hydroxy-4-methoxy benzaldehyde	curcumin	harmine	72 A-D
73	GZ17-08.55	2-iodo-3-hydroxy-4-methoxy benzaldehyde	curcumin	harmine	73 A-D
74	GZ17-08.56	isovanillin	(1E,4E)-1,5-bis(3,5-dimethoxyphenyl)-1,4-pentadien-3-one	harmine	74 A-D
75	GZ17-08.57	isovanillin	cardamonin	harmine	75 A-D
76	GZ17-08.58	isovanillin	2'-hydroxy-3,4,4',5'-tetramethoxychalcone	harmine	76 A-D
77	GZ17-08.59	isovanillin	2,6'-2'-dihydroxy-4',dimethoxychalcone	harmine	77 A-D
78	GZ17-08.60	isovanillin	(1E,4E)-1,5-Bis(2-Hydroxyphenyl)-1,4-pentadien-3-one	harmine	78 A-D
79	GZ17-08.61	isovanillin	curcumin	1,2,3,4-tetrahydroharmane-3-carboxylic acid	79 A-D

[0794] These test results confirm that all of the compositions were effective anti-cancer agents.

Example 80

[0795] In this series of tests, the following compositions were prepared:

Composition	Isovanillin Component	Curcumin Component	Harmine Component
GZ17-10.00	orthovanillin	curcumin	harmaline
GZ17-10.01	orthovanillin	—	harmaline
GZ17-10.02	orthovanillin	curcumin	—
GZ17-10.03	—	curcumin	harmaline
GZ17-10.04	orthovanillin	—	—
GZ17-10.05	—	curcumin	—
GZ17-10.06	—	—	harmaline

GZ17-10.00 is identical with the above-described GZ17-6.02, having the identical amounts of the components and method of preparation. The two-component compositions have the same relative ratios, namely 7.7:1.3 for GZ17-10.01, 7.7:1 for GZ17-10.02, and 1:1.3 for GZ17-10.03. The single-component compositions contain the same amount of component as used in the three- and two-component compositions.

[0796] The respective compositions of this Example were tested against different cancer cell lines, as previously identified, using the methods of Examples 1-6, as set forth in the accompanying relevant graphs, **80**A-**80**R. Six of these (FIGS. **80**G, H, L, M, Q, and R) are comparative bar graphs setting forth the theoretical additive effect of the components, and the results obtained using the complete formulations, thereby demonstrating the synergistic effects of the compositions of the invention.

[0797] These test results confirm that all of the compositions were effective anti-cancer agents.

Example 81

[0798] In this series of tests, the following compositions were prepared:

Composition	Isovanillin Component (ratio component = 7.7)	Harmine Component (ratio component = 1.3)
GZ17-08.512	isovanillin	harmine
GZ17-08.513	isovanillin	harmaline
GZ17-08.514	isovanillin	harmane
GZ17-08.515	isovanillin	harmalol
GZ17-08.516	isovanillin	harmol
GZ17-08.517	vanillin	harmine
GZ17-08.518	vanillin	harmaline
GZ17-08.519	vanillin	harmane
GZ17-08.520	vanillin	harmalol
GZ17-08.521	vanillin	harmol

[0799] The respective compositions of this Example were tested against different cancer cell lines, as previously identified, using the methods of Examples 1-6, as set forth in the accompanying relevant graphs, **81**A-**81**DD.

[0800] These test results confirm that all of the compositions were effective anti-cancer agents.

Example 82

[0801] In each of the following examples, respective compositions having different combinations of isovanillin, curcumin, and harmine components were tested as set forth in Examples 1-3, against lung cancer, lymphoma, and leukemia cells to determine the anti-cancer effectiveness thereof. The compositions were prepared by individually mixing the listed components in 3 mL of ethanol followed by adding the so-mixed components together to form the resultant compositions. A separate graph is provided for each test, which identifies the cancer cells tested. Specifically, FIGS. **82-1** through **82-41** set forth the results of the lung cancer (LC)

tests using the compositions, FIGS. **82-42** through **82-82** give the results for the lymphoma (LY) tests, and FIGS. **82-83** through **82-123** give the results of the leukemia (LK) tests.

[0802] The first Table below sets forth the identities of the isovanillin components i01-i15, the harmine components h01-h13, and the curcumin components c01-c13, used in these tests. The second Table below sets forth the multiple-component compositions tested, GZ08.065-GZ08.105, for lung cancer, lymphoma, and leukemia cells and the respective Figure numbers associated with each such composition and cell line. The recitation "curcumin (syn)" refers to essentially pure synthetically-derived curcumin.

[0803] All of the second Table compositions exhibited anti-cancer activity against lung cancer, lymphoma, and leukemia cells. In addition, FIGS. **82-124** through **82-167** are comparative bar graphs confirming the synergism found in exemplary compositions of this Example, at various concentration levels, against lung cancer, lymphoma, and leukemia cells.

Code	Compound	CAS#	MW
i01	o-anisaldehyde	135-02-4	136.15
i02	isovanillin oxime	51673-94-0	167.166
i03	ethyl vanillin	121-32-4	166.18
i04	vanillin isobutyrate	20665-85-4	222.24
i05	veratraldehyde	120-14-9	166.18
i06	5-nitrovanillin	6635-20-7	197.14
i07	vanillin acetate	881-68-5	194.18
i08	3-benzyloxy-4-methoxybenzaldehyde	6346-05-0	242.27
i09	3-hydroxy-5-methoxybenzaldehyde	672-13-9	152.15
i10	methyl isovanillate	6702-50-7	182.18
i11	acetovanillone (apocynin)	498-02-2	166.17
i12	2-hydroxy-4-methoxybenzaldehyde	673-22-3	152.15
i13	trans-ferulic acid	537-98-4	194.18
i14	3-hydroxy-4-methoxycinnamic acid	537-73-5	194.18
i15	caffeic acid	331-39-5	180.16

-continued

Code	Compound	CAS#	MW
h01	norharmane	244-63-3	168.19
h02	6-methoxyharmalan	3589-73-9	214.26
h03	bromo harmine	na	372.06
h04	2-methyl harmine	21236-68-0	227.28
h05	4,9-dihydro-3H-beta-carbolin-1-yl methyl ether	na	200.24
h06	1-(4-nitrophenyl)-2,3,4,9-tetrahydro-1H-beta-carboline hydrochloride	3380-77-6	329.79
h07	1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole {THbC}	16502-01-5	172.23
h08	1,2,3,4-tetrahydro-beta-carboline-1-carboxylic acid	na	216.24
h09	6-Methoxy-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole	20315-68-8	202.25
h10	3-hydroxymethyl-b-carboline	65474-79-5	198.22
h11	2,3,4,5-tetrahydro-8-methoxy-1H-pyrido[4,3-b]indole	na	202.25
h12	6-Methoxy-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole-1-carboxylic acid	17952-63-5	246.26
h13	ethyl b-carboline-3-carboxylate	74214-62-3	240.26
c01	tetrahydro curcumin	36062-04-1	372.41
c02	demethyl curcumin	149732-51-4	354.35
c03	demethoxy curcumin	22608-11-3	338.35
c04	1,3-diphenyl-2-propanone	102-04-5	210.27
c05	caffeic acid phenethyl ester	104594-70-9	284.31
c06	(1E,4E)-1,5-bis[3,5-bis(methoxymethoxy)phenyl]-1,4-pentadiene-3-one	917813-62-8	474.51
c07	1,7-di(1-naphthyl)-2,6-heptanedione	na	380.49
c08	trans,trans-1,5-Bis[4-(trifluoromethyl)phenyl]-1,4-pentadien-3-one	103836-71-1	370.29
c09	1,5-dibenzoylpentane	28861-22-5	280.36
c10	(2E,5E)-2,5-dibenzylidenecyclopentanone	895-80-7	260.33
c11	2,6-bis(4-fluorobenzal)cyclohexanone	62085-74-9	310.34
c12	(1E,4E)-1,5-bis(4-fluorophenyl)-1,4-pentadien-3-one	na	354.4
c13	FLLL31	52328-97-9	424.49

Comp.	Isovanillin Component (176 mg/3 mL EtOH)	Harmine Component (30 mg/3 mL EtOH)	Curcumin Component (23 mg/3 mL EtOH)	Total (mg/mL)	Total (mM)	LC Fig. Nos.	LY Fig. Nos.	LK Fig. Nos.
08.065	i01	harmine	curcumin (syn)	76.3	498.8	82-1	82-42	82-83
08.066	i02	harmine	curcumin (syn)	76.3	418.8	82-2	82-43	82-84
08.067	i03	harmine	curcumin (syn)	76.3	420.9	82-3	82-44	82-85
08.068	i04	harmine	curcumin (syn)	76.3	331.9	82-4	82-45	82-86
08.069	i05	harmine	curcumin (syn)	76.3	420.9	82-5	82-46	82-87
08.070	i06	harmine	curcumin (syn)	76.3	365.5	82-6	82-47	82-88
08.071	i07	harmine	curcumin (syn)	76.3	370.0	82-7	82-48	82-89
08.072	i08	harmine	curcumin (syn)	76.3	310.1	82-8	82-49	82-90
08.073	i09	harmine	curcumin (syn)	76.3	453.5	82-9	82-50	82-91
08.074	i10	harmine	curcumin (syn)	76.3	389.9	82-10	82-51	82-92
08.075	i11	harmine	curcumin (syn)	76.3	421.0	82-11	82-52	82-93
08.076	i12	harmine	curcumin (syn)	76.3	453.5	82-12	82-53	82-94
08.077	i13	harmine	curcumin (syn)	76.3	370.0	82-13	82-54	82-95
08.078	i14	harmine	curcumin (syn)	76.3	370.0	82-14	82-55	82-96
08.079	i15	harmine	curcumin (syn)	76.3	393.5	82-15	82-56	82-97
08.080	isovanillin	h01	curcumin (syn)	76.3	465.9	82-16	82-57	82-98
08.081	isovanillin	h02	curcumin (syn)	76.3	453.1	82-17	82-58	82-99
08.082	isovanillin	h03	curcumin (syn)	76.3	433.3	82-18	82-59	82-100
08.083	isovanillin	h04	curcumin (syn)	76.3	450.4	82-19	82-60	82-101
08.084	isovanillin	h05	curcumin (syn)	76.3	456.3	82-20	82-61	82-102
08.085	isovanillin	h06	curcumin (syn)	76.3	436.7	82-21	82-62	82-103
08.086	isovanillin	h07	curcumin (syn)	76.3	464.5	82-22	82-63	82-104
08.087	isovanillin	h08	curcumin (syn)	76.3	452.6	82-23	82-64	82-105
08.088	isovanillin	h09	curcumin (syn)	76.3	455.8	82-24	82-65	82-106
08.089	isovanillin	h10	curcumin (syn)	76.3	456.8	82-25	82-66	82-107
08.090	isovanillin	h11	curcumin (syn)	76.3	455.8	82-26	82-67	82-108

-continued

Comp.	Isovanillin Component (176 mg/3 mL EtOH)	Harmine Component (30 mg/3 mL EtOH)	Curcumin Component (23 mg/3 mL EtOH)	Total (mg/mL)	Total (mM)	LC Fig. Nos.	LY Fig. Nos.	LK Fig. Nos.
08.091	isovanillin	h12	curcumin (syn)	76.3	447.0	82-27	82-68	82-109
08.092	isovanillin	h13	curcumin (syn)	76.3	448.0	82-28	82-69	82-110
08.093	isovanillin	harmine	c01	76.3	453.3	82-29	82-70	82-111
08.094	isovanillin	harmine	c02	76.3	454.3	82-30	82-71	82-112
08.095	isovanillin	harmine	c03	76.3	455.4	82-31	82-72	82-113
08.096	isovanillin	harmine	c04	76.3	469.2	82-32	82-73	82-114
08.097	isovanillin	harmine	c05	76.3	459.7	82-33	82-74	82-115
08.098	isovanillin	harmine	c06	76.3	448.9	82-34	82-75	82-116
08.099	isovanillin	harmine	c07	76.3	452.8	82-35	82-76	82-117
08.100	isovanillin	harmine	c08	76.3	453.4	82-36	82-77	82-118
08.101	isovanillin	harmine	c09	76.3	460.0	82-37	82-78	82-119
08.102	isovanillin	harmine	c10	76.3	462.1	82-38	82-79	82-120
08.103	isovanillin	harmine	c11	76.3	457.4	82-39	82-80	82-121
08.104	isovanillin	harmine	c12	76.3	454.3	82-40	82-81	82-122
08.105	isovanillin	harmine	c13	76.3	450.8	82-41	82-82	82-123

[0804] All of the foregoing tests confirmed significant anti-cancer activity against lung cancer cells, H358, lymphoma cells, M0205, and leukemia cells, jurkat E6-1. Accordingly, all combinations of i01-i15, h01-h13, and c01-c13, whether three-component or two-component, would exhibit such anti-cancer activity. Moreover, as shown above, the combinations of harmine and curcumin with i01-15, isovanillin and curcumin with h01-h13, and isovanillin and harmine with c01-c13 all have useful anti-cancer activity.

[0805] Moreover, as noted previously, the compounds i01-i15, h01-h13, and c01-c13 may be individually and independently in the form of the corresponding esters, metal complexes, pharmaceutically acceptable salts, and mixtures thereof. That is, e.g., a given curcumin component may be in the form of an ester, complex, or salt, independently of the form of the remaining components of the composition.

Example 83

[0806] In another series of tests, compositions were prepared containing: (1) orthovanillin+curcumin+harmaline; and (2) single-component compositions containing orthovanillin, curcumin, and harmaline, respectively. The three-component composition had a weight ratio of orthovanillin: curcumin:harmaline of 771:130.3:98.7, and the single-component compositions contained varying amounts of orthovanillin, curcumin, and harmaline.

[0807] These compositions were prepared by mixing together quantities of solid synthetic orthovanillin (99% by weight purity), synthetic harmaline (92% by weight purity), and a commercial turmeric product (ResCu) in ethanol, and allowing the mixtures to react for a period of 24 hours.

[0808] These compositions were tested against lymphoma (M0205), leukemia (jurkat E6-1), and breast cancer (du4475) cell lines, using the assays described in Examples 1-3.

[0809] The results of the lymphoma tests are set forth in FIGS. **83**A-**83**D. These tests confirmed that the combination of orthovanillin+curcumin+harmaline (FIG. **83**D) exhibited synergistic results as compared with the individual tests of orthovanillin, curcumin, and harmaline (FIGS. **83**A-**83**C).

[0810] In like manner, the leukemia tests (FIGS. **83**E-**83**H) confirmed that the combination of orthovanillin+curcumin+harmaline (FIG. **83**H) exhibited synergistic results as compared with the individual tests of orthovanillin, curcumin, and harmaline (FIGS. **83**E-**83**G).

[0811] To a similar effect, the breast cancer tests (FIGS. **83**I-**83**L) confirmed that the combination of orthovanillin+curcumin+harmaline (FIG. **83**L) exhibited synergistic results as compared with the individual tests of orthovanillin, curcumin, and harmaline (FIGS. **83**I-**83**K).

Example 84

[0812] In this Example, GZ17-6.02 was tested with pancreatic cancer cells (52-007) to determine whether it had an effect on cancer stem cell proteins using the techniques described in Examples 1-3, and it was found that the treatment decreased the number and size of the pancreatic cancer spheres at both the IC_{50} concentration and a concentration of half that amount (see FIG. **84**A). In additional tests (FIG. **84**B), treated cells exhibited a dose-dependent decline in doublecortin calmodulin-like kinase 1 (Dclk-1), a microtubule-associated protein that serves as a marker for intestinal and pancreatic cancer stem cells (Mwangi, S. M. et al. "DCAMKL-1: a new horizon for pancreatic progenitor identification." *Am J Phys-Gastro Liver Physiol* 299 (2010): G301-302), and also differentiates between tumor stem cells and normal stem cells (Nakanishi, Y. et al. "Dclk1 distinguishes between tumor and normal stem cells in the intestine." *Nature Gen* 45 (2013):98-103). Epithelial cell adhesion molecule (EpCAM) is another cancer stem cell marker and it also decreased in level with GZ17-6.02 exposure. Likewise, the leucine-rich-repeat containing G-protein-coupled receptor 5 (LGR5) is another cancer stem cell marker and its levels decreased with the GZ17-6.02 treatment (FIG. **84**B).

[0813] When tumors from treated mice were analyzed, the tumors also showed a clear reduction in EPCAM, DCLK1, LGR5, and SOX9 (FIG. **84**C). GZ17-6.02 is thus seen to block pancreatic spheroid formation and cancer stem cell marker expression, both in cancer cells grown and treated in vitro and in tumor samples from mice treated with GZ17-6.02.

[0814] GZ17-6.02 significantly reduced tumorigenesis both with in vitro and in vivo pancreatic cancer cell models, partially via a route that inhibits the presence of cancer stem

cells. In this regard, it appears that GZ17-6.02 has several different mechanisms of action resulting in decreased tumor growth and inhibition of metastases. FIG. **84**D illustrates a possible pathway for the action of GZ17-6.02 on both cancer stem cells (CSC) and on the other cancer cells within the tumor. With respect to the cancer stem cells, the GZ17-6.02 decreased the common biomarkers of cancer stem cells (Dclk1, LGR5, EpCam, and Sox9). It apparently did this by acting through the Sonic Hedgehog pathway (FIG. **84**D, SHH). Simultaneously, GZ17-6.02 blocked the bulk tumor cells in two ways by directly inducing apoptosis via the caspase pathway, as measured by the BAX/Bcl2 ratio, and through the EGFR pathway. All three of these mechanisms led to reduced tumor size, inhibition of metastasis and decline in the presence of cancer stem cells. Thus, the compositions of the invention are effective for killing or inhibiting the growth of cancer stem cells.

Example 85

[0815] The purpose of this study was to determine the effect of GZ17-6.02 on the regression of growth and the inhibition of metastases in a pancreatic cancer mouse model. Twelve immunocompromised (nude) mice were treated injected with MiaPaCa-2 cells (a pancreatic cancer cell line) that had been genetically transformed to express TdTomato and luciferin for in vivo tumor imaging. After tumors reached a measurable size (approximately 2 weeks), half of the mice were randomly assigned to the experimental group and the other half to the control group.

[0816] The experimental group was treated with GZ17-6.02 at a daily dose of 100 mg/kg body weight. The drug administration was oral, dissolved in peptamen. Control mice were fed the vehicle (peptamen) alone. Once a week mice were lightly anesthetized in order to use IVIS imaging to detect the tumor sizes. On day 5, there was no statistical difference in the amount of fluorescence measured from the control (placebo-fed) and GZ17-6.02-fed mice. However, by day 20, there was a statistically significant decrease in the amount of fluorescence, indicating a decreased total tumor burden, in the mice fed GZ17-6.02, as compared with the control. In addition, the placebo-treated mice had dramatic levels of peritoneal ascites that were not present in the GZ17-6.02 group.

[0817] At the end of 21 days of treatment with GZ17-6.02 or the placebo, the mice were sacrificed and tumor samples removed from the pancreas, liver, and lungs. The primary pancreatic tumors were weighed. The placebo-fed animals had pancreatic tumors that averaged 2.4 times statistically larger than the GZ17-6.02 fed mice.

Example 86

[0818] A 63-year-old male patient having a Prostate-Specific Antigen (PSA) count of 8.2 began a treatment regimen using a dosage form of GZ17-6.02. Specifically, solid GZ17-6.02 prepared by evaporating the ethanol from the previously described GZ17-6.02 agent was dispersed in water in equal weight amounts, e.g., 5 grams solid GZ17-6.02 in 5 grams water. This dosage form was taken three times daily for six weeks, with each dose being four fluid ounces of the 50%:50% dispersion. At the end of six weeks, the patient's PSA count had dropped to 2.1, and all prostate and urological tests were normal. The treating physician had no explanation for the decline in PSA. The patient experienced no observable adverse reactions to the treatment with GZ17-6.02.

[0819] Although not wishing to be bound by any theory of operation, the inventors believe that the therapeutic agents of the invention ameliorate a number of conditions or illnesses, and especially reduce and/or eliminate cancer and/or the symptoms thereof by augmenting or stimulating the patients' immune systems. In this sense, the invention is believed to be a form of biological therapy. As such, it is considered that the invention is applicable to virtually all cancers, such as the following: Acute Lymphoblastic Leukemia, Adult; Acute Lymphoblastic Leukemia, Childhood; Acute Myeloid Leukemia, Adult; Acute Myeloid Leukemia, Childhood; Adrenocortical Carcinoma; Adrenocortical Carcinoma, Childhood; Adolescents, Cancer in; AIDS-Related Cancers; AIDS-Related Lymphoma; Anal Cancer; Appendix Cancer; Astrocytomas, Childhood; Atypical Teratoid/Rhabdoid Tumor, Childhood, Central Nervous System; Basal Cell Carcinoma; Bile Duct Cancer, Extrahepatic; Bladder Cancer; Bladder Cancer, Childhood; Bone Cancer, Osteosarcoma and Malignant Fibrous Histiocytoma; Brain Stem Glioma, Childhood; Brain Tumor, Adult; Brain Tumor, Brain Stem Glioma, Childhood; Brain Tumor, Central Nervous System Atypical Teratoid/Rhabdoid Tumor, Childhood; Brain Tumor, Central Nervous System Embryonal Tumors, Childhood; Brain Tumor, Astrocytomas, Childhood; Brain Tumor, Craniopharyngioma, Childhood; Brain Tumor, Ependymoblastoma, Childhood; Brain Tumor, Ependymoma, Childhood; Brain Tumor, Medulloblastoma, Childhood; Brain Tumor, Medulloepithelioma, Childhood; Brain Tumor, Pineal Parenchymal Tumors of Intermediate Differentiation, Childhood; Brain Tumor, Supratentorial Primitive Neuroectodermal Tumors and Pineoblastoma, Childhood; Brain and Spinal Cord Tumors, Childhood (Other); Breast Cancer; Breast Cancer and Pregnancy; Breast Cancer, Childhood; Breast Cancer, Male; Bronchial Tumors, Childhood; Burkitt Lymphoma; Carcinoid Tumor, Childhood; Carcinoid Tumor, Gastrointestinal; Carcinoma of Unknown Primary; Central Nervous System Atypical Teratoid/Rhabdoid Tumor, Childhood; Central Nervous System Embryonal Tumors, Childhood; Central Nervous System (CNS) Lymphoma, Primary; Cervical Cancer; Cervical Cancer, Childhood; Childhood Cancers; Chordoma, Childhood; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Myeloproliferative Disorders; Colon Cancer; Colorectal Cancer, Childhood; Craniopharyngioma, Childhood; Cutaneous T-Cell Lymphoma; Embryonal Tumors, Central Nervous System, Childhood; Endometrial Cancer; Ependymoblastoma, Childhood; Ependymoma, Childhood; Esophageal Cancer; Esophageal Cancer, Childhood; Esthesioneuroblastoma, Childhood; Ewing Sarcoma Family of Tumors; Extracranial Germ Cell Tumor, Childhood; Extragonadal Germ Cell Tumor; Extrahepatic Bile Duct Cancer; Eye Cancer, Intraocular Melanoma; Eye Cancer, Retinoblastoma; Gallbladder Cancer; Gastric (Stomach) Cancer; Gastric (Stomach) Cancer, Childhood; Gastrointestinal Carcinoid Tumor; Gastrointestinal Stromal Tumor (GIST); Gastrointestinal Stromal Cell Tumor, Childhood; Germ Cell Tumor, Extracranial, Childhood; Germ Cell Tumor, Extragonadal; Germ Cell Tumor, Ovarian; Gestational Trophoblastic Tumor; Glioma, Adult; Glioma, Childhood Brain Stem; Hairy Cell Leukemia; Head and Neck Cancer; Heart Cancer, Childhood; Hepatocellular

(Liver) Cancer, Adult (Primary); Hepatocellular (Liver) Cancer, Childhood (Primary); Histiocytosis, Langerhans Cell; Hodgkin Lymphoma, Adult; Hodgkin Lymphoma, Childhood; Hypopharyngeal Cancer; Intraocular Melanoma; Islet Cell Tumors (Endocrine Pancreas); Kaposi Sarcoma; Kidney (Renal Cell) Cancer; Kidney Cancer, Childhood; Langerhans Cell Histiocytosis; Laryngeal Cancer; Laryngeal Cancer, Childhood; Leukemia, Acute Lymphoblastic, Adult; Leukemia, Acute Lymphoblastic, Childhood; Leukemia, Acute Myeloid, Adult; Leukemia, Acute Myeloid, Childhood; Leukemia, Chronic Lymphocytic; Leukemia, Chronic Myelogenous; Leukemia, Hairy Cell; Lip and Oral Cavity Cancer; Liver Cancer, Adult (Primary); Liver Cancer, Childhood (Primary); Lung Cancer, Non-Small Cell; Lung Cancer, Small Cell; Lymphoma, AIDS-Related; Lymphoma, Burkitt; Lymphoma, Cutaneous T-Cell; Lymphoma, Hodgkin, Adult; Lymphoma, Hodgkin, Childhood; Lymphoma, Non-Hodgkin, Adult; Lymphoma, Non-Hodgkin, Childhood; Lymphoma, Primary Central Nervous System (CNS); Macroglobulinemia, Waldenstrom; Malignant Fibrous Histiocytoma of Bone and Osteosarcoma; Medulloblastoma, Childhood; Medulloepithelioma, Childhood; Melanoma; Melanoma, Intraocular (Eye); Merkel Cell Carcinoma; Mesothelioma, Adult Malignant; Mesothelioma, Childhood; Metastatic Squamous Neck Cancer with Occult Primary; Mouth Cancer; Multiple Endocrine Neoplasia Syndromes, Childhood; Multiple Myeloma/Plasma Cell Neoplasm; Mycosis Fungoides; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Myelogenous Leukemia, Chronic; Myeloid Leukemia, Adult Acute; Myeloid Leukemia, Childhood Acute; Myeloma, Multiple; Myeloproliferative Disorders, Chronic; Nasal Cavity and Paranasal Sinus Cancer; Nasopharyngeal Cancer; Nasopharyngeal Cancer, Childhood; Neuroblastoma; Non-Hodgkin Lymphoma, Adult; Non-Hodgkin Lymphoma, Childhood; Non-Small Cell Lung Cancer; Oral Cancer, Childhood; Oral Cavity Cancer, Lip and; Oropharyngeal Cancer; Osteosarcoma and Malignant Fibrous Histiocytoma of Bone; Ovarian Cancer, Childhood; Ovarian Epithelial Cancer; Ovarian Germ Cell Tumor; Ovarian Low Malignant Potential Tumor; Pancreatic Cancer; Pancreatic Cancer, Childhood; Pancreatic Cancer, Islet Cell Tumors; Papillomatosis, Childhood; Paranasal Sinus and Nasal Cavity Cancer; Parathyroid Cancer; Penile Cancer; Pharyngeal Cancer; Pineal Parenchymal Tumors of Intermediate Differentiation, Childhood; Pineoblastoma and Supratentorial Primitive Neuroectodermal Tumors, Childhood; Pituitary Tumor; Plasma Cell Neoplasm/Multiple Myeloma; Pleuropulmonary Blastoma, Childhood; Pregnancy and Breast Cancer; Primary Central Nervous System (CNS) Lymphoma; Prostate Cancer; Rectal Cancer; Renal Cell (Kidney) Cancer; Renal Pelvis and Ureter, Transitional Cell Cancer; Respiratory Tract Cancer with Chromosome 15 Changes; Retinoblastoma; Rhabdomyosarcoma, Childhood; Salivary Gland Cancer; Salivary Gland Cancer, Childhood; Sarcoma, Ewing Sarcoma Family of Tumors; Sarcoma, Kaposi; Sarcoma, Soft Tissue, Adult; Sarcoma, Soft Tissue, Childhood; Sarcoma, Uterine; Sezary Syndrome; Skin Cancer (Nonmelanoma); Skin Cancer, Childhood; Skin Cancer (Melanoma); Skin Carcinoma, Merkel Cell; Small Cell Lung Cancer; Small Intestine Cancer; Soft Tissue Sarcoma, Adult; Soft Tissue Sarcoma, Childhood; Squamous Cell Carcinoma; Squamous Neck Cancer with Occult Primary, Metastatic; Stomach (Gastric) Cancer; Stomach (Gastric) Cancer, Childhood; Supratentorial Primitive Neuroectodermal Tumors, Childhood; T-Cell Lymphoma, Cutaneous; Testicular Cancer; Testicular Cancer, Childhood; Throat Cancer; Thymoma and Thymic Carcinoma; Thymoma and Thymic Carcinoma, Childhood; Thyroid Cancer; Thyroid Cancer, Childhood; Transitional Cell Cancer of the Renal Pelvis and Ureter; Trophoblastic Tumor, Gestational; Unknown Primary Site, Carcinoma of, Adult; Unknown Primary Site, Cancer of, Childhood; Unusual Cancers of Childhood; Ureter and Renal Pelvis, Transitional Cell Cancer; Urethral Cancer; Uterine Cancer, Endometrial; Uterine Sarcoma; Vaginal Cancer; Vaginal Cancer, Childhood; Vulvar Cancer; Waldenstrom Macroglobulinemia; Wilms Tumor; Women's Cancers.

We claim:

1. A method of treating a patient suffering from a pancreatic cancer or tumor, comprising the step of administering to the patient an anticancer composition comprising a combination of synergistically effective amounts of at least one curcumin component comprising curcumin, at least one harmine component comprising harmine, and at least one isovanillin component comprising isovanillin, wherein the components of the composition are different.

2. The method of claim **1**, wherein said curcumin is synthetically derived or derived from naturally occurring product(s) containing said curcumin which have been treated so that the curcumin is present at a level of at least about 25% by weight in the treated, curcumin-containing naturally occurring product(s), said harmine is synthetically derived or derived from naturally occurring product(s) containing said harmine which have been treated so that the harmine is present at a level of at least about 25% by weight in the treated, harmine-containing naturally occurring product(s), and said isovanillin is synthetically derived or derived from naturally occurring product(s) containing said isovanillin which have been treated so that the isovanillin is present at a level of at least about 25% by weight in the treated, isovanillin-containing naturally occurring product (s).

3. The method of claim **1**, wherein said curcumin, said harmine, and said isovanillin are each at least about 50% pure.

4. The method of claim **1**, wherein said isovanillin is present in an amount greater than the amounts of the harmine and the curcumin.

5. The method of claim **1**, wherein the ratio of said at least one curcumin component, said at least one harmine component, and said at least one isovanillin component is from about 0.1-5:0.1-5:0.1-25.

6. The method of claim **1**, wherein the at least one isovanillin component is present at a level of from about 25-85% by weight, the at least one harmine component is present at a level of from about 7-50% by weight, and the at least one curcumin component is present at a level of from about 5-40% by weight, based upon the total weight of the three components taken as 100% by weight.

7. The method of claim **1**, wherein said at least one curcumin component consists essentially of curcumin, said at least one harmine component consists essentially of harmine, and said at least one isovanillin component consists essentially of isovanillin.

8. The method of claim **1**, wherein said pancreatic cancer is selected from the group consisting of exocrine pancreatic cancer or islet cell tumor.

* * * * *